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Abstract
The work presented in this thesis was carried out in the
Department of Pharmacology, University of Edinburgh from 1989
to 1992. This thesis contains in vitro and in vivo radioligand
binding studies for the N-methyl-D-aspartate (NMDA) receptor,
the 5-HTia receptor and the 5-HT transporter.
In chapter 2, a novel NMDA antagonist FR115427 ((+)-1-
methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride;
(+)FR), which was developed in New Drug Research Laboratories,
Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan, was
characterised using [3H]MK-801 binding to rat brain membranes.
As observed with (+)MK-801, the affinity of (+)FR was increased
when 10 |iM L-glutamate was added in the assay buffer. (+)FR
inhibited [3H]MK-801 binding to rat cortical synaptosomal
membranes in the presence of added L-glutamate (10 (iM) with a
Ki value of 40 nM although (+)FR was 12-fold less potent than
(+)MK-801. These results indicate that (+)FR is non-competitive
NMDA antagonist. [3H](+)FR synthesised by tritiation of (+)CI-FR
(mono-chlorinated aromatic precursor of (+)FR) was
successfully purified by an open column method. In vivo
distribution of intravenous injection of [3H](+)FR in rats was
analysed. Intravenous injection of [3H](+)FR resulted in a rapid
accumulation of radioactivity in rat brain.
In chapter 3, the possibility of using derivatives of
citalopram (selective 5-HT uptake inhibitor) as a photoaffinity
or SPET ligand for the 5-HT transporter was evaluated using
5-azido-citalopram (5-AC) (photoaffinity ligand) and 5-iodo-
citalopram (5-IC) (SPET ligand).
5-AC had high affinity (Ki = 1.65 nM) for [3H]citalopram
binding sites being only 1.8-fold less potent than citalopram
itself. In the presence of 5-AC, repeated U.V. irradiation (15 W)
of rat cortical membranes produced a significant 20% reduction
respectively in the Bmax value for [3H]citalopram binding
compared with control, indicating that 5-AC covalently bound to
the [3H]citalopram binding site. Therefore radiolabeled 5-AC
may provide a tool for isolation and characterisation of the 5-HT
transporter.
5-IC was 5.8-fold less potent than citalopram as an
inhibitor of [3H]5-HT uptake into rat cortical synaptosomes with
a Ki value of 11.5 nM. This compound had high affinity (Ki = 4.0
nM and 2.9 nM) for [3H]paroxetine and [3H]citalopram binding
sites in rat cortical membranes respectively, being only 1.9- and
3.1-fold less potent than citalopram itself. The pharmacological
profile of radio-iodinated 5-IC ([12 51]5-l C) binding in rat
cortical membranes was consistent with results from
[3H]citalopram binding experiments. Intravenous injection of
[125|]5-IC resulted in a rapid accumulation of radioactivity in rat
brain. At 2hr after injection, highest levels of specific
[125|]5-|Q binding was observed in the brainstem and midbrain
which are known to be rich in serotonergic neuronal cell bodies.
Pretreatment with paroxetine caused a significant reduction in
specific [125|]5-|C binding in the midbrain, rostral cortex and
caudal cortex. These results may indicate that [125|]5-IO is a
potential SPET ligand for the 5-HT transporter in human brain.
In chapter 4, the cellular localisation of 5-HTia binding
sites and 5-HT uptake sites in the rat frontal cortex and
hippocampus were examined using three different neurotoxins,
5,7-DHT, ibotenate and AMPA. Serotonergic lesions by 5,7-DHT
produced a reduction in binding site density for [3H]citalopram
binding in both the cortical and hippocampal membranes. The
lesions of basal forebrain cholinergic neurones using either
ibotenate or AMPA did not effect the binding affinity (Kd value)
and density (Bmax value) for [3H]8-OH-DPAT and [3H]citalopram
binding in either cortical or hippocampal membranes. In
conclusion, firstly, the 5-HT transporter sites are located on
terminals of serotonergic neurons in the cortex and
hippocampus, but not on cholinergic terminals in the cortex.
Secondly, the 5-HTia receptors are not localised on cholinergic
terminals in the cortex, or serotonergic terminals in the cortex
and hippocampus.
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The molecular sites of drug action, i.e. those protein
molecules with which drugs must interact to produce their
pharmacological effects, are called specific receptors. The
development of selective, high affinity radioligands are critical
for progress in the area of receptor pharmacology, since structure-
activity relationship studies with such compounds are based on
the interaction between the drug molecule and the receptor
binding site and can provide important information for future
design of new drugs. These radiolabeled ligands which interact
with a specific binding site are used as tools for the study and
characterisation of numerous neurotransmitter receptors.
During the past 15 years, in vitro radioligand binding assays
with brain membrane preparations have become an important
technique for studying receptors in the brain. However
membrane binding assays are not suitable for analysis of the
detailed anatomical distribution of neurotransmitter receptors.
For this purpose, Young and Kuhar (1979) originally developed
in vitro receptor autoradiography which involves incubation of
slide-mounted microtome tissue sections with receptor specific
radioligands. Autoradiography has contributed to the
characterisation and localisation of receptors in the central
nervous system (CNS).
1.1.1 PET and SPET Liaands
The advent of positron emission tomography (PET) and the
development of suitable receptor- or site-specific agents has
made it possible to study neurotransmitter systems in living
human brain. Suitable positron emitting radionuclides are
1
mainly carbon-11 (ti/2 = 20 min) and fluorine-18 (ti/2 = 110
min). For example, the dopaminergic system can be visualised
both pre- and postsynaptically using 6-[18F]fluoro-L-DOPA
(Garnett et al., 1983) and 3-N-p 1 C]methyl spiperone (Wong et
al., 1984), respectively. Single photon emission tomography
(SPET) is an alternative neuroimaging technique for studying
neurotransmitter receptors of the human brain. In this case,
radioligands labelled with lodine-123 (ti/2 = 13 hr) are suitable
for SPET studies. For example, [i23|]3-quinuclidinyl-4-
iodobenzilate has been used to obtain images of muscarinic
acetylcholine receptor distribution in human brain including that
of a patient with Alzheimer's disease (Eckelman et al., 1984;
Holman et al., 1985). SPET imaging studies in man using
[i23|]jodobenzamide, a dopamine D2 receptor antagonist, have
shown specific regional uptake in the basal ganglia, an area
known from in vitro studies to have a high density of dopamine
D2 receptors (Kung et al., 1990). Although it is well recognised
that the resolution of SPET (full width half maximum; FWHM =
7-15 mm) is lower than that of PET (FWHM = 4-7 mm) (Phelps
and Maziotta, 1985), it has a number of advantages. Because of
their longer half-lives, SPET can be carried out with
commercially available radioisotopes whereas for PET an on site
cyclotron is required and the equipment is more complex and
difficult to maintain. Moreover, again related to the half-life
of the radioisotopes, multiple images can be obtained over a
longer time period following a single dose of radioligand with
SPET allowing more complex studies to be undertaken. Thus in




Photoaffinity labelling is a powerful technique for
biochemical investigation of receptors. Photoaffinity ligands
which are capable of forming a covalent bond at or near the
binding site after photoactivation with light, are useful for
isolation and cloning of native receptors. The radiolabeled
photoaffinity ligand-receptor protein complex can be isolated
and characterised by electrophoresis after all noncovalently
bound ligand is removed by an appropriate procedure such as
extensive dialysis, gel filtration and gradient
ultracentrifugation. From this material it is then often
possible to obtain amino acid sequence information which can be
used to design oligonucleotides suitable for screening of an
appropriate cDNA library. In general, unlike photoaffinity
ligands, reversibly-bound ligands even of very high affinity will
dissociate during chromatographic, electrophoretic or other
procedures which could be used to isolate receptor protein.
Therefore, the ability to label the ligand binding site covalently
with a radiolabeled photoaffinity ligand has allowed significant
progress to be made toward characterisation of receptors. For
example, the nicotinic acetylcholine receptor a-subunit was
isolated and identified from Torpedo marmorata by the photoaffinity
ligand [3H]-p.-(dimethylamino)-benzenediazonium fluoroborate
(Dennis et al., 1988). Using [3H]flunitrazepam as a photoaffinity
ligand, the benzodiazepine receptor protein was identified and
visualised by electron microscopic autoradiography in rat brain
tissue (Mohler et al., 1980). Generally, photoaffinity ligands
contain diazo or azido groups, both of which lose nitrogen by
photoactivation. These intermediates, carbenes and nitrenes
3
from diazo and azido groups respectively, are extremely
unstable and react with the ligand binding site (Hanstein, 1979;
Fedan et al, 1984; Cavalla and Neff, 1985). These properties
are quite suitable for photoaffinity labelling studies. However
most diazo compounds are light sensitive and hydrolyzed or
attacked by nucleophiles such as CI- in acidic solution (Bayley
and Knowles, 1977). In addition some diazo compounds are
subject to photochemical Wolff rearrangements through ketene
intermediates (Bayley and Knowles, 1977). Thus chemical
instability and susceptibility to internal rearrangements has
made carbene precursors of limited use. The nitrenes show a
great deal of diversity in their reactions and some of their
reactions produce a ligand binding site covalent bond (Fig.1.1)
(Cavalla and Neff, 1985). Among azido compounds, arylazides
are most often chosen as photoaffinity ligands because they are
chemically stable in the absence of light and are less
susceptible to rearrangements than other nitrene precursors
(Bayley and Knowles, 1977; Hanstein, 1979). Therefore a
number of radiolabeled arylazides have been developed as
photoaffinity ligands. For example, 4-amino-6,7-dimethoxy-
2-{4-[5-(4-azido-3-[125|] iodophenyl)pentanoyl] -1 - p iperazinyl]
quinazoline (ai adrenergic receptor) (Leeb-Lundberg et al.,
1984), [3H]3-methyl-6-chloro-9-azido-1H-2,3,4,5-tetrahydro-
3-benzazepine (a2 adrenergic receptor) (Regan et al., 1986),
g_-azido-rrL-[125l]iodobenzylcarazolol (p adrenergic receptor)
(Lavin et al., 1982), [3H]-p_-azidoatropine methyl iodide




Fig. 1.1 The diversity in reactions of nitrenes. The azido group
loses nitrogen by photoactivation and produces nitrene.
Because of the extreme instability of nitrene, it shows a great
diversity in its reactions (routes a-e). While this may be an
advantage if the binding site is barren of a functional group that
will react with an alternative labelling agent, it is also a
disadvantage : only some of the reactions of nitrene will produce
a ligand-binding site covalent bond (routes a, b and e).
Rearrangement is one of the reactions that does not result in
photolabelling (Cavalla and Neff, 1985).
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1984), (±)-7-[i25|]jodo-8-hydroxy-3-methyl-1-(4-azidophenyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine (dopamine D-| receptor)
(Niznik et al., 1988) and [3H]azido-N-methylspiperone (dopamine
D2 receptor) (Niznik et al., 1986) have been used to elucidate the
molecular structure and characteristics of receptors.
The major purpose of the work presented in this thesis
was to develop suitable radiolabeled ligands in order to study
receptors for two CNS neurotransmitters, L-glutamate and
5-hydroxytryptamine.
1.2 GLUTAMATE
Glutamate is a major excitatory neurotransmitter in the
mammalian central nervous system (Fonnum, 1984). In 1961,
Curtis et al. reported that glutamate was capable of depolarising
spinal cord neurones in electrophysiological studies. During the
last 25 years, numerous studies demonstrated that glutamate
satisfies all criteria for an endogenous transmitter in the
mammalian CNS. The uptake of glutamate shows an absolute
requirement for sodium (Bennet et al., 1973). L-Glutamate and
D- and L-aspartate are taken up by the same uptake mechanism,
whereas apart from L-S-sulphocysteine no other endogenous
amino acid is taken up to any significant extent by this carrier
(Logan and Snyder, 1971; Balcar and Johnson, 1972; Griffiths et
al., 1992). Depolarisation methods such as high potassium
concentration and electric field stimulation evoke release of
glutamate from brain slices or synaptosome preparations in a
Ca2+-dependent manner (de Belleroche and Bradford, 1972;
Potashner, 1978; Nadler et al., 1977; Nicholls and Sihra, 1986).
6
Glutamine and 2-oxoglutarate are the important precursors for
glutamate synthesis. It has been shown that glutamine is an
excellent precursor for the releasable pool of glutamate
(Hamberger et al., 1979a,b). Glutamate is synthesised from
glutamine by phosphate-activated glutaminase, a mitochondrial
enzyme. In addition, glutamate is synthesised from
2-oxoglutarate by aspartate aminotransferase or ornithine
(^-aminotransferase (Fonnum,1984).
1.2.1 Glutamate Receptors
Glutamate receptors are categorised into two main groups
termed ionotropic and metabotropic receptors. lonotropic
glutamate receptors are ligand-gated ion channels named
corresponding to selective agonists, N-methyl-D-
aspartate (NMDA), DL-a-amino-3-hydroxy-5-methylisoxazole-4-
propionate (AMPA), kainate, and metabotropic receptors are
coupled to G-protein (Sladeczek et al., 1988; Monaghan et al.,
1989; Watkins et al., 1990) (Table1.1, Fig.1.2,1.3). Activation
of NMDA, AMPA and kainate receptors leads directly to opening
of ion channels with different permeabilities to Na+, K+ and Ca2+
ions (Mayer and Westbrook, 1987). The high permeability to
Ca2+ ions by activation of the NMDA receptor-gated ion channel
produces a large increase in intracellular Ca2+ concentration
which can modulate neuronal excitability (Ozawa et al., 1988).
The metabotropic receptors are coupled to multiple second
messenger systems that include increases in phosphoinositide
hydrolysis, activation of phospholipase D, decreases in cAMP
formation, increases in cAMP formation, and changes in ion
7
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Fig. 1.3 AMPA and kainate receptor agonists (a) and AMPA receptor
antagonists (b)
1 0
channel function (Sugiyama et al., 1987; Schoepp and Conn,
1993).
1.2.2 NMDA Receptors
The NMDA receptor is the best characterised excitatory
amino acid receptor subtype. Agonists such as L-glutamate and
NMDA, acting at the NMDA recognition sites, accelerate the
influx of Na+ and Ca2+ ions through the ion channel (MacDermott
et al., 1986). D-2-Amino-5-phosphonopentanoic acid (D-AP5)
(Davies and Watkins, 1982), 3-(2-carboxypiperazin-
4-yl)propyI-1 -phosphonic acid (CPP) (Harris et al., 1986) and
cis-4-phosphonomethyl-2-piperidine carboxylic acid
(CGS19755) (Murphy et al., 1988) act as competitive antagonists
at the NMDA receptor recognition sites (Fig.1.2). More recently,
the most potent competitive NMDA antagonists,
D-(E) -3- (2 -carboxypiperazin -4 -y I)- 1 - p ropenyl -1 -phosphoni c
acid (D-CPPene) (Aebischer et al., 1 989) and
DL-(E)- 2 -amino- 4-met hy I -5 -phosphono -3-penteno ic aci d
(CGP37849) (Fagg et al., 1990) were reported (Fig.1.2). In
contrast to D-AP5, CPP and CGS19755, CGP37849 and its
carboxyethylester analogue, CGP39551 (Fig.1.2) have significant
activity as an anticonvulsant following oral administration
(Fagg et al., 1990). Early ligand binding studies with
[3H]L-glutamate failed to label the NMDA receptor recognition
sites but use of a highly purified membrane preparation or
postsynaptic densities gave a successful labelling of the NMDA
receptor recognition sites by [3H]L-glutamate (Fagg and Matus,
1984; Monahan and Michel, 1987). On the other hand, the
radiolabeled competitive NMDA antagonists [3H]D-AP5
1 1
(Olverman et al., 1984; Olverman et al., 1988), pHjCPP (Olverman
et al., 1986) and [3H]CGS-19755 (Murphy et al., 1988) are highly
selective for the NMDA-sensitive receptors and useful for
labelling the NMDA recognition sites. Sills et al. (1991)
reported the radiolabeled 4-propyl analogue of CGP37849,
CGP 39653 (D,L-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic
acid) (Fig.1.2). [3H]CGP39653 is the first competitive
antagonist radioligand for the NMDA receptor that exhibits a Kd
value in the low nanomolar range (<10 nM). Autoradiographic
studies have shown differential distribution profiles in rat brain
between [3H]CPP and NMDA-sensitive [3H]L-glutamate binding
(Monaghan et al., 1988) and this has been interpreted to suggest
the existence of different states of NMDA receptors,
agonist-preferring and antagonist-preferring which may be
regulated by glycine (Monaghan and Buller, 1994).
Genes encoding two different NMDA receptor subunits have
been identified and cloned (Moriyoshi et al., 1991; Monyer et al.,
1992; Ishii et al., 1993). The NMDA receptor subunit NMDAR1
(NR1) is a protein of approximately 900 amino acid residues
(Moriyoshi et al., 1991). A second subunit NR2 is a large protein
of some 1500 amino acids designated NR2A, B, C and D (Monyer
et al., 1992; Ishii et al., 1993). By analogy with other ligand-
gated ion channel receptors such as GABA and nicotinic
acetylcholine, it is likely that the functional NMDA receptors




AMPA, a structural analogue of L-glutamate, is a potent
neuronal excitant when applied electrophoretically near central
neurons in the cat spinal cord (Krogsgaard-Larsen et al., 1980).
AMPA, quisqualate (Fig.1.3) and glutamate are potent inhibitors
of [3H]AMPA binding to rat brain membranes, whereas kainate
shows moderate inhibition, whereas NMDA is inactive (Honore et
al., 1982; Honore, 1989). The affinity of [3H]AMPA for its
binding site is stimulated by chaotropic ions (SCN-) (Honore and
Nielsen, 1985). Honore and Drejer (1988) have suggested that
the [3H]AMPA binding site can exist in two interconvertible
forms, and that the effect of SCN- is to promote formation of
the state for which [3H]AMPA has a higher affinity. Selective
AMPA receptor antagonists such as 6,7-dinitro-quinoxaline-
2,3-dione (DNQX), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX)
and 6-nitro-7-sulphamoyl-benzo(f)quinoxaline-2,3-dione (NBQX)
have been reported (Honore et al., 1988; Sheardown et al., 1990)
(Fig.1.3). These compounds inhibit [3H]AMPA binding to rat
cortical membranes in submicromolar concentrations. However
NBQX is the most selective, 32 times more potent in inhibiting
[3H]AMPA binding than [3H]kainate binding (Sheardown et al.,
1990). In addition, unlike DNQX and CNQX, NBQX has no or very
low affinity for the NMDA receptor and glycine site. Recently it
has been demonstrated that 6-(1 H-imidazol-1 -yl)-7-nitro-
2,3(1 H,4H)-quinoxalinedione hydrochloride (YM90K) (Fig.1.3) is a
selective antagonist for the AMPA receptor, being approximately
equipotent with NBQX (Ohmori et al., 1994).
1 3
1.2.4 Kainate Receptors
[3H]Kainate has been reported to bind to two populations of
sites with high and low affinity (Foster and Fagg, 1984).
L-Glutamate, kainate, domoiate (Fig.1.3) and quisqualate are
potent inhibitors of pHjkainate binding (London and Coyle, 1979;
Slevin et al., 1983). However domoiate binds preferentially to
low affinity kainate sites rather than to high-affinity kainate
receptors (Nielsen et al., 1992). In autoradiographic studies,
the regional distribution of high affinity pHjkainate binding
sites is unlike those of either AMPA or NMDA receptors, but
corresponds well to those brain locations such as hippocampus
and cortex that are highly vulnerable to the neurotoxic actions
of kainate (Young and Fagg, 1990).
Since a cDNA clone for a functional AMPA-kainate receptor
subunit was described (Hollmann et al., 1989), a growing family
of related subunits that form functional AMPA-kainate receptor
channel complexes has been identified. These subunits can be
subclassified into three groups according to their sequence
similarity and agonist selectivity. The first consists of four
subunits (GluFM, 2, 3, 4) and shows high affinity for AMPA
(Boulter et al., 1990; Keinanen et al., 1990), whereas the other
two groups represent two different kinds of the kainate
selective subunits (GluR5, 6, 7 and KA1, 2) (Bettler et al., 1990;
Egebjerg et al., 1991; Herb et al., 1992).
1.2.5 Metabotropic Glutamate Receptors
In contrast to ionotropic glutamate receptors (NMDA, AMPA
and kainate receptors), metabotropic glutamate receptors
(mGluR's) are coupled to cellular effectors via GTP-binding
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proteins. Molecular cloning studies have revealed the existence
of at least seven subtypes of mGluR's (mGluR1-7) (Abe et al.,
1992; Tanabe et al., 1992; Nakanishi, 1992; Okamoto et al.,
1994). The seven receptor subtypes can be subdivided into
three subgroups according to their sequence similarities :
mGluRI and mGluR5, mGluR2 and mGluR3, and mG!uR4, mGluR6
and mGluR7. The mGluRI and mGluR5 stimulate inositol
trisphosphate formation and intracellular Ca2+ mobilisation (Abe
et al., 1992; Nakanishi, 1992). In contrast, the other mGluR
subtypes inhibit the forskolin-stimulated accumulation of
intracellular cAMP in an agonist-dependent manner (Nakanishi,
1992; Schoepp and Conn, 1993; Okamoto et al., 1994).
Trans-1 -amino-1,3-cyclopentanedicarboxylic acid (trans-ACPD)
(Fig.1.4), a rigid analog of the extended structure of glutamate,
appears to be a selective mGluR agonist. Trans-ACPD
stimulates phosphoinositide hydrolysis with high efficacy in rat
brain slices (Palmer et al., 1989; Desai and Conn, 1990),
cultured striatal neurons and Xenopus oocytes that have
been injected with rat brain mRNA (Manzoni et al., 1990).
Trans-ACPD comprises a 50 : 50 mixture of 1S,3R-ACPD which
is the active constituent and 1R,3S-ACPD (Irving et al., 1990).
Other mGluR agonists that are relatively specific include
L-2-amino-4-phosphonobutanoate (L-AP4) and 2S,1'S,2'S-2-(2'-
carboxycyclopropyl)glycine (L-CCG-I), while quisqualate,
ibotenate and (2S,1'R,2'R,3'R)-2-(2,3-dicarboxycyclopropyl)
glycine (DCG-IV) have potent agonist activity at mGluRs but are
also highly active at ionotropic glutamate receptors (Ishida et
al., 1993; Schoepp and Conn, 1993) (Fig.1.4). However the



























Fig. 1.4 Metabotropic glutamate receptor agonists (a) and
antagonists (b)
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L-Glutamate and trans-ACPD are potent agonists for mGluR2/3
whereas quisqualate and L-AP4 are potent agonists for
mGluR1/5 and mGluR4 respectively (Nakanishi, 1992; Schoepp
and Conn, 1993). L-2-Amino-3-phosphonopropionate (L-AP3)
(Fig.1.4) is a potent and selective antagonist which lacks
appreciable affinity for ionotropic glutamate receptors (Schoepp
et al., 1990). Recently it has been reported that substances
structurally related to phenylglycine such as S-4CPG
(S-4-carboxyphenylglycine) (Fig.1.4) and MCPG ((RS)-a-methyl-
4-carboxyphenylglycine) (Fig.1.4) selectively antagonise the
depolarising responses produced by 1S.3R-ACPD in neonatal rat
motoneurones, with little or no effect on similar
depolarisations produced by the ionotropic glutamate receptor
agonists, NMDA and AMPA (Eaton et al., 1993). The mGluR's
are known to be implicated in physiological and pathological
processes including spatial learning (Richter-Levin et al., 1994)
and neuronal damage (Bruno et al., 1994). When injected
bilaterally into the lateral ventricles, MCPG disrupts the
performance of rats in a spatial learning version of the water
maze task in rats, indicating that activation of MCPG-sensitive
mGluR's is necessary for spatial learning (Richter-Levin et al.,
1994). DCG-IV, a potent agonist of mGluR2/3, protects
cultured cortical neurons against excitotoxicity induced either
by brief exposure to NMDA or a prolonged exposure to kainate,
suggesting a neuroprotective role for mGluR2 or mGluR3 against
excitotoxic neuronal death (Bruno et al., 1994).
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1.2.6 NMDA Receptor-Ion Channel
The NMDA receptor is a receptor-ion channel complex
whose functional activity is modulated by several regulatory
sites (Table 1.1, Fig.1.5). The dissociative anesthetics such as
phencyclidine (N-(1-phenylcyclo-hexyl)piperidine; PCP) (Fig.1.6)
(Honey et al., 1985) and an anticonvulsant dizocilpine ((+)-5-
methyl -1 0,11 -dihydro-5H-dibenzo[a,d]cyclohepten-5,1 0-imine;
MK-801) (Fig.1.6) (Wong et al., 1986) are non-competitive NMDA
antagonists which act by binding to the so-called PCP
recognition sites within the ion channel. Both PCP and MK-801
block the stimulation of Ca2+ influx by NMDA in cultured neurons
(Wroblewski et al., 1987; Yuzaki et al., 1990). L-Glutamate and
NMDA potentiate binding of [3H]MK-801 in rat cortical
membranes and an excellent correlation was shown between
stimulation of [3H]MK-801 binding and inhibition of
NMDA-sensitive L-[3H]glutamate binding by excitatory amino
acid agonists (Foster and Wong, 1987). An unusual feature of
the NMDA receptor is that it is inoperative when target cells are
in a resting state, as under such conditions of negative
intracellular membrane potential the NMDA receptor ion channel
is fully blocked by Mg2+ ions in a voltage-dependent manner and
this block is removed if the target cell is depolarised by
activation of non-NMDA receptors or other excitatory inputs
(Mayer et al., 1984; Collingridge and Singer, 1990). Ligand
binding studies demonstrate that the interaction of Mg2+ with
the [3H]MK-801 binding site is non-competitive as Mg2 +
increases the dissociation rate of [3H]MK-801, indicating that
Mg2+ sites are distinct from MK-801 binding sites (Reynolds and




Fig. 1.5 A proposed model for the NMDA receptor-ion channel
complex. The NMDA receptor gates a cation channel that is
permeable to Ca2+, Na+ and K+. The NMDA receptor-ion channel
is blocked by PCP, MK-801 and Mg2 + , and the complex is
regulated at modulatory sites by glycine, Zn2+ and polyamines.































Fig. 1.6 Non-competitive NMDA antagonists (a), glycine agonists
(b), glycine antagonists (c) and polyamine antagonists (d).
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arylalkylamine spider toxin, argiotoxin 636 may exerts an
inhibitory effect on [3H]MK-801 binding to rat brain membranes
by binding to the Mg2+ sites (Reynolds, 1991).
In addition to these recognition sites, there are at least
three other sites which regulate the NMDA receptor-ion channel
complex. Firstly, glycine is a positive modulator of the NMDA
receptor. Electrophysiological studies have shown that glycine
potentiates NMDA-induced responses via a strychnine-
insensitive mechanism in cultured cortical neurons (Johnson and
Ascher, 1987). Autoradiographic data have demonstrated a
similar anatomical distribution for NMDA-sensitive
[3H]L-glutamate and strychnine-insensitive [3H]glycine binding
(Bristow et al., 1986; Monaghan and Cotman,1985). It has been
shown that glycine can enhance binding of [3H]MK-801 and the
PCP analogue [3H]TCP; N-(1-thienyl)-cyclohexyl-3,4-piperidine)
(Fig.1.6) to rat brain membranes (Wong et al., 1987; Bonhaus et
al., 1987). Other monocarboxylic amino acids such as D-serine
and D-alanine, are agonists at the glycine site (Fig.1.6)
enhancing [3H]TCP binding and inhibiting [3H]glycine binding to
rat brain membranes with almost the same potency as glycine
(Snell et al., 1988). Kleckner and Dingledine (1988) have shown
that agonist occupation of both L-glutamate and glycine
recognition sites is required for NMDA receptor activation
indicating that glycine functions as a co-agonist. On the other
hand, (+)-3-amino-1 -hydroxypyrrolid-2-one ((+)HA-966) (Singh
et al., 1990), 7-chloro-kynurenic acid (7-CI-KA) (Kemp et al.,
1988), DNQX and CNQX (Kessler et al., 1989) are competitive
antagonists for the glycine recognition sites (Fig.1.6).
Recently, Foster et al. (1992) showed that 4-trans-2-carboxy-
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5,7- di chl oro - 4-phenyl ami nocarbonyl ami no- 1 ,2,3,4-
tetrahydroquinoline (L-689,560) (Fig.1.6) inhibits [3H]glycine
binding to rat brain membranes with an IC50 of 7.8 nM, being
substantially more potent than previous compounds such as
7-CI-KA and DNQX. In addition this compound displays a high
degree of selectivity for the glycine site, having ICso values of
>10 jiM in radioligand binding assays for AMPA and kainate
receptors and for the L-glutamate recognition site of the NMDA
receptor. The characteristics of [3H]L-689,560 binding to rat
brain membranes show a close correlation between the potency
of various drugs as inhibitors of [3H]glycine and [3H]L-689,560
binding (Grimwood et al., 1992). Most recently, Kulagowski et
al. (1994) reported that two other analogues of L-689,560,
7-chloro-4-hydroxy-3-[3-(phenoxy)phenyl]quinoli n-2-(1 H)-one
(L-701,324) and 7-chloro-4-hydroxy-3-[3-(3-thienyloxy)phenyl]
quinolin-2-(1 H)-one (L-705,022) are also highly potent and
selective glycine antagonists (Fig.1.6). L-701,324 and
L-705,022 inhibit [3H]L-689,560 binding to rat brain membranes
with an IC50 of 2.0 and 1.4 nM respectively, having no activity at
amino acid receptors labelled by [3H]AMPA, [3H]kainate and
[3H]strychnine at concentrations up to 100 pM. Both compounds
have potent anticonvulsant activity in the DBA/2 mouse model
with EDso values of below 1 mg/kg following i.p. and p.o.
administration, suggesting high oral bioavailability.
Secondly, the divalent cation Zn2+ has been shown to
prevent NMDA-induced channel activation in neurons in a
non-competitive fashion (Westbrook and Mayer,1987).
Biochemical studies of ligand binding have found that Zn2 +
dose-dependently inhibits both the rate of association and
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dissociation of [3H]TCP and [3H]MK-801 (Reynolds and Miller,
1988b; Yeh et al., 1990). Recently, it has been demonstrated
that a range of tricyclic antidepressants and phenothiazine
derivatives inhibit [3H]MK-801 binding and their actions may be
mediated by the zinc recognition sites (Reynolds and Miller,
1988a).
Finally, it has been reported that the naturally occurring
polyamine compounds such as spermidine and spermine increase
the binding of [3H]MK-801 and [3H]TCP to rat brain membranes
(Ransom and Stec, 1988; Sacaan and Johnson, 1990). Ransom
and Stec (1988) showed an additive effect of spermidine when
combined with maximally stimulating concentrations of
glutamate and glycine on [3H]MK-801 binding, indicating a
distinct site for the polyamines. Ifenprodil and SL820715
(( ± ) - a-(4-c hlorophenyl)-4-[(4 - fluorophenyl)met hy I ] - 1 -
piperidineethanol) (Fig.1.6), developed as potential cerebral
antiischaemic agents, have been suggested to exert these
effects via an interaction with the polyamine sites (Carter et
al., 1989; Carter et al., 1990). Although the polyamine site is
shown to be extracellular in fig.1.5, its location on the NMDA
receptor is still not clear. It has been shown that spermidine
and spermine enhance NMDA-induced currents in striatal and
hippocampal cultured neurones in electrophysiological studies
using whole cell patch-clamp recordings (Sprosen and Woodruff,
1990; Williams et al., 1990). Thus the NMDA receptor complex
has been shown to have at least six distinct modulatory sites.
Some investigators have demonstrated the labelling of the
NMDA receptor protein by photoaffinity ligands, azido analogues
of PCP and MK-801 (Haring et al., 1986; Sonders et al., 1990).
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The labelling of several polypeptides (Mr 90,000-95,000) has
been shown using [3H]meta-azido-PCP in rat brain membranes
(Haring et al., 1986). Sonders et al. (1990) reported that
[3H]3-azido-MK-801 labels a single protein band using guinea pig
brain membranes (Mr 120,000) and rat brain membranes
(Mr 115,000). The molecular size of the cloned NMDA receptor
subunit (NR1) (Mr 105,500) is consistent with that for the
polypeptide identified by [3H]3-azido-MK-801.
1.2.7 NMDA Receptor-mediated Physiological and Pathological
Processes
The NMDA receptor is known to be implicated in a number
of physiological and pathological processes such as long-term
potentiation (Artola and Singer, 1987), learning and memory
(Collingridge, 1987), ischaemic neuronal damage (Gill et al.,
1987; Boast et al., 1988) and in several CNS disorders such as
epilepsy (Meldrum, 1985), Huntington's disease (Foster et al.,
1985) and Alzheimer's disease (Greenamyre et al., 1987). Low
frequency transmission is mediated by glutamate acting
principally via AMPA receptors, since NMDA receptor operated
channels are blocked by Mg2 + . During high frequency
transmission the Mg2+ block is removed and Ca2+ enters neurones
via activated NMDA receptor channels (Collingridge and Singer,
1990). Long-term potentiation (LTP) in the CA1 region of the
hippocampus is a widely studied model of activity-dependent
change in synaptic efficacy. It is usually induced by a period of
high frequency stimulation and is manifest as an increase in the
size of the synaptic response evoked by low frequency
stimulation of the Schaffer collateral-commissural pathway
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(Collingridge et al., 1983). A brief high frequency stimulation
of presynaptic neurons facilitates synaptic efficacy at
postsynaptic neurons and this phenomenon can be observed to
last for several days (Bliss and Lomo, 1973). AP5 and PCP block
induction of LTP in the hippocampus, indicating that the NMDA
receptors are responsible for mediating LTP (Collingridge et al.,
1983; Stringer et al.,1983). Morris et al. (1986) demonstrated
that AP5 impairs spatial learning in rats in the water maze test
in addition to inhibiting LTP indicating that LTP may be closely
associated with certain forms of learning and memory.
PCP is a potent psychotomimetic agent that produces a
psychosis resembling schizophrenia. The similarity in
symptoms between the PCP-induced psychosis and schizophrenia
has led to the hypothesis that PCP is a better drug than
amphetamine for the study of schizophrenia (Allen and Young,
1978). PCP and MK-801 produce symptoms resembling the
action of high doses of amphetamine in experimental animals
(Freed et al., 1980; Clineschmidt et al., 1982). Tanii et al.
(1991) showed that intracerebro-ventricular injections of
agonists for the NMDA receptor glycine site, such as D-serine
and D-alanine, inhibit PCP-induced hyperactivity in rats.
Moreover it has been demonstrated that D-serine antagonises
PCP- and MK-801-induced stereotyped behaviour and ataxia in
rats (Contreras, 1990). These studies may indicate that
positive modulators of NMDA receptor function are a useful
supplement in the therapy of psychotic disorders
Brain neuronal degeneration may be a result of excessive
release of excitatory amino acids following ischaemia (Hagberg
et al., 1985). Short periods of cerebral ischaemia produce
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delayed neuronal death in the hippocampus of gerbils (Kirino,
1982). The hippocampal CA-i and CA2 pyramidal neurons are
most vulnerable to cerebral ischaemia and have a large number
of NMDA receptors (Monaghan and Cotman, 1985). It has been
shown that competitive NMDA receptor antagonists such as CPP
and CGS19755 protect against hippocampa! damage following
cerebral ischaemia in gerbils (Boast et al., 1988). The potent
non-competitive NMDA antagonist MK-801 is also effective in
the global ischaemia model in gerbils (Gill et al., 1987). In
addition, these NMDA receptor antagonists can protect against
selective neuronal loss in the CA-i region of hippocampus
following transient ischaemia in rats (Swan and Meldrum, 1990).
Recently it was suggested that the neuroprotective effect of
MK-801 in gerbils is due to drug-induced hypothermia rather
than NMDA receptor antagonism (Buchan and Pulsinelli, 1990).
However, Gill and Woodruff (1990) showed that MK-801 is still
efficacious in the gerbil global ischaemia model where core body
temperature is maintained at 37°C for 24 hr following
is'chaemia. These results suggest a substantial involvement of
NMDA receptors in delayed neuronal death in animal models. The
most widely used model of stroke is middle cerebral artery
(MCA) occlusion in rodents. MK-801 has been reported to reduce
ischaemic cortical damage in a rat MCA occlusion model (Park et
al., 1988). In the rat MCA occlusion model, a marked increase in
the extracellular concentrations of excitatory amino acids such
as L-glutamate and L-aspartate are observed in the brain during
and shortly after a period of transient ischaemia (Butcher et al.,
1990). These results indicate that the cerebroprotective effect
of MK-801 in the rat focal ischaemia model results from NMDA
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receptor antagonism. Electrophysiological and ligand binding
studies have demonstrated that MK-801 acts in a use-dependent
mode, i.e. the degree of NMDA receptor blockade is increased in
the presence of NMDA receptor agonists (Huettner and Bean,
1988; Foster and Wong, 1987). This property is expected to
give an advantage over competitive antagonists in that the drug
may show little blocking action on the physiological functions of
NMDA receptors but it may selectively block the NMDA receptor
ion channels under ischaemia conditions. Thus non-competitive
NMDA antagonists might be useful in the treatment of human
ischaemic neuropathologies.
Chapman et al. (1983) reported that [3H]2-amino-7-
phosphonoheptanoic acid (AP7), a potent competitive NMDA
antagonist, is taken up into mouse brain following
intraperitoneal injection and that the time course for the uptake
of AP7 parallels the period of anti-convulsant protection. The
characterisation of in vivo receptor binding with [3H]MK-801 in
the mouse brain was reported by Price et al. (1988a,b).
Furthermore it has been demonstrated that radioiodinated
[125|](+)-3-jodo-MK-801 may be useful as a radioligand for
in vivo imaging of the NMDA receptor complex (Gibson et al.,
1992).
Like MK-801, an isoquinoline derivative FR115427 ((+)-1-
methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride)
(Fig.1.7) is a novel non-competitive NMDA antagonist and has
antiischaemic and anticonvulsive effects in animals (Nakanishi
et al., 1994; Katsuta et al., 1995).
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Fig. 1.7 Chemical structure of FR115427 ((+)-1-methyl-1-
phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride)
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The aim of the work presented in chapter 2 was therefore
firstly to characterise FR115427 using in vitro [3H ] M K-801
binding to rat brain membranes, and secondly to synthesise and
purify [3H]FR115427 and to examine its in vivo distribution in
rats.
1.3 5-HYDROXYTRYPTAMINE (5±TQ
Rapport et al. (1947) reported the existence of a
vasoactive substance in serum. Shortly after, this substance
was identified as 5-HT (Rapport, 1949). Twarog and Page
(1953) demonstrated that 5-HT exists in mammalian brain. The
biosynthesis and metabolism of 5-HT follow the pathway shown
in fig.1.8. Tryptophan is converted into 5-hydroxytryptophan by
the action of tryptophan hydroxylase and then into 5-HT by
L-aromatic acid decarboxylase (Udenfriend et al., 1953;
Freedland et al., 1961). Degradation of 5-HT occurs mainly by
metabolism by monoamine oxidase and subsequent
transformation of the aldehyde by aldehyde dehydrogenase into
5-hydroxyindoleacetic acid (5-HIAA) (Leeper et al., 1958; Smith
and Wortis, 1960). Under normal physiological conditions,
tryptophan hydroxylase may only be half saturated (Carlsson and
Lindqvist, 1972). Consequently, changes in the levels of its
substrate, tryptophan, will trigger alterations in 5-HT synthesis
and metabolism. Tryptophan circulates in the blood in free form
(normally 10-20%) and albumin-bound form (McMenamy et al.,
1957) and is taken up into the brain by a saturable and
stereospecific carrier which also transports other large neutral




























Fig. 1.8 Biosynthesis and metabolism of 5-HT
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cerebrum (Fernstrom and Wurtman, 1972; Pardridge, 1977).
Exocytotic release of 5-HT is regulated by processes such as
synthesis of 5-HT and neuronal firing rate. For example,
pretreatment with the tryptophan hydroxylase inhibitor
^.-chlorophenylalanine (PCPA) decreases p.-chloroamphetamine
(PCA)-induced 5-HT release in striatum (Marsden et al., 1979).
Electrical stimulation of raphe nuclei, where serotonergic cell
bodies are located, accelerates the release of 5-HT from nerve
terminals (Marsden et al., 1979; Hery and Ternaux, 1981).
1.3.1 5-HTi Receptors
Evidence for the existence of serotonergic receptors was
first presented by Gaddum and Picarelli (1957). They described
two types of receptors (D and M receptors) controlling muscle
contraction in order to account for two distinct effects of 5-HT
in isolated guinea pig ileum. The classification and
identification of multiple 5-HT receptors has been largely based
on radioligand binding studies (Table 1.2) but more recently,
really, superceded by molecular biological data (Humphrey et al.,
1993). 5-HT receptors were first classified as 5-HTi and 5-HT2
by Peroutka and Snyder (1979). 5-HTi sites are labelled by
[3H]5-HT with nanomolar affinity, whereas 5-HT2 sites are
labelled by [3H]spiroperidol in rat cortical membranes. The
5-HTi receptor was subdivided further into 5-HTia (high affinity
for spiroperidol) and 5-HTib (low affinity for spiroperidol)
(Pedigo et al., 1981).
5-HTia receptors have been more selectively labelled with
[3H]8 -hydroxy- 2 - (di - n-propylami no) -t et r a li n(8-OH- DPAT)
(Fig.1.9) (Hall et al., 1985). The receptor binding profile shows
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Fig. 1.9 5-HTi and 5-HT2 agonists (a) and antagonists (b)
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that 8-OH-DPAT displays high affinity for central 5-HTia
receptors and weak or negligible affinity for other 5-HT
receptor subtypes. Another class of 5-HTiA-active compounds
are the pyrimidinyl-piperazines such as buspirone and ipsapirone
(Fig.1.9) (Traber and Glaser, 1987). In contrast to buspirone,
ipsapirone displays weak affinity for dopamine D2 receptors.
5-HTia receptors are highly localised in hippocampus and
cerebral cortex and also in the raphe nuclei which contain
serotonergic cell bodies (Pazos and Palacios, 1985; Waeber et
al., 1989). In raphe nuclei, the 5-HTia receptors act as
somatodendritic autoreceptors regulating the firing of
serotonergic neurons. 5-HTia agonists such as buspirone and
ipsapirone have anxiolytic properties in man (Goldberg and
Finnerty, 1979; Glaser, 1988). The effect of buspirone is
probably to decrease 5-HT function because administration of
buspirone decreases raphe cell activity (Van der Maelen and
Wilderman, 1984). The selective 5-HTia receptor ligand shown
to display unequivocal 5-HTia receptor antagonist properties at
both presynaptic and postsynaptic 5-HTia receptors is
N- tert-butyl-3-4(2-methoxy-phenyl-piperazin- 1 - y I - 2-
phenylpropanamide dihydrochloride (WAY-100135) (Fig.1.9)
(Fletcher et al., 1991; Jones and Haskins, 1991). WAY-100135
has high affinity for the 5-HTia binding site (ICso = 34 nM) and
shows at least 70-fold selectivity against other 5-HT,
noradrenergic and dopaminergic sites (Fletcher et al., 1991).
Anxiolytic properties of WAY-100135 have been demonstrated in
the mouse light/dark box model of anxiety and in the rat
potentiated acoustic startle model (Fletcher et al., 1992a,
1992b). Recently, Fletcher et al. (1994) reported that N-(2-
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(4- (2 - m et hoxy phenyl )-1-piperazinyl)ethyl)-N-(2-pyridyl)
cyclohexane-carboxamide trihydrochloride (WAY-100635)
(Fig.1.9) is a new selective 5-HTia receptor antagonist with
higher affinity than WAY-100135.
5-HTib sites are labelled with p25|]jodo-cyanopindolol in
the presence of isoprenaline to block p-adrenergic receptor
sites (Hoyer et al., 1985). Selective pharmacological tools to
characterise 5-HTib receptors are not yet available. The 5-HTib
receptor subtypes are observed in rat and mouse brain but not in
human brain (Pazos and Palacios, 1985; Hoyer et al., 1985;
Martial et al., 1989). The highest density of 5-HTib receptors
has been found in substantia nigra, globus pallidus, dorsal
subiculum and superior colliculi. A major function of the
5-HTib receptors is the control of 5-HT release from the
serotonergic neuron terminals (Engel et al., 1986). 5-HTib
receptors are also located on nonserotonergic terminals where
they inhibit the release of other neurotransmitter such as
acetylcholine and dopamine (Maura and Raiteri, 1986; Benloucif
and Galloway, 1991). Thus 5-HT-ib receptors may play an
important role in the control of CNS function by modulating the
release of neurotransmitters.
On the basis of [3H]5-HT binding studies with bovine brain
in the presence of drugs masking 5-HTia, ib and ic subtypes, the
existence of the 5-HTid receptor subtype was proposed by
Heuring and Peroutka (1987). Human genes encoding two
5-HTid receptor subtypes, 5-HTiD«and 5-HTidp, have been
described and the 5-HTi Dp receptor has been shown to exhibit
very high sequence homology (93% overall; 96% in the
transmembrane regions) with the rodent 5-HTib receptor but
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5-HTiDpand 5-HTib receptors exhibit completely different
pharmacological profiles (Adham et al., 1992). A single amino
acid substitution of Thr to Asn at position 355 in the seventh
transmembrane region accounts for the profound differences in
pharmacology displayed by these two receptors (Parker et al.,
1993). GR43175 (3-(2-dimethylamino)ethyl-N-methyl-1 H-
indole-5-methane- sulfonamide, sumatriptan) (Fig.1.9) has been
reported as one of the most selective agonists for 5-HTid sites
although this drug recognises 5-HTib sites with a similar
affinity and 5-HTia sites with a slightly lower affinity
(Peroutka and McCarthy, 1989). Since sumatriptan has an
antimigraine effect in human, the 5-HTid receptor may prove to
be an important target in the acute treatment of migraine
(Doenicke et al., 1988). Recently, N-(4-methoxy-3-(4-methyl-
1 -piperazinyl)phenyl)-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-
3-y I) (1,1 -bipheny!)-4-carboxamide (GR127935) (Fig.1.9) has
been identified as a very potent and selective 5-HTid receptor
antagonist (Skingle et al., 1993). GR127935 inhibits binding
to 5-HTid receptor (pKi 8.5) and shows low or moderate affinity
at 5-HTia (6.9), 5-HTic (6.4) and 5-HT2 receptors (6.6), and
antagonises sumatriptan-induced contractions in dog basilar
arterial rings (Skingle et al., 1993).
5-HTic sites were initially identified using [3H]5-HT,
[3H]mesulergine and [3H]lysergic acid diethylamide (LSD) (Pazos
et al., 1985). As in the case of 5-HTib receptors, truly
selective 5-HTic ligands have not yet been reported. The
serotonergic drugs that are antagonistic at 5-HT2 receptors
generally are also recognised by 5-HTic sites with high affinity.
The most frequently used 5-HTic ligand is mesulergine (Fig.1.9)
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which has a high affinity for 5-HTic, 5-HT2, and D2 receptors.
It has been demonstrated that there is a high concentration of
5-HTic receptors in the choroid plexus of pig and humans (Pazos
et al., 1985; Hoyer et al., 1986b). Pazos et al. (1985) suggested
that 5-HTic sites may play a role in the regulation of
cerebrospinal fluid (CSF) production and in cerebral circulation
because the main physiological role of the choroid plexus is the
control of the volume and composition of CSF. In rats, several
in vivo responses to the putative 5-HTic receptor agonist, 1-(3-
chlorophenyl)piperazine (mCPP) (Fig.1.9) have been suggested to
be mediated by 5-PITic receptor activation. These include
mCPP-induced hypolocomotion (Kennett and Curzon, 1988a),
hypophagia (Kennett and Curzon, 1988b) and anxiety (Kennett et
al., 1989). In addition it has been reported that mCPP produces
anxiety in healthy volunteers and to a greater extent in patients
with either panic disorder or obsessive compulsive disorder
(Kennett, 1993). Therefore specific 5-HTic receptor antagonists
may be anxiolytics.
5-FITie and 5-HTif receptor cDNAs have been cloned and the
recombinant proteins classified as 5-HT1 receptor subtypes on
the basis of their amino acid homology and their negative
coupling to adenylyl cyclase in cell lines (Amlaiky et al., 1992;
Adham et al., 1993).
1.3.2 5-HT2 Receptors
5-HT2 binding sites have been characterised by the first
potent and still most frequently used agent, [3H]ketanserin
(Fig.1.9) (Leysen et al., 1982). There is growing evidence that
blockade of 5-FIT2 receptors improves schizophrenic symptoms
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and that 5-HT systems are involved in its pathogenesis. A
selective 5-HT2/5-HT1 c receptor antagonist, ritanserin (Fig.1.9),
either alone or in combination with a neuroleptic, reduces
negative symptoms in patients with schizophrenia (Gelders et
al., 1986). Silver et al. (1989) reported that the mixed
5-HT1/5-HT2 antagonist, cyproheptadine (Fig.1.9), is effective in
alleviating both positive and negative symptoms in an open pilot
study. These beneficial effects of the 5-HT receptor antagonist
in schizophrenia may suggest that 5-HT receptor function is
altered in some schizophrenic patients.
Recently 5-HT2 receptors have been sub-classified into
5-HT2A, 5-HT2B and 5-HT2C receptor subtypes (Humphrey et al.,
1993). The 5-HT2A receptor subtype refers to the classical
5-HT2 receptor. The 5-HT2B mRNA transcript has been identified
in rat stomach fundus (Foguet et al., 1992) and in the small
intestine, kidney, heart and cerebellum of the mouse (Loric et
al., 1992), but not in rat brain (Foguet et al., 1992). The 5-HTic
receptor is now recognised as belonging to the 5-HT2 receptor
family on the basis of marked amino acid sequence homology
(Saltzman et al., 1991) and also because it is coupled to
phospholipase C rather than to adenylate cyclase. Therefore the
5-HTic receptor has been renamed as the 5-HT2C receptor.
(N-(1 - methyl - 5 - indolyI)-N'- (3-py ridyl)urea hydrochloride
(SB200646A) (Fig.1.9) is the first reported antagonist with
selectivity for the 5-HT2C over the 5-HT2A receptor (Forbes et
al., 1993). It shows 50-fold selectivity for the 5-HT2C over the
5-HT2A receptor, and 80-fold or greater selectivity over other
neurotransmitter receptors tested (Forbes et al., 1993; Kennett
et al., 1994). However SB200646A is also equipotent at the
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5-HT2B receptor in rat stomach fundus. This compound can
block mCPP-induced hypolocomotion, hypophagia and
anxiogenesis, indicating that 5-HT2C/2B receptor blockade
induces anxiolysis (Kennett et al., 1994).
1.3.3 5-HT3 Receptors
5-HTi-like receptors have been found to modulate
adenylate cyclase activity (Bouhelal et al., 1988; De Vivo and
Maayani, 1986; Schoeffter et al., 1988), whereas 5-HT2
receptors stimulate phosphatidyl inositide hydrolysis (Conn and
Sanders-Bush,1984; Hoyer et al., 1988). In contrast, the 5-HT3
receptor, formerly the classical M-type receptor of Gaddum and
Picarelli (1957), appears to be directly linked to a cation
channel selectively permeable K+ and Na+(Derkach et al., 1989).
Specific 5-HT3 binding sites in the CNS were initially
demonstrated by Kilpatrick et al. (1987) using [3HJGR65630
(3-(5-methyl-1H-imidazol-4-yl)-1 - (1-methyl-1 H-indol-3-yl)-
1-propanone) (Fig.1.10). Since the first published 5-HT3
antagonist, 1-aH-3a-5aH-tropan-3-yl-3,5-dichlorobenzoate
(MDL72222), many potent 5-HT3 antagonists such as
(3-a-tropanyl)1 H-indole-3-carboxylic acid ester (ICS205-930,
tropisetron), (endo-N-(9-methyl-9-azabicyclo[3.3.1 ]non-3-yl)-
1 -methyl-imidazole-3-carboxamide (BRL43694, granisetron),
4-amino-N-(1 -aza-bicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxy-
benzamide (zacopride) and (±)-1,2,3,9-tetrahydro-9-methyl-
3[(2-methyl - 1H- imidazol - 1-yl)methyl]-4H- carbazol - 4- o ne
(GR38032, ondansetron) have been reported (Watling, 1988)
(Fig.1.10). These compounds display subnanomolar affinity for
5-HT3 receptors, whereas affinity for other 5-HT receptor
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Fig. 1.10 5-HT3 and 5-HT4 agonists and antagonists
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subtypes is negligible. The regional distribution of 5-HT3
receptors in the CNS has been studied in various species such as
mouse, rat, ferret, rabbit and human brain (Kilpatrick et al.,
1987, 1989; Barnes et al., 1989). These studies have
demonstrated that 5-HT3 receptors occur in various brain
regions such as entorhinal cortex, frontal cortex, hippocampus
and thalamus. The highest density of 5-HT3 receptors is
observed in the area postrema which is involved in the emesis
mechanism. Clinical studies have established that 5-HT3
antagonists are potent inhibitors of cytotoxic drug-induced
vomiting in humans (Leibundgut and Lancranjan, 1987;
Carmichael et al., 1988; Miln and Heel, 1991). Costall et al.
(1990) proposed that 5-HT3 receptors in the brain contribute to
the control of behaviour. For example 5-HT3 antagonists can
inhibit the hyperactivity caused by the infusion of dopamine into
the limbic areas of rat and marmoset brain and have anxiolytic
properties in experimental anxiety models such as the social
interaction test and the light/dark exploration test (Costall et
al., 1987; Costall et al, 1989; Tyers et al., 1987).
1.3.4 5-HT4 Receptors
The existence of an additional 5-HT receptor, the 5-HT4
receptor, which is positively coupled to adenylyl cyclase
activity was demonstrated in primary neuronal cell cultures of
mouse embryo colliculi (Dumuis et al., 1988). Dumuis et al.
(1988, 1989, 1991) showed that 5-methoxy-tryptamine, cis-4-
amino-5-chloro-N-{1 -[3-(4-fluoro-phenoxy)propyl]-3-methoxy-
4-piperidinyl}-2-methoxybenzamide (cisapride), zacopride and
(endo-N-8-methyl-8-azabicyclo[3.2.1 ]oct-3-y l)-2,3-dihydro-3-
41
i sop ropy I-2-oxo-1 H-benzimidazol-1 -carboxamide hydrochloride
(BIMU8) (Fig.1.10) have 5-HT4 receptor agonist activity. Until
recently, the only 5-HT4 receptor antagonist was ICS205-930, a
5-HT3 antagonist with a relatively low affinity and poor
selectivity for the 5-HT4 receptor (Craig and Clarke, 1990). It
has been shown that the benzamide derivative, 2-methoxy-
4-amino-5-chloro-benzoic acid 2-(diethylamino)ethylester
(SDZ205557) and the benzimidazolone derivative, endo-6-
methoxy-8-methyl-8- azabicyclo[3.2.1 ]oct3-y I-2 ,3-d ihydro-2-
oxo-1 H-benzimidazole-1 carboxylate hydrochloride (DAU6285)
(Fig.1.10) are more potent and selective antagonists for 5-HT4
receptors in comparison with ICS205-930 (Buchheit et al., 1991;
Dumuis et al., 1992). In 1993, Grossman et al. developed a
radioligand for 5-HT4 receptors using the indole derivative,
[1 -[2-[(methylsulphonyl-amino)ethyl]-4-piperidinyl]methyl -1 -
methyl-1 H-indole-3-carboxylate (GR113808) (Fig.1.10), a highly
potent and selective 5-HT4 antagonist. Specific pH]GR1 13808
binding in homogenates of guinea-pig striatum and hippocampus
is potently and stereoselectively inhibited by agonists and
antagonists acting at the 5-HT4 receptor but not by compounds
selective for other 5-HT receptors or other neurotransmitter
receptors. Autoradiographic studies using [3H]GR113808 in
guinea-pig and rat brain showed a discrete localisation with
high concentration of binding in brain areas such as striatum,
substantia nigra and olfactory tubercle.
1.3.5 Other 5-HT Receptors
Genes encoding two putative 5-HT receptors, 5-HTsa and
5-HT5B, have been isolated from mouse and rat cDNA libraries
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(Plassat et a!., 1992; Erlander et al., 1993; Matthes et al., 1993).
The proteins encoded by these genes possess all the features of
a seven transmembranes, G-protein coupled receptor, but no
second messenger system has yet been identified.
Experiments hybridising 5-HTsa mRNA show its localisation in
the cortex, hippocampus and hypothalamus. 5-HTsb receptor
mRNA has been found only in the habenula and CA1 field of the
hippocampus. A 5-HT6 receptor gene has been recently cloned
from a rat cDNA library (436 amino acids) (Monsma et al., 1993;
Ruat et al., 1993a). This receptor exhibits poor structural
homology with other 5-HT receptors (<40%). Although it is
positively linked to cAMP formation and in this respect
resembles the 5-HT4 receptor, the pharmacological profiles of
these two receptors are very different. In situ hybridization
studies indicate a concentration of the 5-HT6 receptor message
in the striatum, olfactory tubercle, cortex and hippocampus.
The 5-HT7 receptor is the most recent receptor to have been
characterised, the gene having been cloned from rat (448 amino
acids) and mouse (448 amino acids) cDNA libraries (Ruat et al.,
1993b; Plassat et al., 1993). This receptor couples to the
activation of adenylate cyclase like the 5-HT4 and 5-HT6
receptors. In brain, mRNA is particularly well represented in
the thalamus, hippocampus and discrete regions of the limbic
system.
1.3.6 5-HT Transporter
5-HT is concentrated in neurons by two transport
processes. One is a re-uptake process which acts to terminate
the action of 5-HT released from presynaptic nerve terminals,
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and the other is part of the storage process in the synaptic
vesicles (Kannengiesser at al.,1973). The neuronal plasma
membrane transporter for 5-HT is functionally dependent on the
transmembranal electrochemical gradients generated by the
ouabain sensitive Na+/K+ ATPase (Tissari et al., 1969;
Bogdanski et al., 1979). Many studies on the plasma membrane
5-HT transport have been carried out using platelets because
blood platelets are considered to accumulate and store 5-HT in a
manner similar to that occurring in serotonergic nerve terminals
(Pletscher, 1968; Stahl, 1977). In particular, the use of
plasma membrane vesicles prepared from platelets has
contributed towards the understanding of the mechanism of
5-HT transport since experimental work can be carried out with
this preparation in the absence of intracellular events such as
storage and metabolic enzymes. Studies with platelet plasma
membrane vesicles provided direct evidence that 5-HT is
accumulated only when appropriate Na+/K+ gradients are
constructed (Rudnick, 1977; Talvenheimo et al., 1979).
Accumulation of 5-HT by platelet plasma membrane vesicles
under physiological conditions (high internal K+. low internal
Na + ) suggests that 5-HT is actively transported into intact
platelets prior to uptake into storage organelles. In this
system, ouabain does not inhibit 5-HT transport, indicating that
5-HT uptake is not directly coupled to the Na+/K+ ATPase. On
the other hand, uptake is inhibited strongly by tricyclic
antidepressants and by ionophores such as gramicidin which
catalyze transmembrane exchange of Na+ and K+ dissipating the
transmembrane ionic gradients (Rudnick, 1977). In addition,
5-HT transport is absolutely dependent on the presence of
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external Na+and CI- (Rudnick, 1977; Nelson and Rudnick, 1982).
From these studies using platelet plasma membrane vesicles, a
model for the translocation cycle of the 5-HT transporter was
proposed (Rudnick, 1977; Rudnick and Nelson, 1978; Nelson and
Rudnick, 1982). In the first step of the cycle 5-HT, Na+ and Cl-
bind to the transporter on the extracellular side and then they
are translocated to the cytoplasmic surface where they
dissociate. K+ binds to the cytoplasmic side of the transporter
and is translocated to the exterior side and the cycle is
completed when K+ dissociates (Fig.1.11). Studies with plasma
membrane vesicles from mouse brain showed that the
pharmacology of the 5-HT transporter corresponds well with
that reported for rat brain synaptosomes (O'Reilly and Reith,
1988). Amine uptake in brain vesicles is driven by a Na+
gradient ([Na+]out > [Na+]in) and a K+ gradient ([K+]in > [K+]out).
External Na+ cannot be replaced by Li+, K+ or sucrose, and
external CI- gives higher uptake than NO2 - or S2O2-3. In addition,
internal K+ cannot be replaced by Li+ or sucrose. Thus the
mechanism for 5-HT uptake proposed by studies using plasma
membrane vesicles from mouse brain is similar to that for the
corresponding amine transporter in platelets (O'Reilly and Reith,
1988; Reith et al., 1989).
The uptake of 5-HT into the storage vesicle occurs by the
operation of two sequential processes (Toll and Howard, 1978;
Johnson and Scarpa, 1979). First, a vacuolar ATP-driven H+
pump generates an electrochemical gradient across the vesicular
membrane for H+ (inside > outside). The subsequent coupling of
protons to the 5-HT transporter then provides the energy for
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Fig. 1.11 Model for translocation cycle of the 5-HT transporter.
In the first step of 5-HT uptake in the platelets, 5-HT, Na+ and
CI- bind to the transporter (To) on its exterior plasma membrane
side and then they are translocated across the membrane. Upon
dissociation of this complex at the cytoplasmic side of the
membrane, the binding of K+ to the transporter (Ti) serves to
reorientate the 5-HT binding site to the extracellular membrane
surface, (adapted from Graham and Langer, 1990)
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from the movement of H+ ions down their electrochemical
potential gradient. Therefore this transporter functions in an
antiport configuration as 5-HT is taken up into the storage
vesicle in exchange for H+ ion extrusion. 5-HT accumulation is
dependent on both a transmembrane pH difference (ApH) and a
transmembrane electrical potential difference (AY) (Rudnick and
Clark, 1993). Because the amine substrate is exchanged for
the equivalent of two H+ ions, a 10-fold H+ concentration
gradient (one pH unit) will lead to a 100-fold gradient of
substrate. The vesicular monoaminergic uptake system is
inhibited by reserpine which binds at the site of amine
recognition with a Ki value in the subnanomolar range (Scherman
and Henry, 1984; Darchen et al., 1989). The vesicle transport is
relatively non-selective and appears to be the same in all amine
storage organelles.
1.3.7 5-HT Uptake Inhibitors
Inhibition of amine uptake into serotonergic and
noradrenergic terminals is a pharmacological characteristic of
the tricyclic antidepressants such as imipramine and
chlorimipramine (Fig.1.12) (Kannengiesser et al., 1973;
Richelson and Pfenning, 1984). In addition, a deficit in
serotonergic neurotransmission has been implicated in the
aetiology of clinical depression (Goodwin and Post, 1983).
Therefore, during the past two decades a number of
pharmaceutical companies have developed potent and selective
5-HT uptake inhibitors (SSRI's) as new antidepressant drugs, the
most widely used drug being prozac (fluoxetine) (Fig.1.12).
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Fig. 1.12 5-HT uptake inhibitors
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(Fig.1.12) have revealed that they are as effective as the
tricyclic antidepressants and are devoid of the undesirable
side-effects such as nausia, dry mouth and cardiac toxicity seen
with tricyclic antidepressant treatment (Pedersen et al.,1982;
Benfield et al., 1986; Milne and Goa, 1991). Other possible
applications for SSRI's include their use in the treatment of
obesity and alcoholism. Preliminary studies have indicated that
fluoxetine leads to reductions in body weight in nondepressed
obese human patients (Ferguson, 1986). In addition, citalopram
has been shown to decrease alcohol consumption in nondepressed
heavy drinkers (Naranjo et al., 1987), and it is interesting to
note that fluoxetine has been claimed to enhance memory
processing in certain animal models (Flood and Cherkin, 1987).
In initial studies [3H]imipramine (Fig.1.12) was used to
label the 5-HT transporter (Langer et al., 1980a, 1980b).
Recently more selective 5-HT uptake inhibitors such as
[3H]citalopram (D'Amato et al., 1987a), [3H]paroxetine (Habert et
al., 1985), [3H]norzimelidine (Hall et al., 1982) and [3H]indalpine
(Benavides et al., 1985) were utilised to label 5-HT uptake sites
in brain (Fig.1.12). In autoradiographic studies, the distribution
patterns of [3H]paroxetine and [3H]citalopram binding in rat brain
are consistent with the organisation of serotonergic terminals
and cell bodies (DeSouza and Kuyatt, 1987; Hrdina et al., 1989;
D'Amato et al., 1987a). The effects of various 5-HT uptake
inhibitors on transport of tritiated amine (5-HT, noradrenaline
(NA), dopamine (DA)) into rat brain synaptosomes were compared
by Hyttel (1982). Paroxetine (ICso = 0.31 nM), chlorimipramine
(IC so = 1.5 nM)(Fig.1.11), citalopram (ICso = 1.8 nM), indalpine
(ICso = 2.4 nM) and fluoxetine (ICso = 6.9 nM) are among the most
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potent 5-HT uptake inhibitors. Citalopram is the most selective
of the SSRI's showing a much greater ratio (ICso for NA / ICso
for 5-HT) than other compounds. Most 5-HT uptake inhibitors
are devoid of an inhibitory effect on amine uptake into
dopaminergic neurones. Radioligand binding studies showed
that paroxetine and citalopram have little affinity for ai,oc2 or (3
adrenoceptors, dopamine (D2), 5-HTi, 5-HT2 or histamine (Hi)
receptors at concentrations below 1 fiM (Thomas et al., 1987).
Paroxetine has weak affinity for muscarinic receptors (Ki =
89 nM) whereas citalopram (Ki = 2900 nM) is much less potent.
Thus while citalopram is the most selective 5-HT uptake
inhibitor, paroxetine is the most potent uptake inhibitor.
Administration of paroxetine and citalopram at doses up to
5 mg/kg, p.o. and 10 mg/kg, i.p. respectively produces a
dose-related inhibition of [3H]5-HT uptake into rat brain
synaptosomes ex vivo with little effect on [3H]NA uptake (Hyttel,
1982; Thomas et al., 1987). In addition, both compounds can
prevent the reduction of rat brain 5-HT content by 5-HT
depleting drugs such as PCA. These observations indicate 5-HT
uptake blockade in vivo by paroxetine and citalopram. It has
been demonstrated that [3H]paroxetine and [3H]citalopram are
selective agents for in vivo labelling of cerebral 5-HT uptake
sites (Scheffei and Hartig, 1989; Scheffel and Ricaurte, 1990;
Hume et al., 1991). Therefore paroxetine and citalopram might
be potentially useful prototype molecules for the development of
SPET ligands for the 5-HT transporter in serotonergic neurones.
It has been proposed that [3H]2-nitroimipramine may be a
valuable tool for isolation and subsequent purification of the
5-HT transporter site since this ligand has a higher specific
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activity and a higher affinity than [3H]imipramine in human
platelets and rat brain membranes, having an extremely slow
dissociation rate (t-1/2 > 30 hr) when incubations are carried out
at 0-4°C (Rehavi et al., 1982). Rotman and Pribluda (1982)
showed that a photoaffinity ligand for the 5-HT transporter,
[3H]azidoimipramine, binds covalently to guinea-pig brain
synaptosomes and platelets. Studies with more selective
compounds than imipramine, such as paroxetine and citalopram,
could provide more suitable photoaffinity ligands for isolating
the 5-HT transporter.
The aim of the work presented in chapter 3 was therefore
to examine the possibility of using citalopram derivatives as
photoaffinity and SPET ligands for the 5-HT transporter.
A reduction of cortical and hippocampal [3H]imipramine
binding site densities has been reported in suicide and
depression using post-mortem human brain (Stanley et al., 1982;
Perry et al., 1983). On the other hand, the binding of
[3H]imipramine has been reported to be unchanged in post¬
mortem human brain from suicide victims with a clinical history
of depression (Owen et al., 1986). In addition, it has been
reported that there is no significant difference in [3H]paroxetine
binding site density in post-mortem human brain from depressed
suicides compared with controls (Lawrence et al., 1990).
D'Amato et al. (1987b) reported a reduction in [3H]citalopram
binding site density in post-mortem human brain with
Alzheimer's disease (AD) and Parkinson's disease without a
change in the affinity of the ligand for the remaining
transporters. Thus [3H]citalopram and [3H]paroxetine appear to
be useful tools for studies of the 5-HT transporter in
post-mortem human brain with various CNS disorders. On the
other hand, Middlemiss et al. (1986) showed that a loss of
[3H]8-OH-DPAT binding sites is observed in frontal cortex from
post-mortem AD brain in comparison with normal brain,
suggesting that 5-HTia receptors are reduced in AD as well as
5-HT uptake sites. However in general it is not clear whether
these changes of serotonergic neurones are specific since
non-specific neuronal loss is observed in neurodegenarative
disorders such as AD.
The aim of the work presented in chapter 4 was to examine
the neuronal location of 5-HTia receptors using [3H]8-OH-DPAT
and 5-HT uptake sites using [3H]citalopam in rat forebrain
following cholinergic and serotonergic lesions.
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CHAPTER 2
CHARACTERISATION OF THE NMDA RECEPTOR ANTAGONIST,
FR115427
2.1 INTRODUCTION
Non-competitive NMDA antagonists such as POP, TCP and
MK-801 have been used to develop in vitro ligand binding assays
that effectively monitor the state of activation of the NMDA
receptor linked ion channel. Studies of [3H]MK-801 and [3H]TCP
binding to rat brain membranes showed that MK-801 is the most
potent inhibitor in comparison with other PCP-like compounds
(Wong et al., 1988). PCP and TCP interact with other sites such
as the haloperidol-sensitive sigma receptor and dopamine
reuptake sites with lower affinity than for the PCP recognition
sites in the NMDA receptor ion channels (Wong et al., 1988;
Rothman et al., 1989). However, the affinity of MK-801 for the
sigma receptor and dopamine reuptake sites is much lower than
those of PCP and TCP. Thus MK-801 is the most potent and
selective non-competitive NMDA antagonist among a number of
the well-known PCP-like compounds. For these reasons,
[3H]MK-801 has been most commonly used for studying the NMDA
receptor linked ion channels. [3H]MK-801 binding sites in rat
brain membranes are heat-labile, stereoselective and regionally
specific (Wong et al., 1986). As described in chapter 1,
[3H]MK-801 binding is modulated by various compounds such as
L-glutamate, glycine, Zn2+ and polyamines, acting at distinct
recognition sites. Recently, Bakker et al. (1991) reported
binding of [3H]MK-801 to a gel filtered (to remove endogenous
compounds) rat brain membrane preparation solubilised by
sodium deoxycholate. L-Glutamate, glycine, polyamines and
desipramine (zinc recognition site) showed effects on soluble
NMDA receptors similar to those observed in rat brain
membranes, indicating that their sites of action are directly on
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the receptor protein. In quantitative autoradiographic binding
experiments using rat brain sections, [3H]MK-801 binding was
heterogeneously distributed throughout the brain with high
concentrations in the hippocampus, cerebral cortex and
thalamus, and was consistent with the pattern of NMDA
receptors labelled with [3H]L-glutamate and [3H]TCP (Bowery et
al., 1988; Sakurai at al., 1991). The pharmacology of
[3H]MK-801 binding in rat brain sections was similar to that
described in binding studies of the PCP recognition sites using
brain membranes. In addition, [3HJMK-801 binding studies using
human postmortem brain tissue showed the existence of high and
low affinity binding sites (Quarum et al., 1990). The high
affinity site showed a different regional distribution of
receptor density (cortex > hippocampus > striatum) compared to
the low affinity binding site (cerebellum > brainstem). The
regional distribution and pharmacology of [3H]MK-801 binding in
the human brain were similar to that reported using [3HJMK-801
in rat brain (Bowery et al., 1988; Sakurai at al., 1991).
Price et al. (1988a,b) reported the characterisation of
in vivo receptor binding with [3H]MK-801 in mouse brain. In vivo
binding of [3H]MK-801 was inhibited by various non-competitive
NMDA antagonists such as MK-801 and TCP. The potency of
these drugs was highly correlated with their functional effects
as antagonists of NMDA-induced convulsions. Recently it has
been demonstrated that (+)-3-p25|]jodo-MK-801 is a useful
radioligand for in vitro and in vivo autoradiography and that
receptor-mediated localisation of a similar MK-801 analogue
may allow in vivo imaging of the NMDA receptor complex (Gibson
et al., 1992). In vivo localisation of (+)-3-p25|]jodo-MK-801 in
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rat brain is stereoselective and blocked by coinjection of
unlabelled MK-801 (4 mg/kg) and is in concordance with in vitro
autoradiographic studies.
It has been shown that an NMDA receptor antagonist, an
isoquinoline derivative FR115427 ((+)-1 -methyl-1 -phenyl-
1,2,3,4-tetrahydroisoquinoline hydrochloride, (+)FR(HCI salt))
(Fig.2.1) prevents hippocampal damage in a gerbil global cerebral
ischaemia model (Nakanishi et al., 1994) and reduces cerebral
infarct volume and neurological deficit in a rat MCA occlusion
model (Katsuta et al., 1995), indicating that (+)FR might be
useful in the treatment of human ischaemic neuropathologies
such as stroke and trauma. However, the mode of action of
(+)FR at the NMDA receptor has not been defined.
The purpose of the work presented in this chapter was to
examine the mode of action of (+)FR using ligand binding
techniques. Initially the effects of (+)FR and its analogues on
the binding of [3HJMK-801 to rat cortical membranes, including
the modulatory effect of L-glutamate, were examined and
compared with MK-801. Secondly, tritium-labelled (+)FR was
synthesised and a method developed for purifying millicurie
quantities of [3H](+)FR. Subsequently its in vivo distribution in
rats, following intravenous injection, was studied.
2.2 METHODS
2.2.1 Preparation of Rat Brain Membranes
a) Whole brain membranes
The cerebral cortex from male Sprague Dawley rats
(200-300g) was dissected and homogenised in 40 vols (V/W) of
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R = H : (+)-1-methyl-1-phenyl-1,2,3,4-tetrahydro-
isoquinoline hydrochloride; FR115427
R = CI: (+)CI-FR
*
MK-801 (Dizocilpine)
Fig. 2.1 Chemical structures of FR115427 analogues and MK-801
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ice-cold 5 mM Tris-HCI buffer (pH 7.4 at 25°C) using a glass
teflon homogeniser. The homogenate was centrifuged at
50,000g at 4°C for 10 min. To remove endogenous excitatory
amino acids the resultant pellet was resuspended in 40 vols of
Tris-HCI buffer, incubated at 37°C for 30 min then recentrifuged
(50,000g, 4°C, 10 min). After the second wash, the pellet was
resuspended with 10 vols of Tris-HCI buffer and stored at -20°C
in aliquots sufficient for individual experiments until required.
On the day of the experiment, the membrane suspension was
thawed at room temperature, diluted to 40 vols with Tris-HCI
buffer and centrifuged (50,000g, 4°C, 10 min). Finally, the
pellet was resuspended with 50 vols of 5 mM Tris-HCI buffer
(pH 7.4 at 25°C) and kept at 4°C until required for the binding
assay.
b) Synaptosomal membranes
The cerebral cortex from male Sprague Dawley rats
(200-300 g) was dissected and homogenised in 15 vols (V/W) of
ice-cold 0.32 M sucrose using a glass teflon homogeniser. The
homogenate was centrifuged at 1,000g at 4°C for 10 min, then
the supernatant centrifuged at 17,000g at 4°C for 20 min. To
remove endogenous excitatory amino acids the resultant P2
pellet was lysed with 40 vols of glass distilled water (GDW),
incubated at 37°C for 30 min then centrifuged (50,000g, 4°C, 10
min). The supernatant was discarded and the pellet washed by
resuspension in GDW (40 vols) and centrifugation (50,000g, 4°C,
10 min). The resultant pellet was resuspended with 10 vols of
GDW and stored at -20°C until required. On the day of the
experiment, the membrane suspension was thawed at room
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temperature, diluted to 40 vols with GDW and centrifuged
(50,000g, 4°C, 10 min). The final pellet was resuspended in 30
vols of 5 mM Tris-HCI buffer (pH 7.4 at 25°C) and kept at 4°C
until required for the binding assay.
2.2.2 [3H1MK801 Binding to Rat Cortical Membranes
[3H]MK-801 binding to rat cortical membranes was carried
out according to the method of Wong et al. (1988). Duplicate
0.5 ml samples of membrane suspension were preincubated with
10 concentration of test drug (10-1o M to 10-4 m, final
concentrations) or 5 mM Tris-HCI buffer, pH 7.4, (total binding)
for 2 min at 25°C before addition of [3HJMK-801 (specific
activity 28.8 Ci/mmol, final concentration 1 nM) to give a final
assay volume of 1 ml. Samples were vortexed briefly then
incubated at 25°C for 45 min to reach equilibrium binding.
Incubation was terminated at room temperature by rapid
filtration under vacuum on a Brandel Cell Harvester using
Whatman GF/B filters then washed twice with 5 ml of 5 mM
Tris-HCI buffer. The filters were transferred to scintillation
vials and 100 pi of formic acid (100%) added to digest the
membrane protein followed 10 min later by 4 ml of scintillation
fluid (Packard Emulsifier Safe). The radioactivity in the vials
was measured in a Packard 1900CA liquid scintillation analyser
using automatic quench correction. Unlabelled (+)MK-801
(10 pM final concentration) was used to define specific binding.
Assays were carried out in the absence or presence of added
L-glutamate (final concentration 10 pM). Quadruplicate 100 pi
samples of [3H]MK-801 as standards were counted in order for
the exact ligand concentration to be calculated for individual
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experiments.
2.2.3 Data Analysis of Binding Experiments
Data from individual experiments were analysed by least
squares fit to the logistic expression :
Y = MXP/ (XP + IC50)
where Y is the amount bound at the inhibitor concentration, X ; P
corresponds to the Hill co-efficient, ICso is the inhibitor
concentration giving 50% inhibition of [3H]MK-801 binding.
Equilibrium dissociation constants (Ki values) for inhibitors of
binding were calculated using the equation (Cheng and Prusoff,
1973) :
Ki = ICso / (1 + L/Kd)
where L is the [3H]MK-801 ligand concentration used in the
experiment and Kd is the equilibrium dissociation constant for
MK-801. When the inhibitor used was unlabelled (+)MK-801, its
Kd value was calculated using the equation :
Kd = ICso - L
and subsequently the density of [3H]MK-801 binding sites
calculated from the equation :
b = Bmax L / (L + Kd)
Where b is the amount of [3H]MK-801 bound (fmol/mg tissue) at
the [3H]MK-801 ligand concentration L. The values for Kd, Ki
and Bmax were expressed as mean ± S.E.M. from three to six
independent experiments. The Student's t-test or Dunnett's
t-test was used for statistical comparison between drugs or
conditions when necessary.
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2.2.4 Preparation and Purification of f3H]FR1 15427
a) Column Chromatography of (+)FR and (+)CI-FR
Since the amounts of [3H](+)FR required to be purified
exceeded the capacity of our HPLC, an open column
chromatography method was used to isolate, purify and identify
FR115427 and in particular to separate it from the precursor
used for the tritiation, (+)-1 -(3-chlorophenyl)-1 -methyl-
1,2,3,4-tetrahydroisoquinoline ((+)CI-FR, Fig.2.1). Waters
Preparative C-18 resin (55-105p, 1.5g) in 20ml of solvent
(CH3CN : aq. 0.1% CF3COOH (TFA); 3:7) was sonicated for 3 min to
remove air bubbles. The resin was applied slowly to a
disposable plastic column (BioRad, 0.7 x 8 cm) until a packed
5 cm column of resin was obtained. A sample of solvent
(200 pi) containing 200 pg (+)FR(free base) and 200 pg
(+)CI-FR(free base) was then carefully applied to the column.
The column was eluted with solvent (CFI3CN : aq. 0.1% TFA ; 3:7)
and 350 pi fractions collected in microcentrifuge tubes. Each
fraction was frozen in dry ice (-80°C) and the solvent was
removed by freeze drying. After addition of GDW (20 pi) to each
fraction and vortexing, a 5 pi was applied to a silica gel plate
and thin layer chromatography (TLC) carried out using CHCI3 :
MeOH = 9:1 as developing solvent. (+)FR and (+)CI-FR were
detected under U.V. light (254 nm) and Rf values calculated.
b) Synthesis and Purification of |"3.H]FR115427
(+)CI-FR (23.2 mg in a preweighed ampoule), the
mono-chlorinated aromatic precursor of (+)FR (Fig.2.1) was
custom tritiated by Amersham International. (+)CI-FR in
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methanol was tritiated for 2 hr at room temperature with
tritium gas. After removal of methanol, [3H](+)FR was extracted
with ethyl acetate and water, and stored at a radiochemical
concentration of 10 mCi/ml in ethyl acetate. A batch of the
crude material (200 mCi) was delivered to the Department of
Pharmacology, University of Edinburgh and stored in 0.5 ml
aliquots (10 mCi/ml) under liquid nitrogen prior to purification.
For purification of [3H](+)FR, after removal of ethyl
acetate, 4.02 mCi of crude [3H](+)FR was dissolved with 402 pi
of the eluting solvent (CH3CN : aq. 0.1% TFA; 3:7) then 4 mCi
(400 pi) applied to the column. The open column method was
carried out as described above in order to isolate authentic
[3H](+)FR. Fractions (500 pi) were collected in microcentrifuge
tubes and a subsample (2 pi) of each fraction was diluted
1 : 10,000 with GDW and recovery determined by scintillation
counting. In order to calculate the exact amount of crude
[3H](+)FR added to the column, standards were obtained by
diluting 2 pi of the original 402 pi of radioactivity 1 : 12,500
and counting 100 pi in quadruplicate. Fractions corresponding
to [3H](+)FR were combined and freeze-dried. Purified [3H](+)FR,
now as the trifluoroacetate salt (TFA salt), was diluted to
10 pM in GDW and stored under liquid nitrogen in volumes
sufficient for individual experiments. The specific activity
(15.7 Ci/mmol) was calculated from Amersham's report that
1.24 Ci was obtained from catalytic reaction of 23.2 mg of
(+)CI-FR (M.W. 294.22) with tritium gas. Thus the concentration
of [3H](+)FR was calculated from the amount of radioactivity of
[3H](+)FR.
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2.2.5 Purity of f3H1FR115427
The purity of [3H](+)FR was checked by TLC. Each 3 or 2 pi
of [3H](+)FR (1.78 pCi/ml) and 3 or 2 (il respectively 10 mM
unlabelled (+)FR as carrier was spotted on silica gel plates.
After TLC development by CHCl3-MeOH (9:1), the plate was cut
into 3 mm by 10 mm strips parallel to the origin. Each strip
was transferred to a scintillation vial and 300 pi glass distilled
water was added to elute the radioactivity. After 1 hr, 4 ml
scintillation fluid added and the radioactivity in each strip
determined by liquid scintillation counting. The radioactivity in
each strip was calculated as a recovery % from the total
radioactivity applied to the origin. Immediately before cutting
the TLC, (+)FR was detected under U.V. light, its Rf value and the
strip numbers corresponding to the spot noted.
2.2.6 In Vivo Distribution of [3HjFR115427
Male Sprague Dawley rats (250-320 g) were allowed
access to food and water ad libitum prior to the experiments.
Under urethane anaesthesia (10% solution, 10 ml/kg, i.p.), the
left femoral vein was catheterised with polyethylene tubing for
drug administration. Rats were injected over 30 sec with
500 pi of saline containing 50 pCi of [3H](+)FR (corresponding to
3.2 nmol of [3H](+)FR) and 10 unit of heparin through the cannula
placed in the left femoral vein. To complete the drug injection,
500 pi of heparinised saline was used to flush the cannula
immediately following infusion of the [3H](+)FR. At various
times post-injection (15, 30, 60, 90 and 180 min), samples of
blood (~5ml) were taken in a heparinised syringe from the
inferior vena cava then the rats were killed by decapitation.
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Three animals were used for each time point. The brains were
removed, divided into 7 regions : rostral cortex, caudal cortex
(cerebral cortex - rostral cortex), hippocampus, striatum,
brainstem, midbrain and cerebellum. In addition, liver, kidney
and heart were removed, blotted dry and weighed. Samples,
120 to 400 mg, of each organ were taken, again blotted to
remove as much blood or urine as possible and transferred to
glass scintillation vials, then treated the same way as brain
tissue for determination of radioactivity. The tissues were
weighed in glass scintillation vials and dissolved with tissue
solubiliser (Soluene-350, 1ml/200mg) at 37°C for 2 days.
After being cooled to room temperature, 10 ml of Packard
Hionic-Fluor scintillation fluid was added to each sample and
radioactivity determined in a Packard 1900CA liquid
scintillation analyser. For the 60 min and 180 min rats, the
right femoral artery was also cannulated to obtain blood
samples at several times post injection of [3H](+)FR. At each
time the first 100 pi of blood was discarded since it probably
represented the dead volume in the cannula. A 300 pi sample
was then collected in a heparinised microcentrifuge tube.
A 200 pi sample was transferred to a glass scintillation vials,
and 1ml of Soluene-350 was added and left for 2 hr. 0.5 ml of
30% hydrogen peroxide (H2O2) was then added to bleach the blood
and left for 1 hr. After incubation of vials at 40°C for 30 min,
10 ml of Packard Hionic-Fluor was added and radioactivity
determined. The same procedure was carried out for the 5 ml
blood samples taken from the vena cava of all animals. The
results for the tissue distribution study were expressed as %
injected dose per gram of tissue (%D/g) or fmol per milligram of
63
tissue (fmol/mg), and results for the blood distribution study
were expressed as % injected dose per ml of blood (%D/ml). In
order to calculate the exact amount of [3H](+)FR injected to rats,
standards were obtained by diluting radioactivity used for
injection 1 : 200 and counting 100 pi in quadruplicate. The
data for whole brain were obtained from summation of the
amounts of radioactivity and weight of all brain regions.
2.2.7 Pharmacokinetic Analysis
The data for radioactivity in blood expressed as %D/ml
after [3H](+)FR injection were fitted to biexponential functions
using least squares regression analysis. The equation used was
Y = A x e(-at) + B x e(-pt), where t is time after administration, Y
is the measured radioactivity, A and B are the coefficients of
the exponential terms, a is the apparent distribution rate
constant, (3 is the apparent terminal rate constant. The data for
radioactivity in brain and peripheral tissues were fitted to
monoexponential functions using least squares regression
analysis. The equation used was Y = A x e(-Ke • t)f where Ke is the
elimination rate constant. The following pharmacokinetic
parameters were calculated : 1) half-life (ti/2) = 0.693/Ke or a
or P; 2) the area under the radioactivity concentration-time
curve from zero to time infinity (AUC). AUC was calculated
using the trapezoid method (Chiou, 1978).
2.2.8 Materials
FR compounds and MK-801 were synthesised by Mr.M.Ohkubo
in the New Drug Research Laboratories, Fujisawa Pharmaceutical
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Co. Ltd., Osaka, Japan. FR compounds obtained as HCI salts were
dissolved in GDW, FR compounds obtained as free bases were
dissolved in equimolar HCI, and MK-801 was dissolved in
aqueous diluted HCI. [3H](+)MK-801 (specific activity : 28.8
Ci/mmol) was obtained from NEN. [3H](+)MK-801 was diluted to
1 p.M in GDW and stored under liquid nitrogen in volumes
sufficient for individual experiments. Normally between 10
and 16 sets of tubes (24 tubes/set) were processed on the
Brandel Cell Harvester in a single experiment.
2.3 RESULTS
2.3.1 [3H]MK-801 Binding to Rat Cortical Whole Membranes
In order to examine the interaction of (+)FR with all NMDA
receptors including potentially non-neuronal and synaptic NMDA
receptors, the two preparations (whole and synaptosomal
membranes) were used for [3H]MK-801 binding.
The effects of (+)FR, (+)MK-801 and their enantiomers on
[3H]MK-801 binding to rat cortical whole membranes were
examined in the absence and presence of added L-glutamate
(final concentration 10 |iM) (Table 2.1). Fig.2.2 shows
representee inhibition curves comparing MK-801 and (+)FR as
inhibitors of [3H]MK-801 in the presence and absence of added
L-glutamate. (+)FR inhibited the binding of [3H]MK-801 to whole
membranes with Ki values of 55.2 ± 2.9 nM and 48.1 ± 5.9 nM in
the absence and presence of added L-glutamate, respectively.
(+)MK-801 was found to be 16-fold more potent than (+)FR as an
inhibitor of [3H]MK-801 binding with a Kd value of 3.4 ± 0.2 nM
(p<0.05 vs (+)FR) in the presence of added L-glutamate.
However the difference in affinity between (+)MK-801 and (+)FR
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TABLE 2.1 : Inhibition of ("3H]MK-8Q1 Binding to Rat Cortical
Membranes by Stereoisomers of MK-801 and FR
Kd / Ki (nM)
Whole membranes Synaptosomal membranes
No addition L-Glutamate No addition L-Glutamate
(+)MK-801 7.3 ± 0.8 3.4 ± 0.2** 25.0 ± 6.6# 3.3 ± 0.6*
(-)MK-801 28.3 ± 4.9 15.3 ± 1.6 33.6 ± 8.3 13.9 ± 1.6
(±)MK-801 14.1 ± 0.9 6.9 ± 1.1 30.6 ± 6.3 6.8 ± 1.0
(+)FR 55.2 ± 2.9 48.1 ± 5.9 114.5 ± 30.8 40.0 ± 2.1
(-)FR 4000 ± 269 5270± 205 5650 ± 1950 3910 ± 726
(±)FR 121.2 ± 18.0 91.5 ± 6.2 114.7 ± 8.2 64.8 ± 8.0
Bmax 57.2 ± 5.4 74.3 ± 8.2 45.7 ± 3.1 48.8 ± 5.9
(fmol/mg tissue)
The affinity of the stereoisomers of MK-801 and FR for
[3H]MK-801 binding sites on rat cortical whole membranes or
synaptosomal membranes was studied in the absence or presence
of added L-glutamate (10 |iM) in the assay buffer. Membranes
were incubated with [3H]MK-801 (1 nM) in the absence or
presence of increasing concentrations of test drug for 45 min at
25°C. Non-specific binding was determined in the presence of
10 pM unlabelled (+)MK-801. Ki values were calculated from
the equation Ki = ICso / (1+ L/Kd). Values are mean ± S.E.M. of at
least three independent experiments. *, ** ; p<0.05, 0.01 vs Kd
values of (+)MK-801 in the absence of added L-glutamate, # ;
p<0.1 vs Kd value of (+)MK-801 in the absence of added L-
glutamate with whole membranes.
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Fig. 2.2 Inhibition of [3H]MK-801 binding to whole membranes
by (+) MK-801 and (+)FR : effect of L-glutamate. Cortical whole
membranes were incubated with [3H]MK-801 (1nM) in the absence
or presence of increasing concentrations of test drug for 45 min
at 25°C. Assays were carried out in the absence and presence
of added L-glutamate (10 pM). Non-specific binding was
determined in the presence of 10 pM unlabelled (+)MK-801.
Data are from a representive experiment. Each point is the
mean value of duplicate determinations. # (+)MK-801 in the
presence of added L-glutamate; O (+)MK-801 in the absence of
added L-glutamate; ▲ (+)FR in the presence of added
L-glutamate; A (+)FR in the absence of added L-glutamate.
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was less apparent in the absence of added L-glutamate ; a Kd
value of 7.3 ± 0.8 nM (p<0.001 vs (+)FR) and a Ki value of 55.2 ±
2.9 nM were obtained for (+)MK-801 and (+)FR respectively
demonstrating a 8-fold difference in affinity. Inhibition of
[3H]MK-801 binding by FR and MK-801 showed stereoselectivity
but this was far more pronounced in the case of FR. The
(-)enantiomers of FR and MK-801 were respectively 110- and
4.5-fold less potent than the corresponding (+)enantiomer in the
presence of added L-glutamate. [3H]MK-801 binding was
modulated by addition of L-glutamate in the assay buffer. The
specific binding of [3H]MK-801 at 1 nM in the presence of added
L-glutamate was 2.9 times greater than that in the absence of
added L-glutamate (data not shown). The affinity of (+)MK-801
was significantly (p<0.01) increased by about 2-fold from 7.3 to
3.4 nM in the presence of added L-glutamate with no significant
(p=0.1122) effect on Bmax values (57.2 ± 5.4 fmol/mg tissue in
the absence of added L-glutamate, 74.3 ± 8.2 fmol/mg tissue in
the presence of added L-glutamate). These results suggest
that the effect of L-glutamate is to increase the affinity of
MK-801, but that there is no change in the population of sites
labelled by the ligand. In contrast, the presence of added
L-glutamate had little effect on the affinity of (+)FR for
[3H]MK-801 binding sites (p=0.3409 vs Ki values in the absence
of added L-glutamate) (Fig.2.2). A similar result was found
for the (-)enantiomers of MK-801 and FR; (-)MK-801 affinity
increased about two fold in the presence of added L-glutamate
but little effect on the affinity of (-)FR was observed.
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2.3.2 [3-H]MK-801 Binding to Rat Cortical Synaptosomal
Membranes
The effects of (+)FR, (+)MK-801 and their enantiomers on
[3H]MK-801 binding to rat cortical synaptosomal membranes in
the absence and presence of added L-glutamate are shown in
table 2.1. In the presence of added L-glutamate, (+)FR inhibited
the binding of [3H]MK-801 to rat cortical synaptosomal
membranes with a Ki value of 40.0 ± 2.1 nM (p<0.001 vs
(+)MK-801) which was 12 times less potent than (+)MK-801
(Ki = 3.3 ± 0.6 nM) (Fig.2.3). On the other hand, (+)FR (Ki = 114.5
± 30.8 nM, p<0.05 vs (+)MK-801) was only 4.5-fold less potent
than (+)MK-801 (Ki = 25.0 ± 6.6 nM) in the absence of added
L-glutamate. Thus compared with whole membranes, the
difference in affinity between (+)MK-801 and (+)FR was less
apparent in the absence of added L-glutamate. However there
was no significant defference in the affinity of (+)MK-801 and
(+)FR between synaptosomal and whole membranes in the
absence of added L-glutamate (p=0.0563 for (+)MK-801;
p=0.1953 for (+)FR).
In the presence of added L-glutamate, the affinity of
(+)MK-801 for [3H]MK-801 binding sites was significantly
increased (p<0.05 vs no addition of L-glutamate) by 7.6-fold
from 25.0 to 3.3 nM whereas there was no significant change
(p=0.1372) in the affinity of (+)FR (Fig.2.4). As with whole
membranes, inhibition of [3H]MK-801 binding by FR and MK-801
demonstrated stereoselectivity which was more pronounced in
the case of FR (Fig.2.3). The (-)enantiomers of FR and MK-801
were respectively 98- and 4.2-fold less potent than the
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Fig. 2.3 Inhibition of [3H]MK-801 binding to synaptosomal
membranes by the (+) and (-)enantiomers of MK-801 and FR.
Cortical synaptosomal membranes were incubated with
[3H]MK-801 (1nM) in the absence or presence of increasing
concentrations of test drug for 45 min at 25°C. Assays were
carried out in the presence of added L-glutamate (10 pM).
Non-specific binding was determined in the presence of 10 pM
unlabelled (+)MK-801. Data are from a representive experiment.
Each point is the mean value of duplicate determinations.
#(+)MK-801; O(-)MK-801; A(+)FR; A (-)FR.
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Fig. 2.4 Inhibition of [3H]MK-801 binding to synaptosomal
membranes by (+) MK-801 and (+)FR : effect of L-glutamate.
Cortical synaptosomal membranes were incubated with
[3H]MK-801 (1nM) in the absence or presence of increasing
concentrations of test drug for 45 min at 25°C. Assays were
carried out in the absence and presence of added L-glutamate
(10 jiM). Non-specific binding was determined in the presence
of 10 p.M unlabelled (+)MK-801. Data are from a representive
experiment. Each point is the mean value of duplicate
determinations. # (+)MK-801 in the presence of added
L-glutamate; O (+)MK-801 in the absence of added L-glutamate;
A (+)FR in the presence of added L-glutamate; A (+)FR in the
absence of added L-glutamate.
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corresponding (+)enantiomer in the presence of added
L-glutamate. In the presence of added L-glutamate, (+)MK-801
(Kd = 3.3 nM) had higher affinity than the (-)enantiomer (Ki =
13.9 nM) using synaptosomal membranes. The data obtained from
[3H]MK-801 binding to synaptosomal membranes were also
similar to those for whole membranes ((+)enantiomer; Kd =
3.4 nM, (-)enantiomer; Ki = 15.3 nM) (Table 2.1). These results
are consistent with previous observations that (+)MK-801 (Kd =
3 nM) has higher affinity than (-)MK-801 (Ki = 15 nM) using rat
cortical membranes and that the [3H]MK-801 binding site is
therefore stereoselective (Wong et a!., 1986).
For further characterisation of the interaction of (+)FR
with the NMDA receptor, it was decided to synthesise
tritium-labelled (+)FR. However (+)CI-FR (Fig.2.1), the precursor
compound for [3H](+)FR, was only 4-6 times less potent than
(+)FR with a Ki value of 548.4 ± 65.9 nM and 240.6 ± 78.0 nM in
the absence and presence of added L-glutamate, respectively
(Table 2.2, Fig.2.5). Therefore, it was necessary to have a
method for purifying of [3H](+)FR which would give good
separation of (+)FR from (+)CI-FR and also from potential
autoradiolysis products which may be produced during
radiosynthesis or storage of the [3H]ligand.
2.3.3 Preparation and Purification of f3.H]FR1 15427
Prior to synthesis of [3H](+)FR, an open column method for
separating (+)FR and (+)CI-FR using 200 jig of unlabelled
compounds, (+)FR(free base) and (+)CI-FR(free base), was
evaluated. Since the intention was to purify batches of about
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TABLE 2.2 : Effects of FR115427 Analogues on f3H1MK-801
Binding to Rat Cortical Synaptosomal Membranes
Ki fnM)
No addition L-Glutamate









(+)CI-FR (HCI salt) 548.4 ± 65.9 240.6 ± 78.0
The affinity of FR115427 analogues for [3H]MK-801 binding sites
on rat cortical synaptosomal membranes was studied in the
absence or presence of added L-glutamate (10 p.M) in the assay
buffer. Membranes were incubated with [3H]MK-801 (1 nM) in
the absence or presence of increasing concentrations of test
drug for 45 min at 25°C. Non-specific binding was determined
in the presence of 10 jiM unlabelled (+)MK-801. Ki values were
calculated from the equation Ki = ICso / (1+ L/Kd). Values are
mean ± S.E.M. of at least three independent experiments.
73
Log [drug] M
Fig. 2.5 Inhibition of [3H]MK-801 binding to synaptosomal
membranes by (+)CI-FR and (+)FR. Cortical synaptosomal
membranes were incubated with [3H]MK-801 (1nM) in the absence
or presence of increasing concentrations of test drug for 45 min
at 25°C. Assays were carried out in the presence of added
L-glutamate (10 llM). Non-specific binding was determined in
the presence of 10 |iM unlabelled (+)MK-801. Data are from a
representee experiment. Each point is the mean value of
duplicate determinations. # (+)FR; A (+)CI-FR.
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15 mCi of the crude radioactive material following tritiation,
200 pg of (+)FR and (+)CI-FR therefore represent the amount of
(+)FR expected to be present in 15 mCi of the crude radioactive
material and the maximum amount of (+)CI-FR depending on the
success of the tritiation. After each fraction (350 pi) eluted
from the column was freeze-dried, GDW (20 pi) was added to
each fraction, then 5 pi was applied to TLC, and (+)FR and
(+)CI-FR were detected by U.V. light. As shown in fig.2.6, (+)FR
started to elute at fraction 5 (1.4-1.75 ml) and the peak was at
fractions 6 and 7 (1.75-2.45 ml) whereas (+)CI-FR started to
elute at fraction 9 (2.8-3.15 ml) with a peak at fractions 11 and
12 (3.5-4.2 ml). This eluting pattern for (+)FR and (+)CI-FR was
very similar in three separate experiments. Thus this open
column method gave good separation of (+)FR from (+)CI-FR and
was also very reproducible, indicating that the method was
suitable for purification of [3H](+)FR.
Using the open column, 4 mCi of crude [3H](+)FR synthesised
from (+)CI-FR was purified. Judging from fraction volumes
(500 pi) used in this experiment and results with unlabelled
(+)FR and (+)CI-FR, it was expected that major peaks of [3H](+)FR
and (+)CI-FR should have been in fractions 4 and 5, and fractions
7 and 8, respectively. As shown in fig.2.7, the radioactivity
started to elute at fraction 5 (2-2.5 ml) and with major amount
of [3Hjligand in fractions 6-8 (2.5-4 ml, 95% of added
radioactivity). Thus only one peak was observed with major
fractions 6-8, indicating that almost no radiolysis products
were produced during tritiation of (+)CI-FR. Although major
fractions (6-8) of [3H]ligand were later than expected (fractions
4 and 5), it was shown by the open column and TLC
75
® (+)CI-FR
«s> ^ ^ •=• -<— (+)FR
5 6 7 8 9 10 11 12
Fraction Number
Fig. 2.6 TLC after separation of unlabelled (+)FR and (+)CI-FR by
open column method. Resin (Waters Preparative C-18,
55-105 y, 1.5 g) was applied onto disposal column ( 0.7 x 8 cm)
and packed to 5 cm from the bottom of the column. Then
unlabelled compound, (+)FR(free base) (200 yg/200 y\) and
(+)CI-FR (free base) (200 yg/200 y\) in solvent (CH3CN : aq.0.1 %
CF3COOH (TFA) = 3:7) was applied to the column, and the eluting
solution (350 ^l/fraction) was collected. Each fraction was
frozen on dry ice and the solvent evaporated by freeze drying.
After addition of glass distilled water (20 y I) to each fraction,
5 y\ was applied to silica gel thin layer chromatography (TLC)
plates, developed (CHCI3 : MeOH = 9:1) and detected by U.V. light.
Data are from a representive experiment.
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Fig. 2.7 Purification of [3H](+)FR by open column. (+)CI-FR
(23.2 mg) was custom tritiated by Amersham International and
stored at a radiochemical concentration of 10 mCi/ml in ethyl
acetate. After removal of ethyl acetate, 4.02 mCi of crude
[3H](+)FR was dissolved in 402 fjI with the eluting solvent
(CH3CN : aq.0.1 % CF3COOH (TFA) =3:7) then 4 mCi (400 fjI)
applied to the column. Fractions (500 fj I) were collected and a
subsample (2 jl/I) of each fraction was made up to 1 ml then
50^1 taken and diluted to 1 ml. Of this final dilution 100/vl
was counted. Of the proportion, remaining (not added to the
column) 2 fj\ was made up to 1 ml then 40 (J I taken and diluted
to 1 ml. Of this final dilution 100 fj\ was counted and these
standards allowed the % of tritium recovered in each fraction to
be calculated. The recovery from fractions 6 to 8 was
calculated to be 95 %.
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methods that fractions 6-8 did indeed correspond to (+)FR (see
section 2.3.5). Fractions 6-8 were combined as [3H](+)FR, and
freeze-dried to remove the eluting solvent. After dilution to 10
|iM in GDW, [3H](+)FR was stored under liquid nitrogen until
required.
After purification by open column, because CH3CN-TFA is
used as the eluting solvent of column [3H](+)FR is obtained as a
TFA salt. Therefore, the effects of different salts of (+)FR on
[3H]MK-801 binding to rat cortical synaptosomal membranes
were examined.
2.3.4 Effects of Different (+)FR Salts on r3H]MK-801 Binding to
Rat Cortical Synaptosomal Membranes
Using synaptosomal membranes, the effects of the free
base and the TFA salt of (+)FR on [3HJMK-801 binding were
examined in the absence and presence of added L-glutamate and
compared with FR115427 (HCI salt of (+)FR) (Table 2.2). The HCI
salt, TFA salt and free base of (+)FR inhibited [3H]MK-801
binding to synaptosomal membranes with almost identical Ki
values of 40.0 ± 2.1 nM, 50.2 ± 7.1 nM and 37.5 ± 10.3 nM in the
presence of added L-glutamate, respectively. These Ki values
were about 3-fold lower than the Ki values (HCI salt;
114.5 ± 30.8 nM, TFA salt; 170.7 ± 44.1 nM, Free base;
113.7 ± 54.3 nM) obtained in the absence of added L-glutamate.
Statistical analysis by Dunnett's t-test showed that there was
no significant difference in the affinity of (+)FR for [3H]MK-801
binding in the absence and presence of added L-glutamate when
measured using the free base, HCI or TFA salts.
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2.3.5 Confirmation of f2H"|f+1FR Purity
In the open column with unlabelled (+)FR (200 jig,
approximately 900 nmol), (+)FR started to elute with 1.4 ml of
solvent (Fig.2.6) whereas following application of crude
[3H](+)FR to the column (4 mCi, approximately 250 nmol)
[3H](+)FR started to elute with 2 ml of solvent (Fig.2.7).
(+)CI-FR (200 pg, approximately 900 nmol) started to elute with
2.8 ml solvent (Fig.2.6). The difference in the volume of
solvent required to elute (+)FR may therefore depend on the
amount of (+)FR applied to column. To clarify this, the open
column separation was carried out with two different amounts
(250 and 900 nmol) of unlabelled (+)FR each containing 4 pCi
[3H](+)FR and in parallel with a small amount using 4 pCi
[3H](+)FR only (0.25 nmol) (Fig.2.8). For the columns with 0.25
nmol and 250 nmol of (+)FR, (+)FR started to elute at 2.5 ml of
solvent with the. peaks at fractions 7 and 6, respectively. On
the other hand, 2 ml of solvent was sufficient to start elution of
(+)FR for the column with 900 nmol of (+)FR . These results
suggest that the amount of (+)FR applied to the column affects
to some extent the eluting pattern and that fractions 6-8 in the
column with 4 mCi (250 nmol) of crude [3H](+)FR (Fig.2.7)
correspond to elution of authentic (+)FR.
The 4 mCi of [3H](+)FR purified using the open column
method was also checked using silica gel TLC (Fig.2.9). When
3 pi of [3H](+)FR (1.78 pCi/ml) overloaded with 3 pi (10 mM)
unlabelled (+)FR in glass distilled water were applied to the TLC
plate, two peaks were observed. The major peak (69% of added
[3H](+)FR) was determined as (+)FR by U.V. detection at strip
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Fig. 2.8 Check of purity of [3H](+)FR by open column. In order to
get three different amounts (0.25, 250 and 900 nmol/400 fj I
respectively) of (+)FR, purified [3H](+)FR (20 /jCi/100 ^ I) was
made up to 1 ml, then 200 ij\ (equivalent to 0.25 nmol) taken and
diluted to 400 fj I by the eluting solvent (CH3CN : aq.0.1 %
CF3COOH (TFA) = 3 : 7) or the solvent containing an appropriate
amount of unlabelled (+)FR (1 mg/ml). These different amounts
was applied to each column then fractions (500 /vI) were
collected. A subsample (5 \jI) of each fraction was taken for
scintillation counting to determine recovery. ■ 0.25 nmol;
£2 250 nmol; □ 900 nmol.
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Strip Number
Fig. 2.9 Confirmation of [3H](+)FR purity by TLC. Each 3 or 2 pi
of (1.78 pCi/ml) [3H](+)FR and 3 or 2 pi respectively 10 mM
unlabelled (+)FR as carrier was spotted on TLC plates.
Following development by CHCh-MeOH (9:1), the TLC plate was
cut into 3 mm by 10 mm strips parallel to the origin. Each strip
was transferred to a scintillation vial and 300 pi glass distilled
water was added to elute the radioactivity. After 1 hr, 4 ml
scintillation fluid added and the radioactivity in each strip was
determined by liquid scintillation counting. The radioactivity in
each strip was calculated as a recovery % from the total
radioactivity applied to the origin by counting 3 or 2 pi of
(1.78 pCi/ml) [3H](+)FR as standards. Immediately before
cutting of TLC, the spot of (+)FR was detected under U.V. light,
its Rf value and the strip numbers corresponding to the spot
noted. ^ 3 pi; □ 2 pi.
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origin. On the other hand, only one major peak (91% of added
[3H](+)FR) corresponding to (+)FR was observed when 2 pi of
labelled and unlabelled (+)FR was applied. This result indicates
that it is better to apply the compound in water in a small an
amount as possible for checking purity by TLC. In addition,
these results also suggest that a tiny amount of compound is not
developed by the solvent (15% 3 pi samples; 3% 2 pi samples)
due to damage of the surface of the silica gel at the origin by
water. Nevertheless, the purity of [3H](+)FR was shown to be
greater than 90% by the TLC method using 2 pi each of [3H](+)FR
and unlabelled (+)FR (Fig.2.9). This compares well with the
open column check of [3H](+)FR purity where, for example, in the
250 nmol and 900 nmol column, 95% and 94% respectively
corresponded to fractions containing authentic (+)FR.
2.3.6 In Vivo Distribution of [3.Hj(+)FR
The time course of the distribution of [3H](+)FR after
intravenous injection to rat was examined. Under anaesthesia,
rats were injected with 500 pi of saline containing [3H](+)FR
(50 pCi, 3.2 nmol). This dose (approximately 1 pg) is much
lower than the minimum dose (100 pg) required for behavioural
effects, i.e. 1/100th. The blood level of radioactivity collected
via the femoral artery or inferior vena cava is shown in table 2.3
and fig.2.10. The arterial blood levels of radioactivity were
similar to those from the venous blood at 15, 30, 60, 90 and 180
min after [3H](+)FR injection (Table 2.3). In blood, the peak
level of radioactivity was obtained within 1 min and a rapid
clearance of radioactivity was observed. After intravenous
administration, the blood level was 0.148 %D/ml at 1 min,
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Fig. 2.10 Time course of radioactivity in arterial blood after
[3H](+)FR injection. Under anaesthesia, rats were injected with
500 pI of saline containing 50 pCi (3.2 nmol) of [3H](+)FR
through the cannula placed in the left femoral vein. Arterial
blood (300 pi) was collected at various time points (1, 3, 5, 10,
15, 30, 45, 60, 90 and 180 min after injection) via femoral
artery and a 200 pi sample was transferred to glass
scintillation vials, and 1 ml of Soluene-350 was added and left
for 2hrs. 0.5 ml of 30% H2O2 was then added to bleach the blood
and left for 1 hr. After incubation of vials at 40°C for 30min,
10ml of Packard Hionic-Fluor was added and the radioactivity
was measured by liquid scintillation spectrometry. Data are
expressed as % injected dose per ml from 2-5 animals. In order
to calculate the exact amount of [3H](+)FR injected to rats,
standards were obtained by diluting of original radioactivity
1 : 200 and counting 100 pi in quadruplicate. Each time point
is the mean value ± S.E.M. of 3-5 or range for 2 animals. The
number of animals is shown in table 2.3.
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followed by a biphasic decline with half lives of 6.513 min (a)
and 2310 min (P) (Table 2.6). The AUC for blood was 9.537
%D • min/ml. The tissue levels of radioactivity at 15, 30, 60,
90 and 180 min after [3H](+)FR injection are shown in tables 2.4,
2.5 and figs.2.11, 2.12, 2.13. In heart, kidney and liver, peak
levels were obtained by 15 min (Table 2.4, Fig.2.11). At 15, 30
and 60 min after [3H](+)FR injection, the 3 tissues contained
radioactivity concentrations greater than that of blood. Liver
had the highest concentrations of radioactivity when compared
with kidney and heart as indicated by their AUC values
(liver : 169.520, kidney : 87.920, heart : 27.042 %D • min/g)
(Table 2.6). The clearance of radioactivity from liver was
slower than from kidney and heart as indicated by their ti/2
values (liver : 191.133 min, kidney : 75.016 min, heart : 83.104
min).
Uptake of [3H](+)FR into whole brain reached a maximum by
15 min with 0.629 %D/g (Table 2.5, Fig.2.12). The radioactivity
in whole brain (0.12 %D/g) was still observed even 3 hr after
injection. At 15, 30 and 60 min after [3H](+)FR injection, whole
brain contained radioactivity concentrations greater than those
of blood and heart, and lower than those of kidney and liver
(Table 2.3, 2.4, 2.5, Fig.2.10, 2.11, 2.12). In all seven brain
regions examined, the amount of radioactivity was highest at
15 min after injection (Table 2.5, Fig.2.13). All brain regions
had similar radioactivity elimination half-lives with a value of
approximately 50 min (Table 2.6). At all time points, although
a significant difference could not be shown, the radioactivity
concentration in the cerebellum was lower in comparison with
other brain regions. The AUC value (46.001 %D • min/g) for
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Fig. 2.11 Time course of radioactivity in heart, kidney and liver
after [3H](+)FR injection. Under anaesthesia, rats were injected
with 500 vI of saline containing 50 /jC\ (3.2 nmol) of [3H](+)FR
through the cannula placed in the left femoral vein. At various
times post-injection (15, 30, 60, 90 and 180 min), rats were
killed, and liver, kidney and heart were removed, blotted dry and
weighed. Samples 120 to 400 mg of each organ were taken,
again blotted to removed as much blood or urine as possible and
transferred to glass scintillation vials and dissolved with
tissue solubilizer (Soluene-350, 1 ml/200 mg) at 37°C for 2
days. After being cooled to room temperature, 1 0 ml of Packard
Hionic-Fluor scintillation fluid was added to each sample and
radioactivity determined in a liquid scintillation analyser. Data
are expressed as % injected dose per g tissue from 3 animals
with the exception of the 60 min group (n=2). In order to
calculate the exact amount of [3H](+)FR injected to rats,
standards were obtained by diluting of original radioactivity
1 : 200 and counting 100 /jI in quadruplicate. Each time point is
the mean value ± S.E.M. of 3 or range for 2 animals. • Heart;
▲ Kidney; ■ Liver.
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Fig. 2.12 Time course of radioactivity in whole brain after
[3H](+)FR injection. Under anaesthesia, rats were injected over
30 sec with 500 pi of saline containing 50 pCi (3.2 nmol) of
[3H](+)FR through the cannula placed in the left femoral vein. At
various times post-injection (15, 30, 60, 90 and 180 min), the
rats were killed by decapitation. The brains were removed,
divided into 7 regions : rostral cortex, caudal cortex,
hippocampus, striatum, brainstem, midbrain and cerebellum.
The tissues were weighed in glass scintillation vials and
dissolved with tissue solubilizer (Soluene-350, 1 ml/200 mg) at
37°C for 2 days. After being cooled to room temperature, 10 ml
of Packard Hionic-Fluor scintillation fluid was added to each
sample and radioactivity determined in a liquid scintillation
spectrometry. The data for whole brain was obtained from total
amounts of radioactivity and weight of all brain regions. In
order to calculate the exact amount of [3H](+)FR injected to rats,
standards were obtained by diluting of original radioactivity
1 : 200 and counting 100 pi in quadruplicate. Data are
expressed as % injected dose per g tissue from 3 animals with
the exception of the 60 min group (n=2). Each time point is the
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Fig. 2.13 Time course of radioactivity in brain regions after
[3H](+)FR injection. Under anaesthesia, rats were injected over
30 sec with 500 ij\ of saline containing 50 ijCi (3.2 nmol) of
[3H](+)FR through the cannula placed in the left femoral vein. At
various times post-injection (15, 30, 60, 90 and 180 min), the
rats were killed by decapitation. The brains were removed,
divided into 7 regions : rostral cortex, cauidal cortex,
hippocampus, striatum, brainstem, midbrain and cerebellum.
The tissues were weighed in glass scintillation vials and
dissolved with tissue solubilizer (Soluene-350, 1 ml/200 mg) at
37°C for 2 days. After being cooled to room temperature, 10 ml
of Packard Hionic-Fluor scintillation fluid was added to each
sample and radioactivity determined in a liquid scintillation
spectrometry. In order to calculate the exact amount of
[3H](+)FR injected to rats, standards were obtained by diluting of
original radioactivity 1 : 200 and counting 100 \j I in
quadruplicate. . Data are expressed as.% injected dose per g
tissue from 3 animals with the exception of the 60 min group
(n=2). Each time point is the mean value of 3 or 2
animals. —O— Rostral cortex; — 0~ Caudal cortex;
—A— Hippocampus; —A— Striatum; —□— Brainstem;
— Midbrain;—O—Cerebellum.
90
TABLE 2.6 : Pharmacokinetic Parameters of l"3H1(+)FR in Rats
After Injection
Co Ke ti/2 AUC
(% D/g or ml) (min-1) (min) (% D • min/g or ml)
Whole brain 0.765 0.01398 49.593 52.475
Rostral cortex 0.782 0.01334 51.958 52.475
Caudal cortex 0.755 0.01290 53.720 55.741
Hippocampus 0.729 0.01205 57.503 57.189
Striatum 0.777 0.01368 50.657 55.741
Midbrain 0.838 0.01614 42.939 55.741
Brainstem 0.838 0.01666 41.605 55.741
Cerebellum 0.668 0.01392 49.800 46.001
Heart 0.255 0.00834 83.104 27.042
Kidney 0.898 0.00924 75.016 87.920
Liver 0.992 0.00363 191.133 169.520
Blood 0.135 0.1064 6.513 9.537
0.052 0.0003 2310
The data of radioactivity in blood after [3H](+)FR injection were
fitted to biexponential functions using least squares regression
analysis. The equation used was Y = A x e(-«0 + B x eC-PO, where t
is time after administration, Y is the measured radioactivity, A
and B are the coefficients of the exponential terms, a is the
apparent distribution rate constant, (3 is the apparent terminal
rate constant. The data of radioactivity in brain and peripheral
tissues were fitted to monoexponential functions using least
squares regression analysis. The equation used was
Y = A x e(-Ke-t); where Ke is the elimination rate constant.
Co : radioactivity at t = 0, t 1/2 (half-life) = 0.693/Ke or a or (3,
AUC : the area under the radioactivity concentration-time curve
from zero to time infinity.
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cerebellum was smallest among the seven brain regions (Table
2.6).
2.4 DISCUSSION
In the present experiments, the effects of (+)FR, (+)MK-801
and their enantiomers on [3H]MK-801 binding to rat cortical
whole membranes and synaptosomal membranes was examined in
the absence and presence of added L-glutamate (10 jiM)
(Table 2.1). In order to examine the interaction of (+)FR with
all NMDA receptors including non-neuronal and synaptic NMDA
receptors, the two preparations (whole and synaptosomal
membranes) were used for [3H]MK-801 binding. In the presence
of added L-glutamate, the Kd values in two membrane
preparation (whole membranes; 3.4 ± 0.2 nM, synaptosomal
membranes; 3.3 ± 0.6 nM) was almost the same with Bmax values
of 74.3 ± 8.2 fmol/mg tissue (whole membranes) and 48.8 ± 5.9
fmol/mg tissue (synaptosomal membranes). The Bmax values
for the two tissue preparations cannot be directly compared
since they are not expressed as per mg of protein, and protein
recovery in the synaptosomal membrane preparation is normally
only about 50% of that of the whole membrane preparation.
Indeed a higher density of NMDA receptors on a mg of protein
basis would be anticipated for the synaptosomal membranes. In
the presence of added L-glutamate, the Ki values of (+)FR in two
membrane preparations (whole membranes; 48.1 ± 5.9 nM,
synaptosomal membranes; 40.0 ± 2.1 nM) was almost the same.
Addition of L-glutamate produced an increase in affinity of (+)FR
and (+)MK-801 for [3H]MK-801 binding sites in both brain
membrane preparations. Binding of L-glutamate to the NMDA
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receptor presumably causes a conformational change that
facilitates the interaction of (+)MK-801 with its binding site
within the NMDA receptor associated ion channel (Foster and
Wong, 1987). This result suggests that (+)FR preferentially
binds to an activated state of the NMDA receptor-ion channel
complex and, like (+)MK-801, its binding site resides on or
within the ion channel. The inhibitory effect of (+)FR on
[3fH]MK-801 binding has been reported by Nakanishi et al. (1995)
who also showed that (+)FR inhibited binding of [3H]TCP but not
[3H]CPP or [3H]glycine to rat brain membranes. In addition,
systemic administration of (+)FR blocked NMDA-induced
convulsions in mice, but not quisqualate- or kainate-induced
convulsions (Nakanishi et al., 1995). These results are
consistent with (+)FR, like MK-801, being a non-competitive
NMDA antagonist.
The effect of L-glutamate was more apparent for
synaptosomal membranes than for whole membranes. These
results indicate that residual endogenous L-glutamate in the
synaptosomal membranes was lower than that in the whole
membranes. Foster and Wong (1987) showed the removal of
endogenous glutamate and aspartate from rat cortical
synaptosomal membranes by repeated washing reduces the
affinity of [3H]MK-801 for its binding site. According to their
report, the Kd value for [3H]MK-801 binding to synaptosomal
membranes before washing was 2.2 nM whereas the Kd value for
the membranes after washing was 16.5 nM. in addition, they
demonstrated that glutamate and aspartate levels in
synaptosomal membranes before washing were 2.98 and 3.67
nmol/mg protein respectively, whereas levels after washing
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were 0.42 and 0.54 nmol/mg protein respectively. In the
present experiments, the Kd value for [3H]MK-801 binding to
synaptosomal membranes was 3.3 nM and 25.0 nM in the presence
and absence of added L-glutamate, respectively. These Kd
values are consistent with the Kd values for synaptosomal
membranes before and after washing shown by Foster and Wong
(1987). Thus the extensively washed synaptosomal membranes
used by Foster and Wong seem to correspond to the synaptosomal
membranes used in the present experiment and to give similar Kd
values, although there are some minor differences in the details
of the membrane preparation protocols. They obtained crude
synaptosomal membranes by three washes (suspension in
distilled water and centrifugation; 50,000g, 20 min) of the P2
pellet followed by resuspension in 5 mM Tris-HCI buffer and
centrifugation. For well washed membranes, a further 4 cycles
of washing with Tris-HCI buffer was carried out. In the present
experiments, synaptosomal membranes were prepared by
washing three times (suspension in distilled water and
centrifugation; 50,000g, 10 min) and incubation at 37°C for
30 min (see section 2.2.1). Therefore inclusion of an incubation
step appears to be a very efficient way of removing endogenous
excitatory amino acids in comparison with repeated washings.
Thus [3H]MK-801 binding using well washed synaptosomal
membranes has an advantage for facilitating study of
L-glutamate modulation of NMDA receptors in comparison with
binding using whole brain membranes.
The L-glutamate-induced increase in affinity of (+)FR for
[3H]MK-801 binding sites was smaller than that of (+)MK-801 in
synaptosomal membranes although the precise significance of
94
this finding remains unclear. The affinity of (+)FR was
increased by about 3-fold from 114.5 to 40.0 nM in the presence
of added L-glutamate without significant difference (p=0.1372),
whereas the affinity of (+)MK-801 was significantly (p<0.05)
increased by about 8-fold from 25.0 to 3.3 nM (Table 2.1). This
finding appears to be supported by results from [3H](+)FR binding
to rat cortical membranes (Sherriffs et al., 1993). It has been
demonstrated that L-glutamate (10 pM) increases specific
[3H](+)FR and [3HJMK-801 binding maximally to 438 and 592% of
control binding, respectively. This difference suggests that
(+)FR and (+)MK-801, as might be expected because they are
different chemical structures, may not interact in the same
manner with identical amino acid residues in the NMDA receptor
ion channel. A common set of amino acid interactions in the
binding site would however be anticipated. Recently, Hodgikiss
et al. (1993) reported that the (+)FR and (+)MK-801 interact with
a common binding site in electrophysiological experiment. In
the presence of increasing concentrations of (+)FR, the density
of [3H]MK-801 binding sites was not altered whereas binding
site affinity was reduced. Dixon analysis of these data
confirmed that (+)FR competitively inhibited [3H]MK-801 binding.
Therefore the access of (+)FR to the same binding site may be
less dependent on the ongoing activity of the NMDA receptor.
(+)FR inhibited the binding of [3H]MK-801 although (+)FR
was 16- and 12-fold less potent than (+)MK-801 in the presence
of added L-glutamate (10 p.M) using whole brain membranes and
synaptosomal membranes, respectively. This result is
consistent with data obtained from the NMDA-induced convulsion
test in mice. (+)FR (0.32 pg, i.e.v.) completely inhibits
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convulsion whereas only 0.032 (ig (+)MK-801 is required,
indicating that (+)FR is 10 times less potent than (+)MK-801 in
this test (Nakanishi et al., 1995). Wong et al. (1988) showed
the inhibition of [3H]MK-801 binding to well washed
synaptosomal membranes by known non-competitive NMDA
antagonists. The order of potency for their antagonists was
(+)MK-801 (Kd = 3 nM) > TCP (Ki = 14 nM) > PCP (Ki = 42 nM) »
ketamine (Ki = 1090 nM). In the present study with synaptosomal
membranes in the presence of added L-glutamate, the Kd value
for (+)MK-801 was 3.3 nM and the Ki value for (+)FR was 40 nM.
Therefore it seems that (+)FR and PCP have a similar potency as
inhibitors of [3H]MK-801 binding to rat cortical membranes.
Sherriffs et al. (1993) showed that a number of NMDA receptor
channel blockers had very similar Ki values as inhibitors of both
[3H]MK-801 and [3H](+)FR binding indicating that both ligands
label the same site (Table 2.7). In addition, it was shown that
the potency of (+)FR was similar to that of PCP (Table 2.7).
This result appears to correspond to previous observations that
(+)FR and PCP have anti-ischaemic effects at similar doses in
the gerbil transient ischaemic model (Katsuta et al., unpublished
data). Interestingly, the dose of (+)FR for producing PCP-like
behaviour (e.g. head-weaving, turning, ataxia) in mice is
significantly higher in comparison with PCP (Shirakawa et al.,
unpublished data), indicating that PCP-like behaviour induced by
(+)FR and PCP may not only be due to antagonism of the NMDA
receptor linked ion channels.
When compared with the corresponding (+)enantiomers,
(-)FR and (-)MK-801 were respectively 98- and 4.2-fold less
potent as inhibitors of [3H]MK-801 binding to synaptosomal
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TABLE 2.7 : Inhibition of |"3H](+)FR and [3.H1MK-801 Binding to Rat
Cortical Synaptosomal Membranes by Non-competitive NMDA
Receptor Antagonists
Kd / Ki (nM)
raHlMFR [3H]MK-8Q1
(+)FR 45.4 ± 3.9 35.4 ± 3.8
(-)FR 4732 ± 395 3756± 227
(+)MK-801 6.45 ± 0.71 3.57 ± 0.4
(-)MK-801 18.4 ± 3.5 16.0 ± 1.6
PCP 35.8 ±2.8 36.2+ 4.5
Ketamine 576±107 354 ± 59.0
N-Allylnormetazocine 304 ± 41.8 31 6 ± 24.8
Cortical synaptosomal membranes were incubated with 10 nM
[3H](+)FR (45 min) or 1 nM [3H]MK-801 (120 min) in the presence
of 10 jiM L-glutamate and increasing concentrations of test
drugs (0.1 nM - 300 p.M). Non-specific binding was determined
in the presence of 30 |iM unlabelled ligand. Ki values were
calculated from the equation Ki = ICso / (1+ L/Kd). Values are
mean ± S.E.M. of at least three experiments performed in
duplicate. (taken from Sherriffs et al., 1993)
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membranes in the presence of added L-glutamate. Thus the two
stereoisomers of FR showed a much larger difference in affinity
when compared with the stereoisomers of MK-801. This
phenomenon was also observed in the mouse NMDA-induced
convulsion test (Nakanishi et al., 1995). For an inhibitory
effect of i.c.v. injection of drugs on NMDA-induced convulsions,
(-)FR is about 100 times less potent than (+)FR whereas
(+)MK-801 and (-)MK-801 have almost the same potency. This
difference is thought to be a reflection of the differences in
their chemical structures and in particular to the quazi-
symmetrical nature of the MK-801 molecule. At the chiral
centre of FR, all four substituents are substantially different,
whereas two of the groups at the chiral centre of MK-801 are
rather similar (Fig.2.1).
In advance of the synthesis of [3H](+)FR, the chlorinated
aromatic precursor (+)CI-FR was tested against [3H]MK-801
binding to rat cortical synaptosomal membranes. (-t-)CI-FR had a
reasonably high affinity for [3H]MK-801 binding sites, being
about 5-fold less potent than (+)FR. Therefore for the small
amount of (+)CI-FR which potentially may remain after
tritiation, a suitable method was required for its complete
separation from (+)FR. As shown in fig.2.2, an open column
method used in the present experiment gave good separation of
(+)FR from (+)CI-FR. This method is also expected to separate
side products after synthesis of [3H](+)FR and radiolysis
products following storage of the material. Using this open
column method, the crude [3H](+)FR synthesised from (+)CI-FR
was purified and [3H](+)FR was obtained as the TFA salt.
(+)FR(TFA salt) had similar characteristics as an inhibitor of
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[3H]MK-801 binding when compared with FR115427 ((+)FR(HCI
salt)), suggesting that [3H](+)FR(TFA salt) is a suitable ligand
for the binding studies. [3H](+)FR obtained by an open column
method had high purity (> 90%) as confirmed by TLC method.
Thus the open column and TLC methods were useful for checking
purity or decomposition of [3H](+)FR during storage under liquid
nitrogen.
Sherriffs et al. (1993) demonstrated that [3H](+)FR can be
used for the pharmacological investigation of the NMDA receptor
ion channel. The [3H](+)FR binding site density is similar to the
Bmax value for [3H]MK-801 in rat cortical synaptosomal
membrane preparation. The Kd (45 nM) for [3H](+)FR binding is in
agreement with the Ki value (35 nM) for (+)FR measured in the
[3H]MK-801 binding assay. The affinities of other NMDA receptor
channel blockers such as PCP and ketamine for the [3H](+)FR
binding site are consistent with binding to a similar site to that
occupied by (+)MK-801. These results indicate that [3H](+)FR
and [3H]MK-801 bind to a similar site within the NMDA receptor
ion channel. Using [3H](+)FR as the radioligand, (+)FR is
approximately 100-fold more potent than (-)FR, whilst there is
only a 3-fold separation in the affinities of the stereoisomers
of MK-801, suggesting that the stereoselectivity of FR is much
greater than that of MK-801. Thus radioligand binding studies
using [3H](+)FR are in agreement with the results in the present
work.
Using purified [3H](+)FR, its in vivo distribution after
intravenous injection to rats was examined. Intravenous
administration of [3H](+)FR resulted in a rapid accumulation of
radioactivity in rat brain, indicating that (+)FR can penetrate the
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blood-brain barrier. The clearance of radioactivity from liver
was slower than kidney and heart. At all time points used,
although a significant difference could not be shown, the
radioactivity concentrations in the cerebellum was lower in
comparison with other brain regions. The ratios of the six brain
regions to cerebellum were shown in table 2.5. Rostral cortex,
caudal cortex, hippocampus and striatum had higher ratio than
midbrain and brainstem with exception of the 15 min time point.
In vitro autoradiography with [3H]MK-801 in rat brain showed
that the highest concentrations of [3H]MK-801 binding sites
occur in brain regions such as hippocampus and cerebral cortex,
and very low levels are detected in brainstem and cerebellum
(Bowery et al., 1988). In addition, an in vivo [3H]MK-801
autoradiography study in mouse brain demonstrated regional
selectivity with the highest density in hippocampus and cortex
and with virtually no specific binding in the cerebellum (Price et
al., 1988b). However in the present study it is not clear if the
[3H](+)FR represented binding to NMDA receptors. For this it
would be necessary to see if the relative distribution of
[3H](+)FR in cortex and hippocampus compared with cerebellum is
altered as a result of saturation of the NMDA receptor ion
channels with unlabelled drug. The time course of radioactivity
in brain regions after [3H](+)FR injection was similar when
compared the time course of in vivo distribution of (+)-3-
[125|]jodo-MK-801 in rat brain regions (Gibson et al., 1992).
Following intravenous administration of (+)-3-p 251 ] j o d o -
MK-801, localisation in 6 brain regions is rapid with peak
concentrations occur within 30 min, and the distributions of
radioactivity at 30, 60, 120 and 240 min post-injection are
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0.6-1.1, 0.3-0.5, 0.1-0.2 and 0.1-0.2 %D/g, respectively. The
blockade of localisation of (+)-3-[i25|]jodo-MK-801 by
unlabelled MK-801 is demonstrable when examined 4 hr post-
injection, sufficient time to permit washout of the non-
specifically bound radioligand, indicating that (+)-3-p25|]j0do-
MK-801 may be a useful in vivo imaging agent for the NMDA
receptor-channel complex (Gibson et al., 1992). However Gibson
et al. (1992) concluded that (+)-3-[i25|]jodo-MK-801 is not ideal
to provide a means of quantitative evaluation of the NMDA
receptor-channel complex because of very high non-specific
binding. Blin et al. (1991) reported PET studies using
18F-Iabelled fluoro-methyl-MK-801 (p8F]FMM) in baboons.
A differential retention of [18F]FMM exists in the cerebral cortex
and striatum relative to cerebellum, with region/cerebellum
ratios values ranging from 1.1 to 1.6. These ratios values are
compatible with those for [3H](+)FR (rostral cortex/cerebellum =
1.15-1.24, striatum/cerebellum = 1.14-1.21). Pretreatment
with pharmacological doses of MK-801 or PCP was not able to
clearly alter [18F]FMM brain regional kinetics, indicating an
extremely high non-specific binding (Blin et al., 1991).
In conclusion, [3H](+)FR may be a useful tool for in vivo
imaging of NMDA receptors. However it will be important to
determine if the higher concentrations (which are quite small)
in brain regions such as rostral/caudal cortex and hippocampus
compared with cerebellum are due to in vivo specific binding of
[3H](+)FR to the NMDA receptor or for example to differences in
pharmacokinetics of [3H](+)FR in cerebellum. It may be possible
to do this by pretreatment with unlabelled drug ((+)FR or
(+)MK-801) at a dose sufficient to saturate the receptors prior
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to injection with [3H](+)FR, as was carried out for [ 1251]5-1c
(see chapter 3 section 3.2.9). In addition, it will be important
to confirm that the radioactivity in the brain is authentic
[3H](+)FR using for example the open column method or TLC. As
described in chapter 1, it is well established that the in vitro
binding of MK-801 is markedly enhanced in the presence of
glutamate, and extracellular levels of glutamate are increased
in cerebral ischaemia. It has been suggested that in vivo
autoradiographic studies with (+)-3-[i25|]jodo-MK-801 show
increased receptor-mediated binding in ischaemic rat brain
(McCulloch and Iversen, 1991). In ischaemic tissues, specific
binding of (+)-3-[i25|]jodo-MK-801 is 4-fold that of non-specific
binding to the cerebellum. Thus (+)-3-[i25|]iodo-MK-801 might
be useful as a possible SPET ligand under ischaemic conditions
such as stroke. Therefore it would be interesting to examine
the in vivo distribution of [3H](+)FR under cerebral ischaemic
conditions in anticipation of the possible future development of
a close structural analogue as a SPET ligand.
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CHAPTER 3
DEVELOPMENT OF PHOTOAFFINITY AND SPET LIGANDS
FOR THE 5-HT TRANSPORTER
3.1 INTRODUCTION
The radiolabelled forms of selective 5-HT uptake
inhibitors have been used in ligand binding experiments for
characterisation of the 5-HT transporter in blood platelets and
brain. [3H]lmipramine was the first blocker to be developed as
a 5-HT transporter radioligand, but it was reported to bind to
high (Kd = 6.9 nM) and low (Kd = 292 nM) affinity sites in brain
tissue (Hrdina, 1984). Tricyclic antidepressants effectively
inhibit the high affinity component of [3H]imipramine binding to
rat cortical membranes with a rank order of potency which
corresponds with their ability to block 5-HT uptake in vitro. In
contrast, the order of potency of drugs tested as inhibitors of
low affinity [3H]imipramine binding, does not correlate with
their ability to inhibit 5-HT uptake. Thus only the high affinity
binding sites for [3H]imipramine correspond to the 5-HT
transporter. Recently more selective 5-HT uptake inhibitors
such as [3H]citalopram (D'Amato et al., 1987a), pHjparoxetine
(Habert et al., 1985), [3H]norzimelidine (Hall et al., 1982) and
[3H]indalpine (Benavides et al., 1985) were utilised to label 5-HT
uptake sites in brain. In contrast to the [3H]imipramine binding
assay which must be conducted at 0°C, presumably to slow
dissociation of the ligand from the transporter, [3H]paroxetine
and [3H]citalopram binding can be conducted at higher
temperatures (25°C or 37°C) (Habert et al., 1985; D'Amato et
al., 1987a). This property could be important for
characterisation of the 5-HT transporter and drug interactions
under physiological conditions. It has been shown that both
[3H]citalopram and [3H]paroxetine bind selectively with very high
affinity (low nanomolar range) to a single class of sites and that
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the potencies , of a range of drugs for inhibition of ligand binding
and 5-HT uptake is closely correlated (D'Amato et al., 1987a;
Habert et al., 1985; Marcusson et al., 1988) thus indicating that
[3H]paroxetine and [3H]citalopram indeed selectively bind to the
5-HT transporter. In addition, ligand binding of both
radioligands are almost completely abolished after lesioning of
5-HT neurons in rat brain whereas [3H]imipramine binding is only
decreased partially, indicating that the binding sites labelled by
[3H]paroxetine and [3H]citalopram corresponds to the neuronal
5-HT transporter (D'Amato et al., 1987a; Habert et al., 1985;
Marcusson et al., 1988). Thus [3H]citalopram and [3H]paroxetine
are superior radioligands for the 5-HT transporter in comparison
with [3H]imipramine. Autoradiographic studies showed that the
distribution pattern of [3H]paroxetine and [3H]citalopram binding
in rat brain are consistent with the organisation of serotonergic
terminals and cell bodies (DeSouza and Kuyatt, 1987; Hrdina et
al., 1989; D'Amato et al., 1987a). In these studies, high
binding densities were found in the brain stem nuclei, thalamus
and hypothalamus, moderate binding in basal ganglia, cortex and
hippocampus, whereas low binding density was detected in
cerebellum. Dissociation of receptor-ligand complex can be
studied either by extensive ("infinite") dilution of the sample or
by addition of high amounts of unlabelled ligands (both of which
really prevent further [3H]ligand-receptor association), and
these two procedures should theoretically give the same result.
However it has been reported that the dissociation of
[3H]imipramine, [3H]paroxetine and [3H]citalopram from the 5-HT
transporter are influenced by several drugs (Plenge and Mellerup,
1985; Plenge et al., 1990; Plenge et al., 1991). For example,
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5-HT (200 (J.M) markedly decreased the dissociation rate of
[3H]imipramine, had a moderate effect on [3H]paroxetine but very
little effect on [3H]citalopram dissociation from platelet
membranes. Almost no dissociation of [3H]paroxetine by 200 pM
of citalopram and paroxetine is observed using rat brain
membranes. In addition, the dissociation rate of [3H]citalopram
is decreased to a greater extent by citalopram than by
paroxetine. These results indicate that the three ligands may
not bind to identical domains on the 5-HT transporter. In human
brain, the relative potencies of various compounds in inhibiting
[3H]paroxetine and [3H]citalopram binding are identical to those
in rat brain, suggesting that binding of both ligands in human
brain exhibit the same pharmacological characteristics as in rat
brain (Backstrom et al., 1989; D'Amato et al., 1987b). However,
80% of pHjcitalopram binding in human cortex is 5-HT sensitive,
whereas only 40% of [3H]paroxetine binding is 5-HT sensitive,
suggesting that the amount of specific binding of [3H]citalopram
is higher than that of [3H]paroxetine (Backstrom et al., 1989;
D'Amato et al., 1987b). Thus [3H]citalopram may be a better
radioligand for studying the 5-HT transporter in human brain.
Neuroimaging techniques such as SPET are potentially very
useful methods for studying neurotransmitter receptors in the
living human brain. The development of SPET ligands for the
5-HT transporter will establish powerful methods for diagnosis
and monitoring the course of psychiatric disorders such as
depression. However, no human studies for the 5-HT transporter
have been reported so far. Previously, Wolfe et al. (1987)
demonstrated that [3H]cyanoimipramine can be given to rats to
provide a measure of 5-HT uptake sites in the brain in vivo.
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Recent work has demonstrated that [3H]paroxetine and
[3H]citalopram are selective agents for in vivo labelling of
cerebral 5-HT uptake sites (Scheffel and Hartig, 1989; Scheffel
and Ricaurte, 1990; Hume et al., 1991). The in vivo distribution
of binding of both radioligands in mouse and rat brain is
consistent with the expected in vitro distribution, and the
binding correlates closely to the localisation of 5-HT uptake
sites. In addition, a profound reduction in in vivo [3H]paroxetine
binding was shown in brains of rats treated with
the psychoactive recreation drug 3,4-methylenedioxy-
methamphetamine (MDMA) (Sheffel and Ricaurte, 1990). This
effect of MDMA was similar to results observed using in vitro
[3H]paroxetine binding in rat brain (Battaglia et al., 1987;
Sharkey et al., 1991). These reports suggest that paroxetine
and citalopram labelled with suitable radionuclides might be
useful for studying the 5-HT transporter in living human brain
using neuroimaging techniques such as PET and SPET.
The topography of the 5-HT transporter including a number
of its amino acid groups was investigated by Langer and Graham
(1989). Covalent modification of cystein residues by the
sulphydryl-alkylating reagent N-ethylmaleiimide (NEM), or of
tyrosine residues by the alkylating reagent Q_-nitrobenzyl-
sulphonyl fluoride, produce large reductions in [3H]paroxetine
binding to rat cortical membranes. These results suggest that
sulphydryl and tyrosine hydroxyl groups are located at, or very
close to the paroxetine binding site on the 5-HT transporter.
Treatment of the cortical membranes with trypsin and
chymotrypsin also produces a reduction in [3H]paroxetine
binding, and [3H]paroxetine binding is decreased after treatment
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of membranes with phospholipase C and A2. Thus the 5-HT
transporter requires an intact protein and lipid environment in
order to maintain its ability to bind [3H]paroxetine. For
characterisation and purification of the 5-HT transporter, it has
been solubilised from rat cortical membranes using digitonin
(Habert et al., 1986). The pharmacological profile of the
solubilised transporter was similar to that of the intact
transporter in cortical membranes. Analysis of the purified
preparation showed a major polypeptide with a molecular weight
of 110,000 (Langer and Graham,1989). Recently, the cloning of
5-HT transporter was reported by two groups (Blakely et al.,
1991; Hoffman et al., 1991). The complementary DNA (cDNA)
sequence from rat brain predicts a protein of 607 amino acids
with a relative molecular mass of 68,000 and displays 11 or 12
transmembrane domains (Blakely et al., 1991). On the other
hand, the study with a cDNA from rat basophilic leukemia cells
predicts a protein of 653 amino acids with 12 to 13 putative
transmembrane domains (Hoffman et al., 1991). The 5-HT
transporter has significant homology to the GABA, dopamine and
noradrenaline transporters. Both studies showed that the 5-HT
transporter expressed from the cDNA has pharmacologically very
similar characteristics to the rat brain 5-HT transporter, with
high affinity sites for selective 5-HT uptake inhibitors such as
citalopram and paroxetine.
Photoaffinity labelling is a powerful technique for
biochemical investigation of receptors. Previously, Rotman and
Pribluda (1982) demonstrated that [3H]azido-imipramine,
a photoaffinity ligand for the 5-HT transporter, binds covalently
to guinea pig brain synaptosome preparations and labels two
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main proteins with molecular weights of 60,000-65,000.
Studies with more selective photoaffinity ligands than
imipramine will provide useful information for understanding of
the native 5-HT transporter.
In the present study, citalopram (Fig.3.1) rather than
paroxetine was chosen as a prototype compound for both
photoaffinity and SPET ligands. [3H]Citalopram binds to a single
site with a Kd value for the 5-HT transporter of about 1 nM
although this is about 10-fold lower affinity than that of
[3H]paroxetine (D'Amato et al, 1987a; Marcusson et al, 1988).
However citalopram has greater selectivity than paroxetine
which has some affinity also for the noradrenaline transporter
(Hyttel, 1982). In addition, of major importance was the ease
of incorporation of site directed "atoms" into citalopram
structure compared with paroxetine.
Bigler et al. (1977) reported the structure-activity
relationships of citalopram analogues using in vitro [14Q]5-HT
uptake into rabbit platelets. As shown in table 3.1, a halogen
atom (F, CI and Br) or a cyano group can be substituted on the
5 and 4' positions of citalopram without loss of biological
activity. Therefore, citalopram analogues containing either an
azide or acylazide moiety at the 5 or 4' position may be suitable
photoaffinity ligands. Similarly, 5 or 4'-iodo-citalopram
analogue might be expected to provide a SPET ligand. Therefore,
5-azido-citalopram (5-AC) (Fig.3.1) and 5-iodo-citalopram
(5-IC) (Fig.3.1) were synthesised by Dr.I.M.Dawson in the
Department of Pharmacology, University of Edinburgh as









Citalopram : R = CN
5-Azido-Citalopram (5-AC) : R = N3
5-lodo-Citalopram (5-IC) : R = I
Paroxetine
Fig. 3.1 Chemical structures of citalopram analogues and paroxetine
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Citalopram : 5 = CN
4' = F
5 4' [14C]5-HT uptake, ICso (nM)
CN F (citalopram) 1 4






Rabbit platelet-rich plasma was incubated with [14C]5-HT in the
presence of test compounds. Platelets were isolated by
centrifugation, and residual radioactivity determined by liquid
scintillation counting (taken from Bigler et al., 1977).
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The purpose of the study in this chapter was to evaluate
5-AC as a photoaffinity ligand and 5-IC as a SPET ligand for the
5-HT transporter.
3.2 METHODS
3.2.1 Preparation of Rat Cortical Synaptosomes
The cerebral cortex from male Sprague Dawley rats
(240-310 g) was dissected and gently homogenised in 20 vols
(V/W) of ice cold 0.32 M sucrose using a glass teflon
homogeniser, and centrifuged at 1,000g at 4°C for 10 min. The
pellet was discarded and the supernatant was centrifuged at
17,000g at 4°C for 20 min. The crude synaptosomal pellet (P2)
was suspended in a modified Krebs-Ringer-phosphate buffer,
pH 7.4 (122 mM NaCI, 4.82 mM KCI, 0.97 mM CaCl2, 1.21 mM.
MgS04, 12.7 mM Na2HP04, 1.5 mM NaH2P04, 10 mM glucose and
1 mM ascorbic acid). For experiments to determine appropriate
incubation time and tissue concentration for [3HJ5-HT uptake,
the P2 pellet was resuspended in 20 or 80 vols, and for
experiments to examine drug potency for inhibition of [3H]5-HT
uptake 20 vols were used.
3.2.2 Preparation of Rat Cortical Membranes
The cerebral cortex from male Sprague Dawley rats
(250-330 g) was dissected and homogenised in 50 vols of ice
cold 50 mM Tris-HCI buffer (pH 7.4) containing 120 mM NaCI and
5 mM KCI using a glass teflon homogeniser. The homogenate
was centrifuged at 30,000g at 4°C for 10 min. The resultant
pellet was washed by resuspension in 50 vols of Tris-HCI buffer
and recentrifuged. The final crude membrane pellet was
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resuspended in Tris-HCI buffer (25 vols) and stored at -20°C
until required. On the day of [3H]paroxetine and [3H]citalopram
binding experiments, the membrane suspension was thawed at
room temperature then diluted to 300 vols of Tris-HCI buffer.
3.2.3 [3H]5-HT Uptake
Uptake of [3H]5-HT into rat cortical synaptosomes was
carried out by preincubating 100 pil aliquots of synaptosomal
suspension (1.25 or 5 mg wet weight tissue/ml for experiments
to determine appropriate incubation time and tissue
concentration, 1.25 mg wet weight tissue/ml for experiments to
examine drug potency) with Krebs-Ringer-phosphate buffer
(control) or 6-7 concentrations of test drug in duplicate for
5 min at 37°C before addition of [3H]5-HT (specific activity :
12 Ci/mmol, final concentration 5 nM) to give a final assay
volume of 500 pi. Samples were vortexed briefly then
incubated at 37°C for various times. Uptake was terminated by
dilution with ice cold Krebs buffer (2 ml) and rapid filtration
(Whatman GF/B filter) followed by two washes with 2 ml ice
cold Krebs buffer. This procedure was carried out within
15 sec. In order to define the active component of [3H]5-HT
uptake, for assessment of the trapping of [3H]5-HT, replicate
zero-time samples (samples incubated in the absence of
[3H]5-HT were diluted with ice cold buffer prior to addition of
[3H]5-HT and then filtered) were carried out. For assessment of
the trapping plus passive diffusion of [3HJ5-HT, incubation of
samples at 37°C was carried out in the presence of 1 pM
citalopram. Both gave the same results (data not shown).
Therefore replicate zero-time samples were routinely used to
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define the active component of [3H]5-HT uptake. The filters
were transferred to scintillation vials, then 100 pi of formic
acid (100%) was added to each vial to digest the membrane
protein followed 10 min later by addition of 4 ml of
scintillation fluid (Packard Emulsifier Safe). The radioactivity
in the vials was measured in a Packard 1900CA liquid
scintillation analyser using automatic quench correction.
Quadruplicate 100 pi samples of [3H]ligand as standards were
counted in order for the exact ligand concentration to be
calculated for individual experiments.
3.2.4 [3H]Paroxetine and [3H]Citalopram Binding
Binding of [3H]paroxetine and [3H]citalopram to rat cortical
membranes was carried out according to the methods of Habert
et al. (1985) and D'Amato et al. (1987a), respectively. Binding
of both radioligands was carried out by preincubating duplicate
0.5 ml aliquots of membrane suspension with 50 mM Tris-HCI
containing 120 mM NaCI and 5 mM KCI (Tris-HCI buffer), pH 7.4
(control) or 10 concentrations of test drug in duplicate for 2 min
at 25°C before addition of [3H]paroxetine (specific activity :
29 Ci/mmol, final concentration 0.2 nM) or [3H]citalopram
(specific activity : 87 Ci/mmol, final concentration 0.5 nM) to
give a final assay volume of 2 ml for [3H]paroxetine binding or
1 ml for [3H]citalopram binding. Samples were vortexed briefly
then incubated at 25°C for various times. 10 pM unlabelled
citalopram was used to define specific binding for both
radioligands. Incubation was terminated at room temperature
by rapid filtration under vacuum on a Brandel Cell Harvester
using Whatman GF/B filters, pretreated with 0.05%
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polyethyleneimine for 60 min, then washed twice with 5 ml
Tris-HCI buffer. The filters were transferred to scintillation
vials, then 100 pi of formic acid (100%) was added to each vial
to digest the membrane protein followed 10 min later by
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addition of 4 ml of scintillation fluid (Packard Emulsifier Safe).
The radioactivity in the vials was measured in a Packard
1900CA liquid scintillation analyser using automatic quench
correction. Quadruplicate 100 pi samples of [3H]ligand as
standards were counted in order for the exact ligand
concentration to be calculated for individual experiments.
3.2.5 Photoinactivation of The 5-HT Transporter by 5-Azido-
Citalopram (5-AC)
A flow diagram for the photoinactivation experiments is
shown in fig.3.2. Rat cortical membranes were prepared as
described in section 3.2.2. Membrane suspensions (50 mg wet
weight/5 ml) in 50 mM Tris-HCI buffer containing 120 mM NaCI
and 5 mM KCI (pH 7.4) were incubated in the dark in the absence
or presence of 5-AC (final concentration 200 nM) at 25°C for
30 min to reach equilibrium binding. After the 30 min
incubation, for photolysis, the membrane suspensions (50 mg
wet weight/5 ml) were contained in plastic petri dishes (60 x
15 mm) 2 cm (for 400 W irradiation) or 12 cm (for 15 W
irradiation) below a U.V. lamp and irradiated for various times.
Following irradiation, the membrane suspensions were
transferred to centrifuge tubes, the petri dishes washed with
3 x 5 ml Tris-HCI buffer then tubes were centrifuged at 30,000g
at 4°C for 10 min. The membrane pellets were resuspended in
20 ml of Tris-HCI buffer, incubated for 10 min at 25°C to allow
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1) Suspension of rat cortical membranes
(50 mg wet weight/5 ml)
1. Incubate with 5-AC (200 nM) in the dark
25°C, 30 min
y
2) Irradiation with U.V. light (400 W or 15 W)
1. Add 5-AC (200 nM)
2. Incubate (25°C, 30 min)
3) Irradiation with U.V. light
y
4) Wash membrane free of 5-AC
1. 30,000 g, 4°C, 10 min
2. Resuspend in buffer
3. Incubate (25°C, 10 min)
4. 30,000 g, 4°C, 10 min
5. Resuspend in buffer
6. Incubate (25°C, 10 min)
7. 30,000 g, 4°C, 10 min
8. Resuspend in buffer
y
5) Determine specific binding for [3H]citalopram binding and
compare with control membrane suspension
Fig.3.2 Flow diagram for photoinactivation of the 5-HT
transporter by 5-AC. For single irradiation, procedure 2) was
omitted.
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reversibly bound drug to dissociate, then recentrifuged in order
to remove unbound 5-AC and its photoactivated products. This
washing and incubation procedure was repeated one additional
time. Finally, pellets were resuspended in 15 ml of Tris-HCI
buffer (final volumes 20 ml) and used for [3H]citalopram binding.
Membranes were incubated with [3H]citalopram (0.5 nM) in the
presence of 10 concentrations of unlabelled citalopram at 25°C
for 60 min as described in section 3.2.4. For experiments using
two U.V. steps, a second dose of 5-AC (final concentration 200
nM) was added to the membrane suspension immediately after
the first irradiation, and the incubation continued for a further
30 min at 25°C followed by a second U.V. irradiation. Following
the second irradiation, the washing and incubation steps were
carried out as described above.
3.2.6 In Vitro [125115-lodo-citalopram (5-IC) Binding
Rat cortical membranes were prepared as described in
section 3.2.2. The binding assays using appropriate amounts of
[125|]5-IC (2000 Ci/mmol, final concentration 0.05 nM) and a
range of unlabelled 5-IC concentrations were carried out as
described in section 3.2.4 ([3H]citalopram binding). After
filtration, the filter discs were transferred to Sterilin RT-30
plastic tubes and bound [125|]5-|C determined using gamma
spectrometry. 10 pM unlabelled citalopram was used to define
specific binding. Quadruplicate 100 pi samples of [125|]5-|Q as
standards were counted in order for the exact ligand
concentration to be calculated for individual experiments.
1 1 6
3.2.7 Protein Assay
Protein was assayed according to Bradford (1976). 100 ml
of 85% (w/v) phosphoric acid was added to Coomassie Brilliant
Blue (100 mg) in 50 ml of 95% ethanol then diluted to a final
volume of 1 litre and filtered through Whatman Number 1 filter
paper. This reagent (2.5 ml) was added to duplicate 100 pi of
sample in the plastic cuvettes. The optical density of sample
was read 20 min later at 595 nm on a spectrophotometer.
Bovine serum albumin (25-200 pg/ml) dissolved in 50 mM
Tris-HCI buffer was used as standard. The protein concentration
of membrane samples was calculated from the standard curve.
An example of the standard curve is shown in fig.3.3. Samples
outwith the linear part of the standard curve were diluted with
Tris buffer and re-assayed.
3.2.8 Data Analysis of Uptake and Binding Experiments
Data from individual experiments for [3H]5-HT uptake,
[3H]paroxetine and [3H]citalopram binding were analysed by least
squares fit to the logistic expression :
Y = MXp / (XP + IC50)
and Kd or Km values calculated. Ki values were calculated from
the equation :
Ki = ICso / (1 + L/Kd or Km)
where L is ligand concentration. Bmax values were calculated
from the equation :
b = Bmax • L / (L + Kd)
where b is bound ligand concentration at the [3H]ligand
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jjg protein/ml
Fig. 3.3 An example of a typical protein standard curve. The
curve was constructed over the range 25 - 200 jig bovine serum
albumin/ml, and is essentially linear over this range. Protein
concentration of membrane samples was calculated from the
standard curve.
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v = Vmax • S / (S + Km)
where S is [3H]5-HT substrate concentration. The values for
Kd, Km, Ki, Bmax and Vmax were expressed as mean ± S.E.M. from
three to nine independent experiments.
3.2.9 In Vivo Distribution of [125|]5-|C
Male Sprague Dawley rats (220-330 g) were allowed
access to food and water ad libitum prior to the experiments.
Under urethane anaesthesia (10% solution, 10 ml/kg, i.p.), the
left femoral vein was catheterized with polyethylene tubing for
drug administration. Rats were injected over 30 sec with
20 pCi of [125|]5-IC (corresponding to 20 nmol of ["• 25|]5-IC) in
250 pi of saline containing 10% ethanol, 1% Tween-80 and 10
units of heparin through the cannula placed in the left femoral
vein. To complete injection of the drug, 500 pi of the
heparinized saline was used to flush the cannula immediately
following infusion of the [125|]5-IC. For experiments to
determine the time course of [125|]5-IC distribution, at various
times post-injection (30, 60, 90, 180 and 300 min), samples of
blood (~5ml) were taken in a heparinised syringe from the
inferior vena cava and the rats were killed by decapitation.
The brains were removed, divided into 6 regions : rostral cortex,
caudal cortex (cerebral cortex - rostral cortex), hippocampus,
brainstem, midbrain and cerebellum. In addition, liver, kidney,
heart, lung and thyroid were removed, blotted dry and weighed.
Samples 100 to 200 mg of each organ were taken, again blotted
to remove as much blood or urine as possible and transferred to
vials and radioactivity determined using gamma spectrometry.
For the 60 min and 300 min rats, the right femoral artery was
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also cannulated to obtain arterial blood samples at various
times post-injection of [125|]5-IC. At each time point the
first 100 pi of blood was discarded since it probably
represented the dead volume in the cannula. A 300 pi sample
was then collected in a heparinised microcentrifuge tube. A
100 pi sample was transferred to vials and radioactivity
determined.
In order to assess 5-HT transporter bound [ 1251]5-1Q,
heparinised saline or paroxetine (1 mg/kg) was injected via the
left femoral vein 5 min before injection of [125|]5-IO. The rats
were killed 2 hr after [125|]5-|C injection, and brain samples
prepared as described above. The results for the tissue
distribution study were expressed as % injected dose per gram
of tissue (%D/g) or amol per milligram of tissue (amol/mg), and
results for the blood distribution study were expressed as %
injected dose per ml of blood (%D/ml). In order to calculate the
exact amount of [125|]5-iq injected into the rats, standards were
obtained by counting quadruplicate 100 pi samples of a 1 : 500
dilution of original radioactivity used for injection.
3.2.10 Pharmacokinetic Analysis
The data for radioactivity in blood expressed as %D/ml
after [125|]5-|C injection were fitted to biexponential functions
using least squares regression analysis since the fitting to
biexponential functions was better than monoexponential
functions. The equation used was Y = A x e(-at) + B x e(-Pt),
where t is time after administration, Y is the measured
radioactivity, A and B are the coefficients of the exponential
terms, a is the apparent distribution rate constant, (3 is the
1 20
apparent terminal rate constant. The data for radioactivity in
brain and peripheral tissues were fitted to monoexponential
functions using least squares regression analysis. The equation
used was Y = A x e(-Ke • t)) where Ke is the elimination rate
constant. The following pharmacokinetic parameters were
calculated : 1) half-life (ti/2) = 0.693/Ke or a or p, 2) the area
under the radioactivity concentration-time curve from zero to
time infinity (AUC). AUC was calculated using the trapezoid
method.
3.2.11 Statistical Analysis
The Student's t-test was used for statistical comparison
of data of in vitro binding and in vivo binding between drugs or
conditions when necessary. Differences were considered
significant when P was < 0.05.
3.2.12 Materials
5-AC and 5-IC were synthesised in the Department of
Pharmacology, University of Edinburgh by Dr.l.M.Dawson. 5-AC
was dissolved in ethanoL the bottle wrapped in tin foil, and
stored at 4°C in the dark. 5-IC was dissolved in glass distilled
water. [125|]5-|C was synthesised and purified by Dr.I.M.Dawson
in the Department of Pharmacology, University of Edinburgh.
[125|]5-ic was stored at -20°C until required. [3H]5-HT
creatinine sulphate (specific activity : 12 Ci/mmol) and
[3H]citalopram (specific activity : 87 Ci/mmol) were obtained
from Amersham International. [3H]Paroxetine (specific activity
: 29 Ci/mmol) was obtained from NEN. These radioligands were
diluted to 1 pM in glass distilled water and stored under liquid
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nitrogen in volumes sufficient for individual experiments. The
following drugs were donated as gifts : citalopram (SmithKline
Beecham), paroxetine (Ferrosan) and fluoxetine (Eli Lilly). Other
drugs and reagents were obtained from Sigma.
3.3 results
Initial experiments were carried out to establish and
validate the incubation conditions required to measure active
uptake of [3H]5-HT and specific binding of [3H]citalopram and
[3H]paroxetine.
3.3.1 Kinetics and Pharmacology of |"3.h]5-HT Uptake into Rat
Cortical Svnaptosomes
The time course of active [3HJ5-HT (5 nM) uptake into rat
cortical synaptosomes (5 mg or 1.25 mg wet weight tissue/ml)
was linear for only a short time (Fig.3.4). Therefore, in order to
measure approximate initial rates of 5-HT uptake to ensure an
accurate assessment of drug potency, incubations of [3H]5-HT
with synaptosomes were limited to 5 min. At this time point,
active uptake represented about 70% of total uptake. In the
5 min incubation period, 17% (5 mg wet weight tissue/ml) and
7% (1.25 mg wet weight tissue/ml) of the total content of
[3H]5-HT was taken up into synaptosomes. When drugs were
examined using this assay, their potencies were calculated using
the equation :
Ki =IC50/(1 + [S]/Km) ([S] : substrate concentration).
However, the equation is valid only when certain conditions are
satisfied i.e. [S]t = [S]a = [S]p ([S]t : total substrate
concentration, [S]a : ligand concentration in the absence of
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Fig. 3.4 Time course of [3H]5-HT uptake into rat cortical
synaptosomes. Synaptosomes (1.25 or 5 mg wet weight tissue
/ tube) were incubated with [3H]5-HT (5 nM) for various times at
37°C. Replicate zero-time samples were carried out to define
the active component of [3H]5-HT uptake. Data are from a
representive experiment. Each point is the mean value of
duplicate determinations. O 5 mg tissue; • 1.25 mg tissue.
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inhibitor, [S]p : ligand concentration in the presence of
inhibitor). Using 5 mg wet weight tissue/ml of synaptosomes,
[S]a was 4.2 nM since 17% of [3H]5-HT (5 nM) was taken up into
synaptosomes whereas [S]p was 5 nM when test drug completely
inhibited [3H]5-HT uptake. When 1.25 mg wet weight tissue/ml
was used, [S]a is 4.7 nM. Thus, when the latter tissue
concentration of synaptosomes was used for [3H]5-HT uptake
experiments, substrate depletion during the incubation was
essentially absent and so allowed accurate Ki values to be
determined. Therefore, a tissue concentration of 1.25 mg wet
weight tissue/ml was routinely used when the potency of
various drugs as inhibitors of [3HJ5-HT uptake into synaptosomes
were determined. Analysis of [3H]5-HT uptake data using
unlabelled 5-HT from three separate experiments gave a Km
value of 24.1 ± 3.2 nM and a Vmax value of 0.80 ± 0.07
pmol/5min/mg wet weight tissue. These values correspond
well with data shown by Richelson and Pfenning (1984),
Marcusson et al. (1986) and Thomas et al. (1987).
The pharmacology of [3HJ5-HT uptake into rat cortical
synaptosomes was examined using a range of uptake inhibitors
(Table 3.2, Fig.3.5a). The selective 5-HT uptake inhibitors,
paroxetine (Ki = 0.83 ± 0.05 nM), citalopram (Ki = 2.0 ± 0.4 nM)
and fluoxetine (Ki = 11.3 ± 2.0 nM) had high affinity for the 5-HT
uptake sites whereas the tricyclic antidepressant, desipramine
gave a Ki value of 156 ± 11 nM. The Ki value of each compound
for [3H]5-HT uptake was consistent with the known
pharmacology of the amine transport in serotonergic neurons
(Hyttel, 1982; Thomas et al, 1987). Thus the most potent
inhibitor was paroxetine whereas the least potent inhibitor was
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TABLE 3.2 : Pharmacology of 5-HT Transporter
Km/Ko/Ki (nM)
[3H]5-HT uptake [3H]Paroxetine [3H]Citalopram
binding binding
5-HT 24.1 ± 3.2 (3) 836 ± 72 (4) 349 ± 35 (4)
Citalopram 2.0 ± 0.4 (9) 2.1 ± 0.2 (9) 0.94 ± 0.24 (7)
Paroxetine 0.83 ± 0.05 (3) 0.20 ± 0.02 (6) 0.12 ±0.01 (7)
Fluoxetine 11.3 ±2.0 (3) 6.1 ±1.2 (6) 6.3 ±1.1 (6)
Desipramine 1 56 ± 11 (3) 297 ± 49 (6) 1 54 ±11 (5)
Synaptosomes were incubated with [3H]5-HT (5 nM) in the
absence or presence of increasing concentrations of test drug
for 5 min at 37°C. Replicate zero-time samples were carried out
to define the active component of [3H]5-HT uptake. Membranes
were incubated with [3H]paroxetine (0.2 nM) or [3H]citalopram
(0.5 nM) in the absence or presence of increasing concentrations
of test drug for 60 min at 25°C. Non-specific binding was
determined in the presence of 10 fjM unlabelled citalopram. Ki
values were calculated from the equation Ki = ICso / (1 + L/Kd or
Km). Values are the mean ± S.E.M. from the number of separate






Fig.3.5Inhibitionofa)[ H]5-HTup ake,b[3H]paroxetineindi gndcp ljcitalopraminding. Synaptosomeswerincubatedi h[3H]5-HT( M)ths ncopre efi sing concentrationsftesdrugf5mina37°C.Repli a ezero- imesampleswc rr edofi activecomponentf[3H]5-HTuptak .Membr n swerinc atedi h[3H]p roxetin(0.2nM) [3H]citalopram(0.5nM)itheabsenceopres nfincr asingc ncentrationse td ugf60mi 25°C.Non-specificbi dingwasdeterminedithp es cef10MunlabellcitalopramD tar fromarepresentiveex eri ent.E chpoi tisthm avaluefduplic teterminat ons#5-HT; OCitalopram;AParoxetine;Flu■Desipramine.
desipramine which is known to be a noradrenaline uptake
inhibitor rather than a 5-HT uptake inhibitor (Hyttel, 1982;
Richelson and Pfenning, 1984).
3.3.2 Kinetics and Pharmacology of [3H1Paroxetine Binding to
Rat Cortical Membranes
The time course of specific binding of [3H]paroxetine
(0.2 nM) to rat cortical membranes at 25°C reached equilibrium
after approximately 30 min incubation (Fig.3.6). In order to
ensure that equilibrium was attained, an incubation time of
60 min was used for further investigation of [3H]paroxetine
binding. At this concentration, specific binding represented
about 82% of total binding. Specific [3H]paroxetine binding to
rat cortical membranes was shown to be linear with tissue
concentration from at least 25 to 70 fig of protein per 2 ml
assay (Fig.3.7). A final assay volume of 2 ml was used for the
[3H]paroxetine binding assay in order to prevent depletion of the
free ligand concentration. Therefore, protein concentrations
within this range were used for all subsequent experiments.
Analysis of [3H]paroxetine binding data using unlabelled
paroxetine from six separate experiments gave a Kd value of
0.20 ± 0.02 nM and a Bmax value of 0.82 ± 0.08 pmol/mg protein.
These values were consistent with data shown by Habert et al.
(1985).
Inhibition of [3 Hjparoxetine binding to rat cortical
membranes by 5-HT, citalopram, paroxetine, fluoxetine and
desipramine was tested (Table 3.2, Fig.3.5b). 5-HT inhibited
[3H]paroxetine binding to rat cortical membranes, giving a Ki






























Fig. 3.6 Time course of [3H]paroxetine binding to rat cortical
membranes. Membranes were incubated with [3H]paroxetine
(0.2 nM) for various times at 25°C. Non-specific binding was
determined in the presence of 10 pM unlabelled citalopram.
Data are from a representive experiment. Each point is the
mean value of duplicate determinations.
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Fig. 3.7 Effect of protein concentration on [3H]paroxetine and
[3H]citalopram binding. Membranes were incubated with
[3H]paroxetine (0.2 nM) or [3H]citalopram (0.5 nM) for 60 min at
25°C as a final assay volume of 2 ml and 1 ml respectively.
Non-specific binding was determined in the presence of 10 pM
unlabelled citalopram. Data are from a representive
experiment. Each point is the mean value of duplicate
determinations. • [3H]Paloxetine; A [3H]Citalopram.
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citalopram and fluoxetine had high affinity for [3H]paroxetine
binding sites with Ki values of 2.1 ± 0.2 nM and 6.1 ± 1.2 nM
respectively, whereas desipramine (Ki = 297 ± 49 nM) showed
affinity in the high nanomolar range. Of the drugs tested,
paroxetine (Kd = 0.20 ± 0.02 nM) was the most potent inhibitor
for [3H]paroxetine binding followed by citalopram. Data were
consistent with [3H]paroxetine binding to the 5-HT transporter
(Habert et al.,1985).
3.3.3 Kinetics and Pharmacology of faHlCitalopram Binding to
Rat Cortical Membranes
The time course of [3H]citalopram (0.5 nM) binding to rat
cortical membranes at 25°C showed that equilibrium was
attained after approximately 30 min incubation (Fig.3.8), similar
to that found with [3H]paroxetine binding. Therefore an
incubation time of 60 min was used for further experiment of
[3H]citalopram binding. At this concentration, specific binding
represented about 85% of total binding. Specific [3H]citalopram
binding was shown to be linearly related to protein
concentration in the range 25-70 pg protein per 1 ml assay
(Fig.3.7). As a final assay volume, 1 ml was used because there
was virtually no free ligand depletion. Therefore, protein
concentrations in this range were used for all subsequent
experiments. Data analysis of [3H]citalopram binding using
unlabelled citalopram gave a Kd value of 0.94 ± 0.24 nM and a
Bmax value of 0.85 ± 0.13 pmol/mg protein. These values were
consistent with data shown by D'Amato et al. (1987a).
Inhibition of [3 H]citalopram binding to rat cortical
membranes by the same drugs used for [3H]5-HT uptake and
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Fig. 3.8 Time course of pHjcitalopram binding to rat cortical
membranes. Membranes were incubated with [3H]citalopram
(0.5 nM) for various times at 25°C. Non-specific binding was
determined in the presence of 10 jj.M unlabelled citalopram.
Data are from a representive experiment. Each point is the
mean value of duplicate determinations.
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[3H]paroxetine binding was examined (Table 3.2, Fig.3.5c).
Paroxetine and fluoxetine inhibited the binding of [3H]citalopram
to rat brain membranes with a Ki value of 0.12 ± 0.01 nM and
6.3 ± 1.1 nM, respectively. As with [3H]paroxetine binding,
desipramine (Ki = 154 ±11 nM) and 5-HT (Ki = 349 ± 35 nM) were
relatively weak inhibitors for [3H]citalopram binding. Thus the
most potent inhibitor for [3H]citalopram binding was paroxetine
which was approximately eight fold more potent than citalopram
(Kd = 0.94 ± 0.24 nM).
3.3.4 Decomposition of 5-AC by U.V. Irradiation
5-AC was synthesised as a photoaffinity ligand for the
5-HT transporter. Prior to examining whether it binds
irreversibly to the 5-HT transporter following U.V. irradiation,
the required irradiation time for photo-decomposition was
determined in the absence of brain membranes. Petri dishes
containing 5 ml samples of 10 (iM 5-AC in Tris-HCI buffer were
exposed to U.V. light (400 W, wavelength 365 nm or 15 W,
254 nm) for various times then the amount of authentic 5-AC
remaining was determined by HPLC (Table 3.3). After 1 min
irradiation by U.V. light (400 W), 5-AC disappeared completely
whereas 50% of 5-AC remained after irradiation for 30 sec.
U.V. irradiation with 15 W produced an 81% and 98% reduction in
the concentration of 5-AC after 30 sec and 1 min, respectively.
5-AC disappeared completely following 2 min irradiation.
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TABLE 3.3 : Decomposition of 5-AC bv U.V. Irradiation
5-AC concentration (%of control)
Irradiation time








5-AC (10 [jM) in Tris-HCI buffer (5 ml) in petri dishes 2 cm
(400 W) or 1 2 cm (15 W) below a U.V. lamp (400 W, wavelength
365 nm or 1 5 W, wavelength 254 nm ) was irradiated for various
times and then its concentration was determined by HPLC
(column : Ultrasphere ODS 5 /v, 4.6 mm x 15 cm, eluting solvent :
10% 0.1 M NH44+OAc-/90% ethanol, detection 270 nm).
1 33
3.3.5 Effect of 5-AC and U.V. Irradiated 5-AC on [aHICitalopram
Binding
It was important to determine the affinity of 5-AC for the
5-HT transporter. 5-AC was therefore tested as an inhibitor of
[3H]citalopram binding to rat cortical membranes (Table 3.4,
Fig.3.9). 5-AC inhibited [3H]citalopram binding to rat cortical
membranes with a Ki value of 1.65 ± 0.14 nM which was only
1.8-fold less potent than citalopram, indicating that
incorporation of an azido moiety at the 5-position of citalopram
had virtually no effect on affinity for the 5-HT transporter.
Similarly it was also important to determine the affinity of the
U.V. irradiated product of 5-AC for the 5-HT transporter.
Therefore the effect of 5-AC irradiated for 2 min (15 W) on
[3H]citalopram binding to rat cortical membranes was examined
since as shown in table 3.3 virtually no authentic 5-AC remained
under this condition. The decomposed 5-AC (UV-5-AC) inhibited
[3H]citalopram binding to rat cortical membranes with a Ki value
of 14.25 ± 0.78 nM which was about 9 and 15 times less potent
compared with 5-AC and citalopram, respectively (Table 3.4,
Fig.3.9). Because of the lower affinity of UV-5-AC and thus a
faster dissociation rate, removal of UV-5-AC which was not
irreversibly bound to the 5-HT transporter would be easier and
more efficient during the washing procedure compared with
removal of 5-AC.
3.3.6 Membrane Irradiation with 400 W in the Presence of 5-AC
The [3H]citalopram binding assay was used to assess
whether 5-AC could be used as a photoaffinity ligand for the
5-HT transporter. If 5-AC bound irreversibly to the transporter
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TABLE 3.4 : Effect of 5-Azido-citalopram C5-AO and U.V.
Irradiated 5-AC (UV-5-AC) on ["H-UCitalopram Binding to Rat
Cortical Membranes
Kd / Ki (nM)
fTHlCitalopram binding
5-AC 1.65 ±0.14(5)
UV-5-AC 14.25 ±0.78 (3)
Citalopram 0.94 ± 0.24 (7)
Membranes were incubated with [3H]citalopram (0.5 nM) in the
absence or presence of increasing concentrations of test drug
(10-n M to 10-6 M, final concentrations) for 60 min at 25°C.
UV-5-AC was obtained by U.V. irradiation (15W for 2 min) of
5-AC. Non-specific binding was determined in the presence of
10 /jM unlabelled citalopram. Ki values were calculated from
the equation Ki = IC so / (1+ L/Kd). Values are the mean ±S.E.M.
from the number of separate experiments shown in parentheses.
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Fig. 3.9 Inhibition of [3H]citalopram binding to rat cortical
membranes by citalopram, 5-AC and UV-5-AC. Membranes were
incubated with [3H]citalopram (0.5nM) in the absence or presence
of increasing concentrations of test drug for 60 min at 25°C.
Non-specific binding was determined in the presence of 10 jiM
unlabelled citalopram. Data are from a representive
experiment. Each point is the mean value of duplicate
determinations. • Citalopram; O 5-AC; A UV-5-AC.
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following U.V. exposure, a decrease in the density of binding
sites for [3H]citalopram (Bmax) would be predicted. Appropriate
control samples were also carried out firstly to determine the
direct effect of U.V. exposure on the brain membranes and
secondly to determine the efficiency of washing the membranes
free of 5-AC and UV-5-AC prior to [3H]citalopram binding. Rat
cortical membranes were incubated at 25°C for 30 min in the
absence and presence of 5-AC in the dark, at a final
concentration of 200 nM. This concentration of 5-AC is about
100 times its Ki value (Table 3.4) and is thus sufficient to
occupy all the 5-HT transporters as shown by its ability to
completely displace [3H]citalopram binding to rat cortical
membranes (Fig.3.9). After the 30 min incubation, membrane
suspensions were U.V. irradiated with 400 W once (1 min) or
twice (30 sec). Following extensive washing of the membranes
to remove the 5-AC and UV-5-AC, [3H]citalopram binding was
carried out in the presence of a range of concentration of
unlabelled citalopram in order to determine Kd and Bmax values.
a) Single Irradiation with 400 W (Table 3.5)
In control membranes (non-irradiated in the absence of
5-AC), the Kd and Bmax values for [3H]citalopram binding were
1.15 ± 0.43 nM and 1031.6 ± 72.7 fmol/mg protein, respectively.
In the non-irradiated membranes in the presence of 5-AC, the Kd
(1.07 ± 0.13 nM) and Bmax (978.4 ± 48.6 fmol/mg protein) were
not significantly different from those for control membranes.
The Kd values for [3H]cita!opram indicate that 5-AC and UV-5-AC
were removed from the membranes by the washing procedure
prior to the binding assay being carried out. U.V. irradiation for
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TABLE 3.5 : Effect of Sinale U.V. Irradiation (400 W) on
fTHlCitalooram Bindina
Treatment Bmax Kd
U.V. 5-AC N (fmol/mq protein) (nM)
- (control) 4 1031.6± 72.7 1.1 5 ± 0.43
+ 4 978.4± 48.6 1.07 ± 0.13
1 min 3 979.2 ± 46.6 0.94± 0.25
1 min + 4 870.2 ± 93.0 1.23± 0.27
Membranes were incubated in the absence (-) or presence (+) of
5-AC (200 nM) in the dark for 30 min at 25°C and then irradiated
with 400 W for 1 min (- ; non-irradiation). After 3 washing
cycles, membranes were incubated with [3H]citalopram (0.5 nM)
in the absence or presence of increasing concentrations of
citalopram for 60 min at 25°C. Non-specific binding was
determined in the presence of 10 yM unlabelled citalopram.
ICso values were obtained from analysis of the inhibition curves
from the equation Y = MXP / (XP + ICso) and Kd values calculated
(Kd = ICso- [3H]citalopram). Bmax values were determined from
the equation b = Bmax L / (L + Kd). Values are the mean ± S.E.M.
from the number of separate experiments shown in table (N).
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1 min in the absence of 5-AC did not produce an alteration in
Bmax (979.2 ± 46.6 fmol/mg protein) or Kd (0.94 ± 0.25 nM)
compared with those for control membranes. This result
suggests that U.V. irradiation for 1 min did not directly affect
the 5-HT transporters. When compared with the irradiated
membranes in the absence of 5-AC, there was no significant
difference in the Bmax (870.2 ± 93.0 fmol/mg protein) or Kd
(1.23 ± 0.27 nM) for the irradiated membranes in the presence of
5-AC. In addition, as shown in fig.3.10, there was no
significant difference in specific [3H]citalopram binding at the
ligand concentration of 0.5 nM for the irradiated membranes in
the presence of 5-AC compared with the irradiated membranes
in the absence of 5-AC. These results indicate that 5-AC
cannot produce a covalent bond at the [3H]citalopram binding
sites with a single irradiation with 400 W.
b) Repeated Irradiation with 400 W (Table 3.6)
Since no significant change in Bmax was observed with a
single U.V. irradiation, indicating that it was not clear whether
5-AC binds irreversibly to the transporter it was decided to use
repeated irradiation. For these experiments, thirty seconds was
chosen as the irradiation time in order to avoid overheating the
membrane preparations with the U.V. lamp because repeated
irradiation (1 min x 2) in the absence of 5-AC produced a
significant reduction (about 60%) in [3H]citalopram binding in
preliminary experiments (data not shown). Using two 30 sec
irradiations the Bmax (745.7 ± 96.8 fmol/mg protein) and Kd
(0.46 ± 0.12 nM) of [3H]citalopram binding for irradiated
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Fig. 3.10 Effect of single U.V. irradiation (400 W) on specific
binding of [3H]citalopram at 0.5 nM. Rat cortical membranes
were incubated in the absence or presence of 5-AC (200 nM) in
the dark for 30 min at 25°C and then irradiated with 400 W for
1 min. After 3 washing cycles, membranes were incubated with
[3H]citalopram (0.5 nM) for 60 min at 25°C in the absence or
presence of 10 pM unlabelled citalopram. Specific binding at
0.5 nM (fmol / mg protein) was calculated from binding data.
Data are the mean ± S.E.M. from 3 or 4 separate experiments.
Control : non-irradiated membranes in the absence of 5-AC;
5AC : non-irradiated membranes in the presence of 5-AC;
U.V. : irradiated membranes in the absence of 5-AC;
5-AC & U.V. : irradiated membranes in the presence of 5-AC.
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TABLE 3.6 : Effect of Repeated U.V. Irradiation (400W) on
fTHlCitalopram Binding
Treatment Bmax Kd
U.V. 5-AC N (fmol/mq protein) (nM)
(control) 6 848.6 ± 51.0 0.76 ± 0.09
+ 5 808.4 ± 69.4 1.42 ± 0.29 *
30 sec 5 745.7 ± 96.8 0.46 ± 0.12
30 sec + 6 N.D. N.D.
Membranes were incubated in the absence (-) or presence (+) of
5-AC (200 nM) in the dark for 30 min at 25°C then irradiated
with 400 W for 30 sec (- ; non-irradiation). A second dose of
5-AC (200 nM) was added and the incubation and irradiation
repeated. After 3 washing cycles, membranes were incubated
with [3H]citalopram (0.5 nM) in the absence or presence of
increasing concentrations of citalopram for 60 min at 25°C.
Non-specific binding was determined in the presence of 10 /jM
unlabelled citalopram. Bmax and Kd values were determined as
described in table 3.5. Values are the mean ± S.E.M. from the
number of separate experiments shown in table (N). * ; P <0.05
compared with control. N.D. ; calculation of Bmax and Kd value
was not possible.
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membranes in the absence of 5-AC were not significantly
different from those for control membranes (Bmax =
848.6 ± 51.0 fmol/mg protein, Kd = 0.76 ± 0.09 nM). Thus
repeated irradiation (30 sec x 2) did not directly affect the
membranes. In the non-irradiated membranes in the presence
of 5-AC, the Bmax (808.4 ± 69.4 fmol/mg protein) was not
different from that for control membranes, but a significant
difference in Kd value between the two membrane preparations
was observed (control : 0.76 ± 0.09 nM, 5-AC : 1.42 ± 0.29 nM,
P < 0.05 vs control). These results may indicate that 5-AC when
added twice at 200 nM was not completely removed from the
membrane suspensions even with extensive washing. For this
change in apparent Kd value it can be calculated that about 1 nM
5-AC would have been required to remain in the final membrane
suspension. Since UV-5-AC has about 9 fold lower affinity than
5-AC, 1 nM UV-5-AC remaining in the irradiated membranes
would have had virtually no inhibitory effect.
In irradiated membranes in the presence of 5-AC, it was
not possible to analyse the inhibition curves for citalopram
accurately using a logistic fit and thus calculate the Kd and
Bmax values for [3H]citalopram binding because of the small
amounts of specific binding obtained in some experiments.
Therefore the specific [3H]citalopram binding at the ligand
concentration of 0.5 nM was directly compared with those for
other membranes (Table 3.7, Fig.3.11). The specific binding
(176.0 ± 17.3 fmol/mg protein) for non-irradiated membranes in
the presence of 5-AC was significantly smaller than that for
control membranes (P < 0.05 vs control), and as described earlier
it is presumably due to incomplete removal of 5-AC
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TABLE 3.7 : Effect of Repeated U.V. Irradiation (400W) on
Specific Binding of [THICitalopram at 0.5 nM
Treatment Specific Binding
U.V. 5-AC N (fmol/mq protein)
- (control) 6 247.8 + 17.4
- + 5 176.0 + 17.3 *
30 sec - 5 254.2 + 21.2
30 sec + 6 65.2 + 18.8 **, #
Membranes were incubated in the absence (-) or presence (+) of
5-AC (ZOO nM) in the dark for 30 min at 25°C then irradiated
with 400 W for 30 sec (- ; non-irradiation). A second dose of
5-AC (200 nM) was added and the incubation and irradiation
repeated. After 3 washing cycles, membranes were incubated
with [3H]citalopram (0.5 nM) for 60 min at 25°C in the absence
or presence of 10 juM unlabelled citalopram to determine
specific binding. Values are the mean ± S.E.M. from the number
of separate experiments shown in table (N). * ; P < 0.05,
** P <0.001 compared with control. # ; P <0.01 compared with
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Fig. 3.11 Effect of repeated U.V. irradiation (400 W) on specific
binding of [3H]citalopram at 0.5 nM. Rat cortical membranes
were incubated in the absence or presence of 5-AC (200 nM) in
the dark for 30 min at 25°C and then irradiated with 400 W for
30 sec. A second dose of 5-AC (200 nM) was added and the
incubation and irradiation repeated. After 3 washing cycles,
membranes were incubated with [3H]citalopram (0.5 nM) for
60 min at 25°C in the absence or presence of 10 (iM unlabelled
citalopram. Specific binding at 0.5 nM (fmol / mg protein) was
calculated from binding data. Values are the mean ± S.E.M. from
5 or 6 separate experiments. control : non-irradiated
membranes in the absence of 5-AC; 5-AC : non-irradiated
membranes in the presence of 5-AC; U.V. : irradiated membranes
in the absence of 5-AC; 5-AC & U.V. : irradiated membranes in
the presence of 5-AC. * ; P < 0.05, ** P < 0.001 compared with
control. # ; P < 0.01 compared with 5-AC.
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during the 3 washing cycles. In the presence of 5-AC, repeated
irradiation produced a significant 74% reduction (P < 0.001) in
specific binding (65.2 ± 18.8 fmol/mg protein) when compared
with that for control membranes (247.8 ± 17.4 fmol/mg protein)
or irradiated membranes in the absence of 5-AC (254.2 ± 21.2
fmol/mg protein). Following the washing procedure, since
UV-5-AC would not have been present at a sufficiently high
concentration to cause inhibition, the reduction in binding
would be due to a decrease in the Bmax, suggesting that 5-AC
binds irreversibly to about 70% of the 5-HT transporter
following two 30 sec irradiation exposures.
3.3.7 Membrane Irradiation with 15 W in the Presence of 5-AC
Rat cortical membranes were incubated at 25°C for 30 min
in the absence and presence of 5-AC (200 nM) or UV-5-AC
(200 nM) in the dark. After incubation, membrane suspensions
were U.V. irradiated with 15 W once (1, 2 or 4 min) or twice
(2 min) then the membranes were washed three times.
[3H]Citalopram binding to membranes treated under the various
conditions was carried out, and the Kd and Bmax determined are
shown in tables 3.8 and 3.9. In addition specific [3H]citalopram
binding at the ligand concentration of 0.5 nM for each of the
conditions are shown in figs.3.12 and 3.13.
a) Single Irradiation with 15 W (Table 3.8, Fig.3.12)
In control membranes, Kd and Bmax values for
[3H]citalopram binding were 0.74 ± 0.07 nM and 818.0 ± 76.2
fmol/mg protein, respectively. In the non-irradiated membranes
in the presence of 5-AC, the Bmax (1064.7 ± 91.7 fmol/mg
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TABLE 3.8 : Effect of Single U.V. Irradiation (15 W) on
fTHlCitalopram Binding
Treatment Bmax Kd
U.V. 5-AC UV-5-AC N (fmol/ma protein) CnM)
- (control) 4 818.0 ± 76.2 0.74 ± 0.07
+ 5 1064.7 ± 91.7 1.11 ± 0.12 *
+ 3 811.0 ±108.8 0.81 ± 0.15
1 min - 3 908.2 ± 98.3 0.74 ± 0.10
1 min + 4 896.8 ± 38.5 0.82 ± 0.07
2 min - 3 853.0 ± 74.0 0.81 ±0.08
2 min + 5 782.2 ± 60.6 0.81 ±0.04
4 min - 6 710.1 ± 23.5 1.08 ± 0.22
4 min + 3 675.8 ± 20.1 0.94 ± 0.17
Membranes were incubated in the absence (-) or presence (+) of
5-AC (200 nM) or UV-5-AC (200 nM) in the dark for 30 min at
25°C then irradiated with 15 W for 1, 2 or 4 min (- ; non-
irradiation). After 3 washing cycles, membranes were
incubated with [3H]citalopram (0.5 nM) in the absence or
presence of increasing concentrations of citalopram for 60 min
at 25°C. Non-specific binding was determined in the presence
of 10 ^M unlabelled citalopram. Bmax and Kd values were
determined as described in table 3.5. Values are the mean ±
S.E.M. from the number of separate experiments shown in table
(N). * ; P <0.05 compared with control.
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no U.V. U.V. Imin U.V. 2min U.V. 4min
Fig. 3.12 Effect of single U.V. irradiation (15 W) on specific
binding of [3H]citalopram at 0.5 nM. Rat cortical membranes
were incubated in the absence or presence of 5-AC (200 nM) or
UV-5-AC (200 nM) in the dark for 30 min at 25°C and then
irradiated with 15 W for 1, 2 or 4 min. After 3 washing cycles,
membranes were incubated with [3H]citalopram (0.5 nM) for
60 min at 25°C in the absence or presence of 10 (iM unlabelled
citalopram. Specific binding at 0.5 nM (fmol / mg protein) was
calculated from binding data. Data are the mean ± S.E.M.
from 3-6 separate experiments. no U.V. : non-irradiated
membranes; ■ no drug; E2 in the presence of 5-AC; □ in the
presence of UV-5-AC. * ; P < 0.01 compared with non-irradiated
membranes in the absence of drugs.
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protein) was not significantly different from that for control
membranes, but the Kd value (1.11 ± 0.12 nM) was slightly and
significantly higher than that for control membranes. Again
these results indicate that 5-AC was not completely removed
from the membranes by extensive washing and about 1 nM may
have remained in the final suspension used for binding
experiments. In contrast, the Kd (0.81 ± 0.15 nM) and Bmax
(811.0 ± 108.8 fmol/mg protein) values for the non-irradiated
membranes in the presence of UV-5-AC, were not different from
those for control membranes. Thus even if small amounts
similar to those remaining for 5-AC were present, due to the
lower affinity of UV-5-AC very little inhibition of binding would
be expected. It should also be noted that following membrane
irradiation the major component being removed by washing
would be UV-5-AC rather than 5-AC (Table 3.3). U.V. irradiation
for 1 and 2 min in the absence of drugs did not alter Bmax (1 min
: 908.2 ± 98.3 fmol/mg protein, 2 min : 853.0 ± 74.0 fmol/mg
protein) when compared with that for control membranes (Table
3.8). Kd values were also similar (1 min : 0.74 ± 0.10 nM, 2 min :
0.81 + 0.08 nM) compared with control membranes indicating
that the irradiation for 1 or 2 min does not directly affect the
membranes. On the other hand U.V. irradiation for 4 min in the
absence of drugs produced a non significant 13% reduction of
Bmax (710.1 ± 23.5 fmol/mg protein) compared with that for
control membranes (Table 3.8). In addition, a significant 27%
reduction (P < 0.01) in specific [3H]citalopram binding at the
ligand concentration of 0.5 nM for the 4 min irradiated
membranes in the absence of drugs was observed compared with
control membranes (Fig.3.12). These results indicate that the
148
irradiation for 4 min may directly affect the membranes. In the
presence of 5-AC, irradiation (1, 2 and 4 min) did not produce a
significant reduction in the Bmax for [3H]citalopram binding
when compared with those for other membranes (1 min : 896.8 ±
38.5 fmol/mg protein, 2 min : 782.2 ± 60.6 fmol/mg protein,
4 min : 675.8 ± 20.1 fmol/mg protein). In addition, there was no
difference in Kd values between irradiated membranes in the
absence and presence of 5-AC. These results suggest that
>5-AC cannot produce a covalent bond at the [3H]citalopram
binding sites with a single irradiation with 15 W for 1 or 2 min,
and 4 min may not be suitable time for irradiation.
b) Repeated Irradiation with 15 W (Table 3.9, Fig.3.13)
Under nonphotolysing conditions, there was no difference
in Bmax values between membranes in the absence and presence
of 5-AC or UV-5-AC (control : 675.1 ± 53.6 fmol/mg protein,
5-AC : 733.3 ± 26.9 fmol/mg protein, UV-5-AC : 675.1 ± 53.6
fmol/mg protein). However, the Kd value (0.99 ± 0.02 nM) for
5-AC treated membranes was significantly higher than those for
other membranes (control : 0.52 ± 0.02 nM, UV-5-AC :
0.66 ± 0.08 nM). These results were similar to those obtained
with a single 15 W irradiation. For repeated irradiation, 2 min
was chosen as the irradiation time in order to avoid a direct
effect on the membrane preparations as described in section
3.3.6a. In the absence of 5-AC, Bmax (665.6 ± 24.9 fmol/mg
protein) and Kd (0.62 ± 0.08 nM) for irradiated membranes were
not significantly different from those for control membranes,
indicating that the repeated irradiation does not directly affect
the membranes. In the presence of 5-AC, repeated irradiation
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TABLE 3.9 : Effect of Repeated U.V. Irradiation (15 W) on
fTHlCitalopram Binding
Treatment Bmax Kd
U.V. 5-AC UV-5-AC N (fmol/mq protein) (nM)
(control) 3 675.1 ±53.6 0.52±0.02
+ 3 733.3±26.9 0.99±0.02 **
+ 3 687.0±55.2 0.66±0.08
2 min - 3 665.6±24.9 0.62±0.08
2 min + 4 531,4±25.5 * 0.70±0.06
Membranes were incubated in the absence (-) or presence (+) of
5-AC (200 nM) or UV-5-AC (200 nM) in the dark for 30 min at
25°C then irradiated with 15 W for 2 min (- ; non-irradiation).
A second dose (200 nM) of 5-AC or UV-5-AC was added and the
incubation and irradiation repeated. After 3 washing cycles,
membranes were incubated with [3H]citalopram (0.5 nM) in the
absence or presence of increasing concentrations of citalopram
for 60 min at 25°C. Non-specific binding was determined in the
presence of 10 ^vM unlabelled citalopram. Bmax and Kd values
were determined as described in table 3.5. Values are the mean
± S.E.M. from the number of separate experiments shown in
table (N). * ; P <0.05, ** ; P <0.01 compared with control.
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Control 5-AC UV-5-AC U.V. 5-AC & U.V.
Fig. 3.13 Effect of repeated U.V. irradiation (15 W) on specific
binding of [3H]citalopram at 0.5 nM. Rat cortical membranes
were incubated in the absence or presence of 5-AC (200 nM) or
UV-5-AC (200 nM) in the dark for 30 min at 25°C and then
irradiated with 15 W for 2 min. A second dose (200 nM) of 5-AC
or UV-5-AC was added and the incubation and irradiation
repeated. After 3 washing cycles, membranes were incubated
with [3H]citalopram (0.5 nM) for 60 min at 25°C in the absence or
presence of 10 pM unlabelled citalopram. Specific binding at
0.5 nM (fmol / mg protein) was calculated from binding data.
Data are the mean ± S.E.M. from 3 or 4 separate experiments.
Control : non-irradiated membranes in the absence of drugs;
5-AC : non-irradiated membranes in the presence of 5-AC;
UV-5-AC : non-irradiated membranes in the presence of
UV-5-AC; U.V. : irradiated membranes in the absence of drugs;
5-AC & U.V. : irradiated membranes in the presence of 5-AC.
; P < 0.05 compared with control.
151
showed a significant reduction (approximately 20%, P < 0.05 vs
control) in Bmax (531.4 ± 25.5 fmol/mg protein) without
alteration of Kd (0.70 ± 0.06 nM) when compared with those for
control membranes or the irradiated membranes in the absence
of 5-AC (Table 3.9). In addition, the specific [3H]citalopram
binding at 0.5 nM for the irradiated membranes in the presence
of 5-AC was significantly lower than those for control
membranes and the irradiated membranes in the absence of
5-AC (Fig.3.13). Thus a decrease in Bmax but no change in Kd
suggests that 5-AC binds irreversibly to about 20% of the 5-HT
transporter following two 2 min irradiation exposures.
3.3.8 Binding of 5-IC and [125.|]5-IC to the 5-HT transporters
5-IC was synthesised as a potential SPET ligand for the
5-HT transporter by Dr.I.M.Dawson, Department of Pharmacology,
University of Edinburgh. The affinity of 5-IC for the 5-HT
transporter was first determined in vitro by the potency of the
unlabelled form of the compound to inhibit [3H]5-HT uptake into
rat cortical synaptosomes, and [3H]paroxetine and [3H]citalopram
binding to rat cortical membranes (Table 3.10). 5-IC was
5.8-fold less potent than citalopram as an inhibitor of [3H]5-HT
uptake with a Ki value of 11.5 ± 1.5 nM. 5-IC inhibited binding
of [3H]paroxetine and [3H]citalopram to rat cortical membranes
with Ki values of 4.0 ± 0.9 nM and 2.9 ± 0.6 nM respectively,
being 1.9- and 3.1-fold less potent than citalopram as an
inhibitor of [3 H]paroxetine and [3H]citalopram binding
respectively. Thus incorporation of an iodine atom at the
5-position of citalopram produced only a small decrease in
affinity for the 5-HT transporter and not sufficient to prevent
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TABLE 3.1Q : Effect of 5-lodo-citalopram (5-IC) on ["TH15-HT
Uptake. fTJHlParoxetine and ITHICitalopram Binding
Kp/Ki (nM)
[3H]5-HT uptake [3H]Paroxetine [3H]Citalopram
binding binding
5-IC 11.5 ±1.5 (3) 4.0 ±0.9 (4) 2.9 ± 0.6 (4)
Citalopram 2.0 ±0.4 (9) 2.1 ±0.2 (9) 0.94 ± 0.24 (7)
Synaptosomes were incubated with [3HJ5-HT (5 nM) in the
absence or presence of increasing concentrations of test drug
for 5 min at 37°C. Replicate zero-time samples were carried
out to define active component of [3H]5-HT uptake. Membranes
were incubated with [3H]paroxetine (0.2 nM) or [3H]citalopram
(0.5 nM) in the absence or presence of increasing concentrations
of test drug for 60 min at 25°C. Non-specific binding was
determined in the presence of 10 unlabelled citalopram.
IC so values were estimated from the inhibition curves and Ki
values calculated from the equation Ki = ICso / (1+ L/Kd or Km).
Values are the mean ± S.E.M. from the number of separate
experiments shown in parentheses.
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further investigation of 5-IC as a potential SPET ligand.
[125|]5-|C was prepared by Dr.l.M.Dawson, and experiments
carried out to characterise directly binding of [125|]5-IC to the
5-HT transporters. p25|]5-|C (0.05 nM) was incubated with rat
cortical membranes for various times at 25°C and specific
binding reached equilibrium at about 60 min incubation
(Fig.3.14). At equilibrium, specific binding represented about
65% of total binding. An incubation time of 60 min was
therefore used for further investigation of p25|]5-|C binding.
The concentration dependence of p25|]5-ic was investigated by
incubating 0.05 nM in the presence of increasing concentrations
of unlabelled 5-IC (Fig.3.15). Binding was saturable and the
Hill co-efficient was close to unity (Table 3.11a) indicating a
single population of sites. Analysis of data from three separate
experiments gave a Kd value of 1.87 ± 0.25 nM and a Bmax value
of 0.51 ± 0.12 pmol/mg protein. The Bmax value for p25|]5-|C
binding was not significantly different from those for
[3H]citalopram binding (P = 0.157) and [3H]paroxetine binding
(P = 0.064), suggesting that it was labelling the same population
of binding sites. The pharmacology of [125|]5-IC is shown in
table 3.11b. The selective 5-HT uptake inhibitors, paroxetine
and citalopram had high affinity for [125|]5-IC binding sites with
Ki values of 0.12 ± 0.01 nM and 1.42 ± 0.18 nM respectively,
whereas 5-HT (Ki = 248 ± 47 nM) was a relatively weak inhibitor
of [1 251 ] 5 -1C binding. The Ki/KD values for paroxetine,
citalopram, 5-IC and 5-HT were consistent with results
obtained from binding experiments using [3H]paroxetine,
[3H]citalopram and [">25|]5-|C as ligands thus confirming that the
















Fig. 3.14 Time course of 0.05 nM [125|]5-[C binding to rat
cortical membranes. Membranes were incubated with [125|]5-|C
for various times at 25°C. Non-specific binding was determined
in the presence of 10 jiM unlabelled citalopram. Data are from a
representive experiment. Each point is the mean value of
duplicate determinations. # Specific binding; O Non-specific
binding
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Fig. 3.15 Inhibition of [125|]5-IC binding to rat cortical
membranes by 5-IC. Membranes were incubated with [1251]5-1c
(0.05 nM) in the absence or presence of increasing
concentrations of 5-IC (10-n M to 3x10-7 M, final
concentrations) for 60 min at 25°C. Non-specific binding was
determined in the presence of 10 pM unlabelled citalopram.
Data are from a representive experiment. Each point is the
mean value of duplicate determinations.
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TABLE 3.11 : a) Kd. / Bmax / nH values and b) Inhibition of








Kd (nM) 1.87± 0.25 (3) 0.94 ± 0.24 (7) 0.20 ± 0.02 (6)
Bmax
(pmol/mg protein)
0.51± 0.12 (3) 0.85 ± 0.13 (7) 0.82 ± 0.08 (6)









5-HT 248 ± 47 (3) 349 ± 35 (4) 836 ± 72 (4)
Citalopram ro00o+1CM 0.94 ± 0.24 (7) 2.10 ± 0.20 (9)
Paroxetine 0.1 2± 0.01 (3) 0.12 ± 0.01 (7) 0.20 ± 0.02 (6)
5-IC 1.87 ±0.25 (3) 2.90 ±0.60 (4) 4.00 ± 0.90 (4)
Membranes were incubated with [i25|]5-ic (0.05 nM),
[3H]citalopram (0.5 nM) and [3H]paroxetine (0.2 nM) in the absence
or presence of increasing concentrations of test drug for 60 min
at 25°C. Non-specific binding was determined in the presence
of 10 jl/M unlabelled citalopram. ICso and nH (P) values were
obtained from analysis of the inhibition curves from the
equation Y = MX? / (XP + ICso) and Kd values calculated (Kd = ICso -
[3H]ligand). Bmax values were determined from the equation
b = Bmax L / (L + Kd). Ki values calculated from the equation
Ki = ICso / (1+ L/Kd). Values are the mean ± S.E.M. from the
number of separate experiments shown in parentheses.
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3.3.9 In Vivo Distribution of fl£5.l]5-IC
The time course of the distribution of [125|]5-|C following
intravenous injection into the femoral vein of rats was
examined using a tracer dose of 20 |iCi [125|]5-|C corresponding
to 20 nmoles. The blood level of radioactivity of [125 |]5-|C is
shown in table 3.12 and fig.3.16. After intravenous
administration, the arterial blood level was 2.351 %D/ml at
1 min, followed by a biphasic decline with half lives of 0.68 min
(a) and 137.50 min ((3) (Table 3.15). The AUC for blood was
42.185 %D • min/ml. The tissue level of radioactivity at various
time points after [125|]5-ic injection is shown in tables 3.13,
3.14 and figs.3.17, 3.18, 3.19. In kidney, lung and thyroid, peak
levels were obtained by 30 min, whereas the peak levels in heart
and liver were observed at 60 min (Table 3.13, Fig.3.17). At 30
and 60 min after [125|]5-|C injection, these peripheral tissues
contained radioactivity concentrations greater than that of
blood. Among peripheral tissues, liver, lung and kidney had
higher concentrations of radioactivity compared with thyroid
and heart as indicated by their AUC values (liver : 4883.719, lung
: 1068.152, kidney : 591.453, heart : 161.300, thyroid : 156.494
%D ■ min/g ) (Table 3.15). The clearance of radioactivity from
peripheral tissues was relatively slow with a ti/2 value of
286.36 min (heart), 161.92 min (kidney), 1237.5 min (liver),
202.63 min (lung) and 190.38 min (thyroid) (Table 3.15).
Uptake of [125|]5-ic into whole brain reached a maximum
between 30 min and 1 hr at approximately 0.2 %D/g (Table 3.14,
Fig.3.18). Even at 5 hr after injection, significant amounts of
radioactivity were still observed at approximately 0.04 %D/g.
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Fig. 3.16 Time course of radioactivity in arterial blood after
[125|]5-|C injection. Under anaesthesia, rats were injected with
250 pi of saline containing 20 pCi (20 nmol) of [125|]5-|C, 10%
ethanol and 1% Tween-80 through a cannula placed in the left
femoral vein. The arterial blood (300 pi) was collected at
various time points (1, 2, 3, 5, 10, 20, 30, 45, 60, 90, 180 and
300 min after injection) via the femoral artery and the
radioactivity in 100 pi of blood was determined using a Packard
Cobra auto-gamma counter. Data are expressed as % injected
dose per ml. Each time point is the mean value ± S.E.M. of 4
animals for the mean value of 2 animals. The number of animals
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Fig. 3.17 Time course of radioactivity in peripheral tissues
after [125|]5-IC injection. Under anaesthesia, rats were
injected with 250 pi of saline containing 20 pCi (20 nmol) of
[125|]5-|C, 10% ethanol and 1% Tween-80 through a cannula
placed in the left femoral vein. At various times post-injection
(30, 60, 90, 180 and 300 min), rats were killed, and liver,
kidney, lung, thyroid and heart were removed and weighed. The
radioactivity in the thyroid and 100-200 mg weighed samples of
the other tissues were determined using a Packard Cobra
auto-gamma counter. Data are expressed as % injected dose
per g tissue. Each time point is the mean value ± range from
2 animals. # Heart; O Kidney; A Liver; A Lung; ■ Thyroid.
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TABLE3.14:Distributionoffi^ll5-ICnBra Brainreg on _3Q.„
60
a)%injecteddos/gtis ue b)amol/mgtissue _9Q_
180
Brainstem Midbrain Cerebellum
a)0.251,.315(0.283)771 6( . 17) b)16.16,20.226(18.171)17.79 , 0.0183 9 4)
_Z1Q_
_3QCL
Wholebrain)0.254,.183(0.218)697. 3)153,0.127( 140077 059.068) b)19.025,13.688(16. 56)20.129,11.782.955)1.43 9.538(10.489)5.7 5,4 427(5 091) Rostrala)0.270,.333(0.32 )0.336,0.270( .272)18 ,0.155168.093 84. 87)96 cortexb)17.303,21.362(19.3 3)2 .544,13.3017.423)1.650,9.904( 0.777)5 8 5 666. 65 Caudal)0.279,334(0.307). 319( .251)203, .1450 174.089 0 7( .083)9 cortexb)17.91,21.395(19.653)19.451,12.727(16.089).998,9.283415.687,4 9486 3 Hippocampusa)0.243,0.347(0.295).310,0.198( . 54).2 ,0.153178, .0910. 0) b)15.606,22.218(18.912)19.908,1 .67(1 . 93)2.853,9.7941 326 27,5 83517. 30
0.044,0.037( .040) 3.274,2.760(3.017)
a)0.242,84(0.263)329. 06(0.267)190, .091 3.0 8 0. 84. 1)2 b)15.512,18.228(16. 70)2 .070,13.224(1 .147)2.174,6. 19. 936 31,5. 638)5 a)0.270,0.345(0.307)0.317,0.249( .283). 8 , .1 016093 08. 7)94 b)17.289,22.17(19. 03)20.317,5 996(1 .157).518, . 90 5 85. 55 142( 49)6.056 0.128,0.112( .120)060 061.06 )73 8.174,7.21(7.693)3 83 ,3.9.8 9)4 7






















0 i i i i i
0 60 120 180 240 300
Time (min)
Fig. 3.18 Time course of radioactivity in whole brain after
[125|]5-|C injection. Under anaesthesia, rats were injected with
250 j_lI of saline containing 20 |_iCi (20 nmol) of [125|]5-|C, 10%
ethanol and 1% Tween-80 through a cannula placed in the left
femoral vein. At various times post-injection (30, 60, 90, 180
and 300 min), rats were killed, and the brains removed. The
radioactivity was determined in a Packard Cobra auto-gamma
counter. Data are expressed as % injected dose per g tissue.
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Fig. 3.19 Time course of radioactivity in brain regions after
[125|]5-|C injection. Under anaesthesia, rats were injected with
250 jil of saline containing 20 jiCi (20 nmol) of [125|]5-|Q> 10%
ethanol and 1% Tween-80 through a cannula placed in the left
femoral vein. At various times post-injection (30, 60, 90, 180
and 210 min), rats were killed, and the brains removed, divided
into 6 regions : rostral cortex, caudal cortex (the remainder of
the cortex), hippocampus, brainstem, midbrain and cerebellum.
These brain areas were weighed and radioactivity determined in
a Packard Cobra auto-gamma counter. Data are expressed as %
injected dose per g tissue. Each time point is the mean value of
2 animals. # Rostral Cortex; O Caudal Cortex; A Hippocampus;
A Brainstem; ■ Midbrain; □ Cerebellum.
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TABLE 3.1 5 : Pharmacokinetic Parameters of fi25.ll 5-IC in Rats
after Injection
Co Ke t1/2 AUC
(% D/g or ml) (min-i) (min) (% D • min/g or ml)
Whole brain 0.271 0.00669 103.59 40.910
Rostral cortex 0.368 0.00715 96.92 52.908
Caudal cortex 0.362 0.00707 98.02 53.082
Hippocampus 0.337 0.00590 117.46 59.174
Brainstem 0.313 0.00610 1 13.61 52.882
Midbrain 0.379 0.00736 94.16 52.685
Cerebellum 0.321 0.00814 85.14 40.734
Heart 0.382 0.00242 286.36 161.300
Kidney 2.521 0.00428 161.92 591.453
Liver 2.737 0.00056 1237.5 4883.719
Lung 3.563 0.00342 202.63 1068.152
Thyroid 0.569 0.00364 190.38 156.494
Blood 3.658 1.02 0.68 42.185
0.186 0.00504 137.50
The data of radioactivity in blood after [1251]5-IC injection were
fitted to biexponential functions using least squares regression
analysis. The equation used was Y = A x e(-«t) + B x e(-Pt), where t
is time after administration, Y is the measured radioactivity, A
and B are the coefficients of the exponential terms, a is the
apparent distribution rate constant, p is the apparent terminal
rate constant. The data of radioactivity in brain and peripheral
tissues were fitted to monoexponential functions using
least squares regression analysis. The equation used was
Y = A x e(-Ke -t);where Ke is the elimination rate constant.
Co : radioactivity at t = 0, ti/2 (half-life) = 0.693/Ke or a or p,
AUC : the area under the radioactivity concentration-time curve
from zero to time infinity.
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at 30 or 60 min (Table 3.14, Fig.3.19) and all brain regions had
similar radioactivity elimination half-lives (rostral cortex :
96.92 min, caudal cortex : 98.02 min, hippocampus : 117.46 min,
brainstem : 113.61 min, midbrain : 94.16 min, cerebellum :
85.14 min) (Table 3.15). At 30 min, the radioactivity
concentration was similar in all brain regions but at all other
time points the radioactivity concentrations in the cerebellum
was lower in comparison with other 5 brain regions (Table 3.14,
Fig.3.19). The AUC value (40.734 %D • min/g) for cerebellum
was smallest among the 6 brain regions (rostral cortex : 52.908,
caudal cortex : 53.082, hippocampus : 59.174, brainstem :
52.882, midbrain : 52.685 %D ■ min/g) (Table 3.15). At 2 hr
after injection, the radioactivity for cerebellum (0.0732 %D/g)
was significantly lower than those for other five brain regions
(Table 3.16). The ratios of the brain regions to cerebellum were
1.37 (rostral cortex), 1.32 (caudal cortex), 1.46 (hippocampus),
1.58 (brainstem) and 1.51 (midbrain). In order to determine the
proportion of the [125|]5-ic found in each brain which was bound
in vivo to the 5-HT transporters, animals were pretreated with
paroxetine (1 mg/kg, i.v.) and the distribution of [125|]5-lO in the
various brain regions measured at 2 hr. Compared with control
tissue, pretreatment of paroxetine reduced the radioactivity in
rostral cortex, caudal cortex, hippocampus, brainstem and
midbrain, whereas it did not reduce the radioactivity in
cerebellum (Table 3.16). Therefore it was considered that the
radioactivity in the cerebellum represented apparent nonspecific
binding and apparent specific binding was calculated by
subtracting the radioactivity in the cerebellum from that in
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binding was observed in the brainstem (0.042 %D/g) and
midbrain (0.037 %D/g), areas which are known to be rich in
serotonergic neurons. Pretreatment with paroxetine caused a
significant reduction in specific [125|]5-IC binding in all brain
regions 2hr postinjection (Table 3.16, Fig.3.20). The greatest
reductions were observed in the midbrain (84.4%), rostral cortex
(78.1%) and caudal cortex (63.2%). Smaller reductions occurred
in the brainstem (49.8%) and hippocampus (34.8%). Thus a brain
regional variation in the inhibitory effect of paroxetine was
observed.
3.4 DISCUSSION
In order to evaluate appropriate compounds in vitro as
photoaffinity and as SPET ligands for the 5-HT transporter,
assay for [3H]5-HT uptake into rat cortical synaptosomes and the
binding of [3H]paroxetine and [3H]citalopram to rat cortical
membranes were established. For [3H]5-HT uptake into rat
cortical synaptosomes, potent inhibition of [3H]5-HT uptake was
exhibited only by selective 5-HT uptake inhibitors such as
paroxetine (Ki = 0.83 nM), citalopram (Ki = 2.0 nM) and fluoxetine
(Ki = 11.3 nM). Binding of [3H]paroxetine to rat cortical
membranes was also inhibited by low concentrations of the
selective 5-HT uptake inhibitors (paroxetine : Kd = 0.20 nM,
citalopram : Ki = 2.1 nM, fluoxetine : Ki = 6.1 nM). As with
[3H]5-HT uptake and [3H]paroxetine binding, paroxetine (Ki =
0.12 nM), citalopram (Kd = 0.94 nM) and fluoxetine (Ki = 6.3 nM)
were potent inhibitors of [3H]citalopram binding to rat cortical
membranes. The similar Bmax values for [3H]paroxetine (0.82
pmol/mg protein) and [3H]citalopram binding (0.85 pmol/mg
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protein) indicate that they probably label the same population of
sites. In addition, there was a good correlation between the
potency of various drugs to inhibit [3H]5-HT uptake,
[3H]paroxetine and [3H]citalopram binding (Fig.3.21). The relative
potencies of drugs in inhibiting [3H]paroxetine binding closely
parallel their inhibitory effect on [3H]citalopram binding with a
correlation coefficient (r) of 0.995 and a slope of 1.05 (p < 0.05).
On the other hand, the correlations between results for [3H]5-HT
uptake and [3H]paroxetine or [3H]citalopram binding were not
significant (r = 0.869 (P = 0.153), r = 0.898 (P = 0.110)
respectively). However, their correlations for 5 drugs but
excluding 5-HT were excellent with r values of 0.970 (slope =
0.74, P < 0.05, [3H]paroxetine binding vs [3H]5-HT uptake) and
0.985 (slope = 0.76, P < 0.05, [3H]citalopram binding vs [3H]5-HT
uptake). Thus a difference in affinity for 5-HT, the only
substrate for the carrier tested, between 5-HT uptake and ligand
binding assays was observed. This may reflect the difference
in measurement of an equilibrium dissociation constant in the
ligand binding assay compared with a Michaelis constant for
[3H]5-HT uptake into serotonergic neurones which may involve
more than one step. The binding of 5-HT to the surface of the
5-HT transporter is only the first step of the uptake process and
therefore the Kd value and Km value (a steady state constant)
may not reflect identical physiological processes involved in the
uptake of 5-HT (Marcusson et al., 1986). It is concluded that all
three assays were established and can be used for measurement
of drug interaction at the amine transporter in serotonergic
neurones.
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The effect of 5-azido-citalopram (5-AC) synthesised as a
candidate for a photoaffinity ligand was examined using
[3H]citalopram binding to rat cortical membranes. 5-AC had
high affinity (Ki = 1.65 nM) for [3H]citalopram binding which was
only 1.8-fold less potent than citalopram itself. Thus the azide
moiety can be incorporated at the 5 position of citalopram
almost without loss of biological activity compared with
citalopram.
In order to investigate the potential use of 5-AC as a
photoaffinity ligand, the ability of photolysis to induce 5-AC to
covalently bind to the 5-HT transporter was examined.
Initially, the most suitable U.V. irradiation time was determined
using 5-AC in assay buffer in the absence of membranes.
Initially, a U.V. lamp (400 W) with a 365 nm wavelength was
used to irradiate solutions of 5-AC. One minute irradiation
decomposed 5-AC completely whereas 50% of 5-AC was
decomposed by irradiation for 30 sec. Thus 5-AC was
decomposed rapidly and time-dependently by U.V. irradiation
with 400W.
To examine whether 5-AC bound irreversibly to the 5-HT
transporter following 1 min U.V. irradiation, binding of
[3H]citalopram was compared using rat cortical membranes
treated under various conditions. In the presence of 5-AC
(200 nM), 1 min irradiation showed no reduction in Bmax for
[3H]citalopram binding to rat cortical membranes compared with
those for control membranes, non-irradiated membranes in the
presence of 5-AC or irradiated membranes in the absence of
5-AC. These results indicate that 5-AC did not bind irreversibly
to the 5-HT transporter following photolysis for 1 min.
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Since it is known that repeated U.V. irradiation is often
more effective than single irradiation (Bayley and Knowles,
1977; Gozlan et al., 1987), the effect of repeated U.V.
irradiation (30 sec x 2) on pHjcitalopram binding was examined.
In the presence of 5-AC, repeated irradiation produced a
significant reduction in specific [3H]citalopram binding to rat
cortical membranes. When compared with control membranes or
irradiated membranes in the absence of 5-AC, the reduction was
73.6% and 74.3%, respectively. These results suggest that a
covalent bond between 5-AC and the pHJcitalopram binding sites
was formed by repeated U.V. irradiation. However, there was a
variation in the percentage reduction of specific [3H]citalopram
binding between separate experiments (data not shown). In some
experiments, 100% reduction was observed but only a 54%
reduction was observed in other experiments. These variations
between experiments may be partly due to the amount of 5-AC
remaining in the membranes either to differences in the
efficiency of the extensive washing cycles or, because
irradiation for 30 sec does not completely decompose 5-AC, to
differences in the proportion of 5-AC remaining after
irradiation (Table 3.3). A greater proportion of 5-AC remaining
in the membrane would have produced more inhibition of
[3H]citalopram binding since it has 9-fold higher affinity than
UV-5-AC for the transporter. Substantial contamination of the
final membrane preparation with 5-AC and/or UV-5-AC would
have been reflected in a higher apparent Kd value for
[3H]citalopram binding compared with control. Paradoxically
due to the low amounts of [3H]citalopram binding in irradiated
membranes in the presence of 5-AC, it was not possible to
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accurately determine Kd and Bmax values. However it can be
calculated that for 100% inhibition of [3H]citalopram binding by
5-AC or UV-5-AC at least 10-fold of their Ki concentrations
would have been needed to be present (16.5 nM and 142.5 nM
respectively). This is considered unlikely since the washing
procedure following incubation with 200 nM 5-AC was estimated
to reduce the concentration to 1 nM or below (Table 3.6). It
should also be noted that following membranes being incubated
with 200 nM UV-5-AC then washing, no effect on Kd and Bmax
values for [3H]citalopram binding was observed (Table 3.9). In
conclusion although it was not possible to obtain stable and
reproducible results using photolysis with 400 W at least a
proportion of the transporters up to 70% may have been
covalently bound with 5-AC.
In order to confirm whether 5-AC can form a covalent bond
with the 5-HT transporter induced by irradiation, an other type
of U.V. lamp (15 W, 254 nm) was used for photolysis. This
wavelength (254 nm) is known to be suitable for photolysis of
aryl azides (Bayley and Knowles, 1977). Studies of
decomposition of aryl azides, without membranes present, by
photolysis with a 254 nm source have been reported by some
investigators (Hess et al., 1983; Niznik et al., 1984; Hawkinson
et al., 1991). An azide analogue of the ai-adrenergic receptor
antagonist prazocin, CP59430 is decomposed completely using
5 min irradiation (Hess et al., 1983). The photoaffinity ligand
(N3TBOB) for GABA-A receptors has been shown to decompose
using 3 min photolysis (Hawkinson et al., 1991). In addition
Niznik et al. (1984) showed that azidoclebopride used as a
photoaffinity ligand for dopamine D2 receptors is almost
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completely decomposed after irradiation for 30 sec. The
differences in irradiation time for decomposition between these
reports might be due to the chemical structures or to
experimental conditions such as intensity of the light source,
distance from light source and concentration of compound. In
the present experiments, irradiation (15 W, 254 nm) for 2 min
decomposed 5-AC completely whereas 98% and 81% of 5-AC was
decomposed by irradiation for 1 min and 30 sec, respectively.
Compared with 400 W (365 nm), 15 W (254 nm) was more
effective for decomposition of 5-AC (Table 3.3), indicating that
254 nm may be suitable for photolysis of aryl azides as
described above.
Using the 15 W U.V. lamp, the effect of membrane
irradiation for 1, 2 and 4 min in the presence of 5-AC (200 nM)
on [3H]citalopram binding was examined. In the presence of
5-AC, irradiation (1, 2 and 4 min) did not produce a significant
reduction in the Bmax for [3H]citalopram binding when compared
with that for control membranes. However membrane
irradiation for 4 min in the absence of drugs produced a
significant 27% reduction in specific [3H]citalopram binding
when compared with that for control membranes, indicating that
4 min irradiation directly affected the membranes.
The effect of repeated U.V. irradiation (2 min x 2) on
[3H]citalopram binding was therefore examined. In the absence
of 5-AC, the Bmax and Kd values of [3H]citalopram binding to
irradiated membranes were not significantly different from
those for control membranes, indicating that the repeated
irradiation did not directly affect the membranes. In the
presence of 5-AC (200 nM), repeated irradiation showed a
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significant reduction (20%) in the Bmax when compared with
that for control membranes. Unlike the results with 400 W, the
extent of the reduction in Bmax for [3H]citalopram binding was
similar and reproducible between experiments. The Kd value
(0.99 nM) for non-irradiated membranes in the presence of 5-AC
was significantly higher than that for control membranes
(0.52 nM), but the Kd value (0.66 nM) for non-irradiated
membranes in the presence of UV-5-AC (decomposed 5-AC by
2 min irradiation) was not different from that for control
membranes. These results indicate that either UV-5-AC can be
removed from the membranes by the washing procedure or
because of its 9-fold lower affinity (Ki = 14.25 nM) than 5-AC
(Ki = 1.65 nM) the amount remaining is not sufficient to
significantly inhibit binding. However, despite the same
extensive washing, 5-AC remaining in the membranes was
sufficient to produce a 2-fold increase in the apparent Kd value
for [3H]citalopram. For this shift in Kd value, it can be
calculated that approximately 1 nM residual 5-AC remained in
the membranes. In the presence of 5-AC, repeated irradiation
did not produce an alteration of the Kd value when compared
with that for control membranes, suggesting that 5-AC in the
membrane suspensions was decomposed into UV-5-AC by
repeated 2 min irradiations. Thus it is concluded that 5-AC can
produce a covalent bond at the [3H]citalopram binding sites by
repeated U.V. irradiation with 15 W. However, only about 20%
of the [3H]citalopram binding sites could be labelled despite the
use of 5-AC at a concentration that completely inhibits specific
[3H]citalopram binding to rat cortical membranes and showed
therefore saturable all the sites prior to exposure to irradiation.
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Until recently many studies have been carried out using the
arylazide compounds as photoaffinity ligands. For example, the
use of azidoclebopride (a photoaffinity ligand for D2 dopamine
receptors) at a saturating concentration produced about a 60%
reduction of the Bmax value for [3H]spiperone binding to canine
brain membranes (Niznik et al., 1984) and the irreversible
binding of a saturating concentration of the azido-adenosine
analogue R-AHPIA, to A1 adenosine receptors has been indicated
by a reduction in the Bmax (40%) for [3H]N6-phenylisopropyl-
adenosine binding to rat brain membranes (Klots et al., 1985).
These reports could be examples of successful photoaffinity
ligands. Thus the predictable photochemistry of aryl azides,
and the highly reactive nature of the nitrenes have made the
procedure popular. The aryl-substituted nitrenes give the
highest efficiencies which is defined as the probability of a
reversibly bound ligand becoming irreversibly bound, though on
average this is still only 10% (Cavalla and Neff, 1985). The low
efficiency of 5-AC-induced covalent modification may be due to
the preferential reaction of nitrene with solvent rather than
with the binding site (Hess et al., 1983; Niznik et al., 1984).
As one of the reasons for low efficiency, it is known that the
labelling bond of aryl azide photoaffinity ligands is sometimes
unstable (Cavalla and Neff, 1985). In addition, the position of
the photosensitive function, an azido group, on the chemical
structure of the parent compound might be crucial for the
determining the efficiency of a photoaffinity ligand. In this
respect the 4'-azido-citalopram analogue which is predicted to
have high affinity for the 5-HT transporter based on data with
4'-cyano-citalopram reported by Bigler et al. (1977)
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(see introduction to this chapter) may be a possible alternative
to 5-AC as a photoaffinity ligand. In conclusion, 5-AC can bind
irreversibly to 20 % and up to 70 % of the [3H]citalopram binding
sites using repeated U.V. irradiations with 15 W (254 nm) and
400 W (365 nm) respectively. Therefore 5-AC, tritium labelled
to a high specific activity, may provide a suitable photoaffinity
ligand which could be used to isolate and characterise the native
5-HT transporter protein.
As a candidate for a SPET ligand for the 5-HT transporter,
the 5-iodo analogue of citalopram (5-IC) was synthesised. 5-IC
was 5.8-fold less potent than citalopram as an inhibitor of
[3H]5-HT uptake into rat cortical synaptosomes with a Ki value
of 11.5 nM. As an inhibitor of [3H]paroxetine and [3H]citalopram
binding to rat cortical membranes, 5-IC was only 1.9- and
3.1-fold less potent than citalopram (Ki : 4.0 nM and 2.9 nM
respectively). These results suggest that 5-IC has a high
affinity for the 5-HT transporter sites and might be a potential
SPET ligand.
For further characterisation of 5-IC, a study using radio-
iodinated 5-IC ([125I]5-IC) was carried out. For the time course
for [125|]5-|C binding to rat cortical membranes, equilibrium
was reached at 60 min, binding being slower than that for
[3H]citalopram. Binding of [125|]5-ic to rat cortical membranes
was inhibited by 5-IC (Kd = 1.87 nM), paroxetine (Ki = 0.12 nM),
citalopram (Ki = 1.42 nM) and 5-HT (Ki = 248 nM). These Ki
values corresponded well with data from the pharmacology of
[3H]citalopram and [3H]paroxetine binding. As shown in fig.3.22,
there was a good correlation between the potency of various
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drugs to inhibit [125|]5-IC and [3H]citalopram or [3H]paroxetine
binding. Their correlations for 4 drugs with r values of 0.994
(slope = 1.04, P < 0.01, [125|]5_ic binding vs [3H]citalopram
binding) and 0.998 (slope = 1.03, P < 0.01, [125|]5-IC binding vs
[3 Hjparoxetine binding), indicate that [125 |]5-IC, like
[3H]citalopram, is a suitable ligand for the 5-HT transporter.
The Bmax value for [125|]5-IC binding was not significantly
different from those for [3H]citalopram binding (P = 0.157) and
[3H]paroxetine binding (P = 0.064), suggesting that it was
labelling the same population of binding sites.
The ability of [125|]5-IC to label the 5-HT transporter sites
in rat brain in vivo was examined. After injection of [1251]5-1C,
significant accumulation of radioactivity into rat whole brain
was observed, indicating that 5-IC can penetrate the blood-brain
barrier. The radioactivity increase with time in the liver may
reflect the accumulation of metabolites of [125 |]5-IC. In
addition, the relatively low radioactivity in the thyroid
(maximum value : 0.082% of injected [125 |]5-IC at 1 hr
post-injection) might indicate resistance to in vivo deiodination
of [125|]5_ic. In brain regions, at 30 min, the radioactivity
concentration was similar in all brain regions but at all other
time points the radioactivity concentrations in the cerebellum
was lower in comparison with other 5 brain regions. In order
to make accurate measurements of radioactivity in each brain
region and examine the effect of pretreatment with unlabelled
drug (paroxetine) on the brain regional distribution of [1251]5-1c,
2 hr was chosen as a time point after injection, judging from the
dispersion of data from 2 animals and sufficient radioactivity
in each brain region for accurate measurements (Table 3.14,
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Fig.3.19). After 2 hr of [ 1251]5-|c injection, the brain regional
distribution showed lowest radioactivity in the cerebellum
(0.073 %D/g) compared with other brain regions (0.096 - 0.115
%D/g). In addition, the radioactivity in the cerebellum 2hr after
[125|]5-ic administration was not reduced in rats pretreated
with paroxetine (1 mg/kg, i.v.) whereas a reduction of
radioactivity by paroxetine was seen in other brain regions.
Corresponding results to the present study have been shown
using in vivo [3H]cyanoimipramine and [3H]paroxetine binding in
animals (Wolfe et al., 1987; Scheffel and Hartig, 1989;
Scheffel and Ricaurte, 1990). The radioactivity in
hypothalamus and cortex after intravenous injection of
[3H]cyanoimipramine was reduced in rats pretreated with
chlorimipramine, but no effect of chlorimipramine pretreatment
was seen in the cerebellum (Wolf et al., 1987). Pretreatment
with 5-HT uptake inhibitors such as citalopram and sertraline
did not reduce the radioactivity in cerebellum after intravenous
[3H]paroxetine injection using mice or rats (Scheffel and Hartig,
1989; Scheffel and Ricaurte, 1990). It was considered that
the radioactivity in the cerebellum represented nonspecific
binding and specific binding was calculated by subtracting the
radioactivity in the cerebellum from that in other brain regions.
This hypothesis could be supported from in vitro
autoradiographic studies using [3H]paroxetine or [3H]citalopram
which showed that the cerebellum has a relatively low number
of 5-HT uptake sites (DeSouza and Kuyatt, 1987; D'Amato et al.,
1987a; Hrdina et al., 1989). As shown in table 3.16, the
specific binding (%D/g in brain region - %D/g in cerebellum) in
each brain region at 2hr after [125 |]5-IC injection was
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calculated. When it was calculated by (individual brain region -
average of control and paroxetine treated cerebellum (n=6)),
there was no significant difference between control and
paroxetine pretreatment because of the variation between
animals. However when it was calculated by (individual brain
region - individual cerebellum from corresponding animal), there
was a significant difference between control and paroxetine
pretreatment. The second way is valid because of analysis
using matched tissue data. The highest level of specific
[125|]5-|C binding was observed in the brainstem (0.042 %D/g)
and midbrain (0.037 %D/g), areas which are known to be rich in
serotonergic neurons and consistent with previous reports using
in vitro autoradiography with [3H]paroxetine or [3H]citalopram
(DeSouza and Kuyatt, 1987; D'Amato et al., 1987a; Hrdina et al.,
1989). As shown in table 3.16 and fig.3.20, pretreatment of
paroxetine caused a significant reduction in specific p25|]5-|C
binding in all brain regions 2hr postinjection. The greatest
reductions were observed in the midbrain (84.4%), rostral cortex
(78.1%) and caudal cortex (63.2%). Smaller reductions occurred
in the brainstem (49.8%) and hippocampus (34.8%). The reason
for the brain regional variation in inhibitory effect of paroxetine
on the specific [125|]5-IO binding is not clear but similar results
were reported by Scheffel and Ricaurte (1990). According to
their report, pretreatment with citalopram or sertraline reduces
specific in vivo [3H]paroxetine binding in rat brain, but there are
differences in the extent of reduction of specific [3H]paroxetine
binding between brain regions. For example, the greatest
reductions by citalopram (3.2 mg/kg, i.v.) were observed in the
superior colliculus (76%) and hypothalamus (69%), whereas the
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reduction in the hippocampus (25%) was smallest. More
recently, Hume et al. (1991) also reported the brain regional
variation in inhibitory effects of paroxetine (2 mg/kg, i.v.) and
citalopram (2 mg/kg, i.v.) on in vivo [3H]citalopram binding in
rats. These phenomena may indicate that a change in brain
regional delivery of radioligand occurs by a pharmacologically
active dose of drug (in the present experiments, 1 mg/kg
paroxetine (Scheffel and Hartig, 1989)).
As pointed out by Scheffel and Hartig (1989), some
requisites for a successful SPET ligand include good penetration
across the blood-brain barrier, slow dissociation of the ligand
from the binding site, a high ratio of specific to non-specific
binding, and no rapid metabolic conversion of the tracer before
its binding to the appropriate site. In the present study,
[125|]5-IC penetrated the blood-brain barrier and its peak
radioactivity in whole brain was about 0.2 %D/g at 30-60 min
after injection. In addition, the clearance of [125|]5-|C in whole
brain was demonstrated to be relatively slow and its half-life
was greater than 90 min. This clearance pattern was similar in
each brain region except cerebellum ; clearance of radioactivity
from this brain region was faster than that from other brain
regions. 2hr post-injection of [125 |]5-IC, the amount of
radioactivity in each brain region except for cerebellum was
approximately 0.1 %D/g and a clear difference (P < 0.01) in
radioactivity was observed in comparison with cerebellum
(0.07 %D/g). These data suggest that 2hr post-injection is a
suitable time point for studying specific [125|]5-|Q binding in rat
brain regions. Gibson et al. (1984) has reported that about 0.1
%D/g in rat caudate/putamen using [125|]-4|QNB is a sufficient
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level of radioactivity to provide SPET images of the distribution
of muscarinic ACh receptors in human brain. Therefore, the
radioactivity (0.1 %D/g) in brain regions obtained from the
present study might be a sufficient amount for SPET studies in
man. Recently, in vivo binding in rat brain using [SHjcitalopram
and [11 C]citalopram was demonstrated by Hume et al. (1991).
For both ligands, the relatively large nonspecific labelling in
cerebellum results in only a relatively small proportion of
specific binding, the ratios for brain regions to cerebellum at
1 hr after injection being 1.23, 1.39 (frontal cortex), 1.17, 1.40
(thalamus) and 1.22, 1.32 (hippocampus) for [3H] and [11C]
labelled citalopram binding, respectively. These values
correspond well with the results obtained in the present work.
However, it should be noted that they also showed that the
single biologically active (+)enantiomer of [11 Cjcitalopram
improved the ratios of radioactivity in brain regions relative to
cerebellum the ratios being 1.68 (frontal cortex), 1.95
(thalamus) and 1.55 (hippocampus). Thus use of the
(+)enantiomer of [125|]5-IC might be expected to improve the
ratios of specific to non-specific binding. Additionally, it has
been pointed out that higher ratios may be obtained in human
brain as the distribution of the 5-HT uptake sites appear to be
more heterogeneous in human brain compared with rat brain
(Wolfe et al, 1987).
The results from the present work and information from
other reports indicate that [125|]5-ic and, possibly [125l](+)5-IC,
is a potential SPET ligand for the 5-HT transporter in human
brain. Such a SPET ligand would be valuable for monitoring
neuropsychiatric diseases such as depression and for detecting
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and evaluating damage of serotonergic neurons produced by
potent neurotoxins such as MDMA. On the other hand, studies
using other 5-HT uptake inhibitors as a prototype SPET ligands
will yield useful information as to whether they are more
suitable as prototype SPET ligands for the 5-HT transporter. As
reported by Sheffel et al. (1990), the selective 5-HT uptake
blocker fluoxetine does not appear to be a suitable SPET ligand
candidate. The mouse brain regional distribution of
[11 C]fluoxetine at 60 min after i.v. injection was not
proportional to 5-HT uptake site densities unlike that of
[11 Cjcitalopram. Although pretreatment with paroxetine
(1mg/kg) significantly inhibited specific [11 Cjcitalopram
binding, no inhibition of [nCjfluoxetine binding was observed.
Recently, a radioiodinated analogue of 6-nitroquipazine
([i25|]5-jodo-6-nitroquipazine) has been evaluated its in vitro
and in vivo binding properties in rat brain (Mathis et al., 1993;
Biegon et al., 1993). In vitro binding experiments in rat brain
membranes demonstrated that p25|]5-jodo-6-nitroquipazine is
highly selective and has extremely high affinity (Kd = 23 pM) for
5-HT uptake sites (Mathis et al., 1993). In vivo studies using
[i25|]5-jodo-6-nitroquipazine in rats have shown rapid and
efficient penetration of the blood-brain barrier, and regional
brain distribution correlated with the known distribution of
serotonergic uptake sites and terminals (Biegon et al., 1993).
In addition, in vivo imaging studies in non-human primates using
SPET with [i23|].|abelled 5-iodo-6-nitroquipazine demonstrated
that this tracer rapidly penetrates brain and yields good target-
to-background ratios (e.g. brainstem to cerebellar ratio : > 2 by
8 hr after injection), indicating a promising compound for
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imaging the serotonergic reuptake site in primate brain (Jagust
et al., 1993). Finally taking data of in vivo [3H]paroxetine
binding using mice and rats into consideration, paroxetine may
be expected to provide a useful SPET ligand candidate for the
5-HT transporter especially since it has very high affinity.
However, there is no evidence from results shown
usinadiochemical concentration of 10 mCi/ml in ethyl acetate.
A batch of the crude material (200 mCi) was delivered to the
Department of Pharmacology, University of Edinburgh and stored
in 0.5 ml aliquots (10 mCi/ml) under liquid nitrogen prior to
purification. For purification of [3H](+)FR, after removal of
ethyl acetate, 4.02 mCi of crude [3H](+)FR was dissolved
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CHAPTER 4
BINDING OF 5-HTia RECEPTOR AND 5-HT TRANSPORTER LIGANDS
IN RAT CORTEX AND HIPPOCAMPUS FOLLOWING CHOLINERGIC
AND SEROTONERGIC LESION
4.1 INTRODUCTION
In Alzheimer's disease (AD) characterised by progressive
deterioration of cognitive functions, neuropathological
examination of the brains disclose characteristic abnormalities
such as neuritic plaques which consist of abnormal neurites, and
neurofibrillary tangles including bundles of paired helical
filaments (Selkoe et al., 1982). The density of neuritic plaques
in the cortex of AD patients correlates both with the severity of
their cognitive defects and reductions in the activity of choline
acetyltransferase (ChAT), the enzyme that synthesises
acetylcholine (ACh) (Perry et al., 1978). These observations
indicate that cortical cholinergic activity is correlated with the
degree of dementia. This cholinergic deficiency in the cerebral
cortex is thought to be due to a loss of neurons in the nucleus
basalis of Meynert (nbM) which projects to the cerebral cortex
(Coyle et al., 1983). In addition to the cholinergic deficiency,
neurochemical studies have demonstrated that serotonergic
dysfunction also occurs in AD (Bowen et al., 1983; Cross, 1988).
In the brain of AD, it has been shown that 5-HTi and 5-HT2
receptors are reduced using [3H]5-HT (5-HTi) and pHjketanserin
(5-HT2) binding. More recently, Middlemiss et al. (1986) showed
that a loss of [3H]8-OH-DPAT binding sites (5-HTia receptor) is
observed in frontal cortex from post-mortem AD brain compared
with normal brain. In addition, the uptake of [3H]5-HT and the
binding of [3H]imipramine are also significantly reduced (Bowen
et al., 1983). D'Amato et al. (1987b) showed that a significant
reduction of [3H]citalopram binding to the 5-HT uptake sites
without reductions of catecholaminergic markers occurs in
frontal cortex of AD brain. These results suggest that 5-HT
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uptake sites as well as 5-HT receptors are reduced in AD .
In order to study the role of the cholinergic system in
learning and memory by pharmacological means, animal models
with some of the neurochemical abnormalities present in AD
have been developed. Ibotenate is often used to destroy the nbM
in animals (Johnston et al., 1981; Wenk et a!., 1984). The nbM
lesioned rats have memory impairment which can be reversed
pharmacologically with the ACh esterase inhibitor,
physostigmine (Haroutunian et al., 1986), indicating that drugs
that enhance central cholinergic activity can overcome the
behavioural deficits produced by an nbM lesion. Recently, it has
been shown that administration of the serotonergic depleting
agent g.-chloroamphetamine to nbM lesioned rats blocks the
memory-enhancing effects of physostigmine (Santucci et al.,
1989). This result may suggest that the serotonergic and
cholinergic systems interact on a functional level in memory
processing. Cross and Deakin (1985) observed a significant
loss of cortical 5-HTi receptors using nbM lesioned rats with a
large decrease in ChAT activity, indicating that a proportion of
cortical 5-HTi receptors may be present on cholinergic
terminals in the frontal cortex.
The aim of the work presented in this chapter was to
investigate whether 5-HTia binding sites and 5-HT uptake sites
are located on cholinergic nerve terminals in rat frontal cortex
using selective neurotoxic lesion models. To destroy the
cholinergic innervation of the cortex, two separate neurotoxins,
ibotenate and AMPA, were injected directly into the nbM. AMPA
infusions destroy more ChAT-immunoreactive neurons and cause
greater reductions in cortical ChAT activity than ibotenate
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infusions (Page et al.,1991). In addition, the location of 5-HTia
binding sites and 5-HT uptake sites in the frontal cortex and
hippocampus was investigated in lesioned rats by intra¬
ventricular injection of the 5-HT neurotoxin 5,7-dihydroxy-
tryptamine (5,7-DHT) to destroy 5-HT terminals. After
producing the lesion with the neurotoxins, the binding site
density and affinity for the 5-HTia and 5-HT uptake sites were
examined using [3H]8-OH-DPAT and [3H]citalopram binding,
respectively.
4.2 METHODS
For these studies, surgery and stereotaxic injection of
neurotoxins was carried out by Dr.S.P.Butcher in the Department
of Pharmacology, University of Edinburgh.
4.2.1 Ibotenate and AMPA Lesions
Cholinergic neurones in the nbM were destroyed by direct
injection of either ibotenate or AMPA according to the method of
Wenk et al. (1984). Male Sprague Dawley rats (280-300 g) were
allowed access to food and water ad libitum prior to the
experiments. Under anaesthesia with pentobarbitone (60 mg/kg,
i.p.), rats were placed in a Kopf stereotaxic frame (nose bar =
0.2 mm). Burr holes were drilled above nbM (AP -0.9 mm, ML
±2.6 mm) and 0.5 pi of either ibotenate (25 nmoles in 0.1 M
phosphate buffered saline, pH 7.4) or AMPA (7.5 nmoles in 0.1 M
phosphate buffered saline, pH 7.4) was injected over a 5 min
period (DV -6.8 mm). The needle was left in place for 5 min
before removal. Seven days after surgery, the rats were
sacrified by decapitation and their brains were removed and
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rapidly dissected on ice. The frontal cortex and hippocampus
were isolated and stored at -20°C either for binding studies or
for determination of ChAT activity. Control values were
obtained from tissue samples derived from the hemisphere
contralateral to the injection site with lesion data being
obtained from the ipsilateral hemisphere.
4.2.2 ChAT Activity Assay
ChAT activity was determined according to the method of
Fonnum (1975). Rats were killed and the cortices and
hippocampi were dissected and homogenised in 20 vols of buffer
(0.1% Triton X-100 in 1mM EDTA (pH 7.0)). The homogenates
were diluted to 200 vols in the same buffer, and 20 pi aliquots
were then added to 20 pi of incubation medium (50 mM NahtePCM
(pH 7.4), 10 mM choline chloride, 0.1 mM eserine, 0.9 mg/ml
albumin, 300 mM NaCI, 10 mM EDTA, 0.2 mM [i4C]acetyl-CoA).
This mixture was incubated at 37°C for 20 min and the reaction
was stopped by flushing the reaction medium into scintillation
vials containig 10 ml scintillant (PPO in toluene) using 7 ml of
extraction medium (5 ml of 10 mM NahtePCU (pH 7.4), 0.18 mg
unlabelled ACh chloride, 37.4 mg sodium tetraphenylboron and
2 ml acetonitrile). The vials were gently inverted and
radioactivity was determined after 60 min.
4.2.3 5.7-DHT Lesion
Male Sprague Dawley rats (280-300 g) were anaesthetised
with pentobarbitone (60 mg/kg, i.p.) and placed in a Kopf
stereotaxic frame. Thirty minutes after i.p. injection of
25 mg/kg desmethylimipramine to protect noradrenergic
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neurones, 5,7-DHT (150 (ig in 20 pi isotonic saline containing
0.1% ascorbic acid) was infused over 2 min into the lateral
ventricle (AP -1.3 mm, ML -1.7 mm). The needle was left in
place for a further 2 min before removal. Two weeks after
surgery, the rats were sacrified by decapitation and their brains
were removed and rapidly dissected at 4°C. The frontal cortex
and hippocampus were isolated and stored at -20°C either for
binding studies or for neurochemical assessment of the lesion by
HPLC determination of 5-HT content. Values for control
(untreated) and lesioned tissues are derived from separate
groups of animals.
4.2.4 Measurement of Tissue 5-HT Concentration
Rats were killed and the cortices and hippocampi were
dissected out, frozen on dry ice and stored at - 70°C. Tissues
were weighed and homogenised in 0.6 M perchloric acid.
Samples were centrifuged at 10,000g for 2 min at 4°C, and 20 pi
aliquots of the supernatant were injected directly onto the
HPLC. The 5-HT concentration in the supernatant was measured
with electrochemical detection (BAS 4B; +0.7 V compared with a
Ag/AgCI reference electrode) after separation by reversed-
phase HPLC. Samples (20 pi) were chromatographed using a C18
Ultrasphere column (250 x 4.6 mm) and eluted with a mobile
phase at a flow rate of 1 ml/min. As a mobile phase, 100 mM
citrate/acetate buffer (pH 5.2 adjusted using NaOH) containing
100 pg/ml octanesulphonic acid, 5% methanol and 2%
tetrahydrofuran was used. The system was calibrated by
injection of 2 ng of 5-HT and the peak was identified by
comparison of retention time.
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4.2.5 Preparation of Membranes for Binding Assays
For binding experiments, individual hippocampi and frontal
cortices were thawed at room temperature then homogenised in
40 vols of ice cold 50 mM Tris-HCI buffer (pH 7.4) and
centrifuged at 30,000g at 4°C for 10 min. The pellet was
washed 3 times by resuspension in 40 vols of Tris buffer and
centrifugation, then resuspended in buffer and incubated at 37°C
for 10 min to remove endogenous 5-HT. After a final
centrifugation, the membranes were resuspended in 8 vols of
Tris buffer and stored at -20°C until required. On the day of
binding experiments, the membrane suspension was thawed at
room temperature and diluted with Tris buffer; cortices 300
vols, hippocampi 500 vols.
4.2.6 f2H18-QH-DPAT Binding to Rat Cortical and Hippocampal
Membranes
Binding of [3H]8-OH-DPAT was carried out by preincubating
duplicate 0.5 ml aliquots of membrane suspension with various
concentrations of unlabelled 8-OH-DPAT or 50 mM Tris-HCI
buffer containing MgS04 (final concentration 5 mM), pH7.4
(control) for 2 min at 25°C before addition of [3H]8-OH-DPAT
(final concentration 0.5 nM) to give a final assay volume of 1 ml.
Samples were vortexed briefly then incubated at 25°C for
30 min. Incubation was terminated at room temperature by
rapid filtration under vacuum on a Brandel Cell Harvester using
Whatman GF/B filters then washed twice with 5 ml Tris buffer.
The filters were transferred to scintillation vials and 100 pi of
formic acid (100%) added to digest the membrane protein
followed 10 min later by addition of 4 ml of scintillation fluid
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(Packard Emulsifier Safe). The radioactivity trapped on the
filter was measured in a Packard 1900CA liquid scintillation
analyser using automatic quench correction. 10 pM 5-HT was
used to define specific binding. Quadruplicate 100 pi samples of
[3H]8-OH-DPAT as standards were counted in order for the exact
ligand concentration to be calculated for individual experiments.
4.2.7 [2H"lCitalopram Binding to Rat Cortical and Hippocampal
Membranes
[3H]Citalopram and [3H]8-OH-DPAT bindings were carried
out in parallel using the same membrane preparations from
control and lesioned rats as described in section 4.2.5.
Therefore the assay was a modification of the method described
in section 3.2.4 since no NaCI or KOI was present in the final
membrane preparation. Instead NaCI and KCI was added directly
to the assay tube to give a final concentration of 120 mM NaCI
and 5 mM KCI. Thus binding was carried out by preincubating
duplicate 500 pi aliquots of membrane suspension and 200 pi of
Tris-HCI buffer containing 600 mM NaCI and 25 mM KCI with
10 concentrations of unlabelled citalopram or Tris buffer
(control) for 2 min at 25°C before addition of [3H]citalopram
(final concentration 0.5 nM) to give a final assay volume of 1 ml.
Samples were incubated at 25°C for 60 min. Incubation was
terminated by rapid filtration on a Brandel Cell Harvester
(Whatman GF/B filter, pretreated with 0.05% polyethyleneimine)
followed by two washes with 5 ml Tris buffer. The filters were
transferred to scintillation vials, and 4 ml of scintillation fluid
(Packard Emulsifier Safe) was added to each vial 10 min after
addition of 100% formic acid (100 pi) to digest the membrane.
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The radioactivity trapped on the filter was measured in a
Packard 1900CA liquid scintillation analyser using automatic
quench correction. 10 |iM unlabelled citalopram was used to
define specific binding. In preliminary experiments this method
for [3H]citalopram binding was compared directly with the
method described in section 3.2.4. When NaCI and KCI were
added to the assay tubes, Kd and Bmax values for
[3H]citalopram binding were 0.9 nM and 0.9 pmol/mg protein
respectively. Using the method described in section 3.2.4, Kd
and Bmax values for [3H]citalopram binding were 0.8 nM and 0.8
pmol/mg protein respectively. Therefore virtually identical
results were obtained allowing a single membrane suspension to
be used as the tissue source for both the [3H]8-OH-DPAT and
[3H]citalopram assays.
4.2.8 Protein Assay
Protein assay was carried out as described in section
3.2.7. In brief, the reagent (2.5 ml) containing phosphoric acid
and Coomassie Brilliant Blue was added to 100 pi samples and
20 min later the optical density of sample was read at 595 nm
on a spectrophotometer. The protein concentration of membrane
samples was calculated from the standard curve using bovine
serum albumin (25-200 pg/ml).
4.2.9 Data Analysis
Data for the binding of [3H]8-OH-DPAT and [3H]citalopram
were analysed by least squares fit to the logistic expression :
Y = MXP/ (XP + IC50)
Ki values were calculated from the equation :
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Ki = ICso / (1 + L/Kd)
where L is ligand concentration. Bmax value were calculated
from the equation :
b = Bmax • L / (L + Kd)
where b is bound ligand concentration. These kinetic variables
together with neurochemical data (ChAT activity and 5-HT
content) were determined for individual animals. Values from
each control and lesion group were then combined to provide a
mean ± S.E.M. and data subjected to statistical analysis using
Wilcoxon signed rank test or a Mann Whitney U-test as
appropriate.
4.2.10 Materials
[i4C]Acetyl CoA (specific activity : 60 mCi/mmol),
[3H]8-OH-DPAT (specific activity : 264 Ci/mmol) and
[3H]citalopram (specific activity : 50 Ci/mmol) were obtained
from Amersham International. [3H]8-OH-DPAT and [3H]citalopram
were diluted to 1 (iM in glass distilled water and stored under
liquid nitrogen in volumes sufficient for individual experiments.
Ibotenate was obtained from Research Biochemicals Inc. and
AMPA was obtained from Tocris Neuroamin. Other drugs and
reagents were obtained from Sigma.
4.3 RESULTS
4.3.1 Effects of Ibotenate and AMPA Lesions on ChAT Activity
Seven days after nbM lesion by ibotenate and AMPA,
cortical and hippocampal ChAT activity was measured. In
experiments using both ibotenate and AMPA, large and
significant reductions in ChAT activity were observed in frontal
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cortex but not in hippocampus (Table 4.1). In the frontal cortex
ipsilateral to the ibotenate injection site, a 49.8% reduction of
ChAT activity (27.3 ± 3.1 nmol/mg protein/hr) was observed in
comparison with that in the contralateral side (54.4 ± 3.9
nmol/mg protein/hr), whereas lesion by ibotenate did not
affected ChAT activity in the hippocampus (control : 61.3 ± 5.8,
lesion : 62.3 ± 5.2 nmol/mg protein/hr). AMPA lesion reduced
the cortical ChAT activity by 67.5 % (control : 46.5 ± 4.1, lesion :
15.1 ±1.7 nmol/mg protein/hr). In contrast, the hippocampal
ChAT activity was not affected by AMPA injection (control :
56.5 ± 5.5, lesion : 55.9 ± 5.3 nmol/mg protein/hr).
4.3.2 Effect of 5.7-DHT Lesions on 5-HT Levels
Two weeks after i.e.v. injection of 5,7-DHT, the 5-HT
levels in the lesioned rats were measured using HPLC and
compared with those in sham controls (Table 4.2). 5-HT levels
in the frontal cortex and hippocampus of 5,7-DHT lesioned
animals were 1.23 ± 0.13 and 0.68 ± 0.09 pmol/mg wet weight
respectively. Corresponding values in untreated animals were
5.53 ± 0.43 and 4.1 ± 0.43 pmol/mg wet weight. Thus 5-HT
levels were reduced by 78% and 83% in the frontal cortex and
hippocampus of lesioned animals.
4.3.3 Kinetic Characteristics of f3H18-OH-DPAT Binding to Rat
Cortical and Hippocampal Membranes (Table 4.3)
In unlesioned tissue of three separate sets of experiments
(ibotenate, AMPA or 5,7-DHT lesion), the binding affinity (Kd) of
[3H]8-OH-DPAT in cortical membranes was 1.38 ± 0.09 nM,
1.21 ± 0.04 nM and 1.46 ± 0.12 nM respectively, whereas the Kd in
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TABLE 4.1 : Effects of Basal Forebrain Lesions on Cortical and
Hippocampal ChAT Activity














15.1 ± 1.7 ** (67.5)
55.9± 5.3
Choline acetyltransferase (ChAT) activity was determined
according to the method of Fonnum (1975). Values are mean
± S.E.M. from 6 animals. Control and lesion data were obtained
from the unlesioned and lesioned hemispheres of the same rat.
**
; P < 0.01 compared with control. % reduction versus control
was shown in parentheses.
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TABLE 4.2 : Effect of 5.7-DHT Lesion on Cortical and
Hippocampal 5-HT Content
5-HT content (pmol/mq wet weight)
Control Lesion
Cortex 5.53 ± 0.43 1.23 ± 0.13*** (78)
Hippocampus 4.10 ± 0.43 0.68 ± 0.09 *** (83)
5-HT levels in the cortex and hippocampus of unlesioned and
5,7-DHT injected (150 (jg, i.e.v.) rats were measured by HPLC.
Results are the mean ± S.E.M. from 6 animals. *** ; P < 0.001
compared with control. % reduction versus control was shown
in parentheses.
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TABLE 4.3 : Effects of Neuronal Lesions on P^18-OH-DPAT










Hippocampus Control 1.23 ±0.12










Hippocampus Control 1.03 ±0.04
















Membranes were incubated with [3H]8-OH-DPAT (0.5 nM) in the
absence or presence of unlabelled 8-OH-DPAT for 30 min at
25°C. Non-specific binding was determined in the presence of
10 pM unlabelled 5-HT. Results are the mean ± S.E.M. from
6 independent samples being derived either from the same rat
(for ibotenate and AMPA lesions, membranes were prepared from
the lesioned and unlesioned hemispheres of the same brain) or
from different animals (for 5,7-DHT lesions, membranes were
prepared from different animals).
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hippocampal membranes was 1.23 ± 0.12 nM, 1.03 ± 0.04 nM and
1.73 ± 0.10 nM respectively. The binding density (Bmax) in
cortical membranes was 0.45 ± 0.02 pmol/mg protein
(ibotenate), 0.44 ± 0.06 pmol/mg protein (AMPA) and 0.68 ± 0.04
pmol/mg protein (5,7-DHT). In hippocampal membranes, the
Bmax was 1.83 ± 0.06 pmol/mg protein (ibotenate), 1.91 ± 0.21
pmol/mg protein (AMPA) and 1.96 ± 0.12 pmol/mg protein
(5,7-DHT). Thus the Bmax in hippocampal membranes was
greater than in cortical membranes in three separate sets of
experiments.
4.3.4 Effects of Neuronal Lesions on [3.H]8-OH-DPAT Binding
a) Ibotenate lesion (Table 4.3)
In the frontal cortex and hippocampus contralateral to the
ibotenate injection site, the bindirrg affinity (Kd) of
[3H]8-OH-DPAT was 1.38 ± 0.09 nM and 1.23 ± 0.12 nM
respectively. The Kd value in cortical and hippocampal
membranes from ibotenate lesioned hemisphere was 1.38 ± 0.06
nM and 1.28 ± 0.08 nM respectively. Thus basal forebrain
cholinergic lesions using ibotenate did not effect the binding
affinity of [3H]8-OH-DPAT. The [3H]8-OH-DPAT binding site
density (Bmax) in membranes from the unlesioned hemisphere
was 0.45 ± 0.02 pmol/mg protein (cortex) and 1.83 ± 0.06
pmol/mg protein (hippocampus), while the Bmax in membranes
from lesioned hemisphere was 0.52 ± 0.03 pmol/mg protein
(cortex) and 1.85 ± 0.14 pmol/mg protein (hippocampus),
suggesting that the ibotenate lesion did not affected the Bmax.
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b) AMPA lesion (Table 4.3)
The Kd of pH]8-OH-DPAT in membranes from unlesioned
hemisphere was 1.21 ± 0.04 nM (cortex) and 1.03 ± 0.04 nM
(hippocampus), while the Kd in membranes prepared from
lesioned hemisphere was 1.19 ± 0.02 nM (cortex) and 0.96 ± 0.03
nM (hippocampus). The Bmax of [3H]8-OH-DPAT in membranes
from the AMPA lesioned hemisphere was 0.47 ± 0.03 pmol/mg
protein (cortex) and 1.75 ± 0.19pmol/mg protein (hippocampus).
These values were not significantly different from those for
unlesioned hemisphere (cortex : 0.44 ± 0.06 pmol/mg protein,
hippocampus : 1.91 + 0.21 pmol/mg protein). These results
suggest that the Kd and Bmax values of [3H]8-OH-DPAT were not
affected by AMPA induced lesions.
c) 5.7-DHT lesion (Table 4.3)
There was no significant difference in the Kd values of
[3H]8-OH-DPAT in membranes between the 5,7-DHT lesioned
animals (cortex : 1.42 ± 0.09 nM, hippocampus : 1.50 ± 0.13 nM)
and unlesioned animals (cortex : 1.46 ± 0.12 nM, hippocampus :
1.73 ± 0.10 nM). The Bmax of [3H]8-OH-DPAT in membranes from
the 5,7-DHT lesioned animals was 0.61 ± 0.07 pmol/mg protein
(cortex) and 1.64 ± 0.12 pmol/mg protein (hippocampus), while
the Bmax in membranes from unlesioned animals was 0.68 ± 0.04
pmol/mg protein (cortex) and 1.96 ± 0.12 pmol/mg protein
(hippocampus). These results suggest that the Kd and Bmax
values of [3H]8-OH-DPAT were not significantly affected by
5,7-DHT lesions.
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4.3.5 Kinetic Characteristics of [3-HICitalopram Binding to Rat
Cortical and Hippocampal Membranes (Table 4.4)
In unlesioned tissue, the binding affinity (Kd) of
[3H]citalopram in cortical membranes was 0.85 ± 0.09 nM
(ibotenate), 3.03 ± 0.28 nM (AMPA) and 2.26 ± 0.14 nM (5,7-DHT)
in three separate sets of experiments. The Kd in hippocampal
membranes was 1.22 ± 0.38 nM (ibotenate), 2.95 ± 0.28 nM
(AMPA) and 0.66 ± 0.17 nM (5,7-DHT). The binding density
(Bmax) in cortical membranes was 1.66 ± 0.15 pmol/mg protein
(ibotenate), 1.77 ± 0.24 pmol/mg protein (AMPA) and 1.59 ± 0.07
pmol/mg protein (5,7-DHT). In hippocampal membranes, the
Bmax was 1.34 ± 0.27 pmol/mg protein (ibotenate), 0.92 ± 0.16
pmol/mg protein (AMPA) and 0.78 ± 0.13 pmol/mg protein
(5,7-DHT). The Kd or Bmax values varied from one set of
experiment to another although the actual value within a set of
experiments showed little variation (data not shown). The
reasons underlying the discrepancy between the Kd or Bmax
values between, the three sets of experiments remain unclear.
In all experiments, the Bmax in cortical membranes was greater
than in hippocampal membranes.
4.3.6 Effects of Neuronal Lesions on f3H]Citalopram Binding
a) Ibotenate lesion (Table 4.4)
The Kd of [3H]citalopram in cortical and hippocampal
membranes from ibotenate lesioned hemisphere was 0.80 ± 0.06
nM and 1.43 ± 0.47 nM respectively. These values were not
significantly different from those for unlesioned hemisphere
(cortex : 0.85 ± 0.09 nM, hippocampus : 1.22 ± 0.38 nM). The
[3H]citalopram binding site density (Bmax) in membranes from
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TABLE 4.4: Effects of Neuronal Lesions on fiHICitalopram
Binding to Rat Brain Membranes
fiHICitalopram binding
Ko.(nM) Bmax (pmol/mg protein)
Ibotenate lesion
Cortex Control 0.85 ± 0.09 1.66 + 0.1 5
Lesion 0.80 ± 0.06 1.33 ± 0.12
Hippocampus Control 1.22 ± 0.38 1.34 + 0.27
Lesion 1.43 ± 0.47 1.37 + 0.34
AMPA lesion
Cortex Control 3.03 ± 0.28 1.77 + 0.24
Lesion 3.34 ± 0.30 1.74 + 0.10
Hippocampus Control 2.95 ± 0.28 0.92 ± 0.16
Lesion 3.76 ± 0.62 1.12 + 0.15
5.7-DHT lesion
Cortex Control 2.26 ± 0.14 1.59 + 0.07
Lesion 3.03 ± 0.36 0.84 + 0.11 ***
Hippocampus Control 0.66 ± 0.17 0.78 ± 0.13
Lesion N.D • N.D.
Membranes were incubated with [3H]citalopram (0.4 nM) in the
absence or presence of unlabelled citalopram for 60 min at 25°C.
Non-specific binding was determined in the presence of 10 /jM
unlabelled citalopram. Results are the mean ± S.E.M. from
6 independent samples being derived either from the same rat
(for ibotenate and AMPA lesions, membranes were prepared from
the lesioned and unlesioned hemispheres of the same brain) or
from different animals (for 5,7-DHT lesions, membranes were
prepared from different animals). *** ; P < 0.001 compared
with control. N.D.; binding was not detectable.
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the unlesioned hemisphere was 1.66 ± 0.15 pmol/mg protein
(cortex) and 1.34 ± 0.27 pmol/mg protein (hippocampus), while
the Bmax in membranes from lesioned hemisphere was
1.33 ± 0.12 pmol/mg protein (cortex) and 1.37 ± 0.34 pmol/mg
protein (hippocampus), suggesting that the ibotenate lesion did
not affected the Bmax.
b) AMPA lesion (Table 4.4)
The Kd of [3H]citalopram in membranes from unlesioned
hemisphere was 3.03 ± 0.28 nM (cortex) and 2.95 ± 0.28 nM
(hippocampus), while the Kd in membranes prepared from
lesioned hemisphere was 3.34 ± 0.30 nM (cortex) and 3.76 ± 0.62
nM (hippocampus). The Bmax of [3H]citalopram in membranes
from the AMPA lesioned hemisphere was 1.74 ± 0.10 pmol/mg
protein (cortex) and 1.12 ± 0.15 pmol/mg protein (hippocampus).
These values were not significantly different from those for
unlesioned hemisphere (cortex :1.77 ± 0.24 pmol/mg protein,
hippocampus : 0.92 ± 0.16 pmol/mg protein). These results
suggest that the Kd and Bmax values of [3H]citalopram were not
affected by AMPA induced lesions.
c) 5.7-DHT lesion (Table 4.4)
There was no significant difference in the Kd values of
[3H]citalopram in cortical membranes between the 5,7-DHT
lesioned animals (3.03 ± 0.36 nM) and unlesioned animals
(2.26 ± 0.14 nM). In the frontal cortex of the 5,7-DHT lesioned
animals, a 47.2% reduction of the Bmax value of [3H]citalopram
(0.84 ± 0.11 pmol/mg protein) was observed in comparison with
that for unlesioned animals (1.59 ± 0.07 pmol/mg protein). In
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the hippocampus, [3 H]citalopram binding was almost
undetectable in lesioned animals. Since it was not possible to
analyse the data accurately and calculate Kd and Bmax values for
[3H]citalopram binding in hippocampus from lesioned animals due
to the small amounts of specific binding, a direct comparison of
the specific binding at a single ligand concentration of 0.5 nM is
shown in table 4.5 for both hippocampus and frontal cortex. In
the hippocampus, 5,7-DHT lesion reduced significantly the
specific [3H]citalopram binding by 87.4% (control; 308.3 ± 16.1
fmol/mg protein, lesion; 38.7 ± 6.7 fmol/mg protein) whereas a
59.5% reduction of specific binding was shown in the frontal
cortex (control; 307.0 ± 19.7 fmol/mg protein, lesion;
124.3 ± 11.1 fmol/mg protein).
4.4 DISCUSSION
The cellular localisation of 5-HTia binding sites and 5-HT
uptake sites in the rat frontal cortex and hippocampus was
examined using three different neurotoxin, ibotenate, AMPA and
5,7-DHT. The relevant binding sites were characterised in
membrane binding assays which used [3H]8-OH-DPAT to study the
5-HTia binding site and [3H]citalopram to identify the serotonin
transport site.
In order to destroy cholinergic terminals, ibotenate and
AMPA was injected into nbM which provides the major
cholinergic projections to the cortex (Coyle et al., 1983). After
lesions, ChAT activity which is a marker for cholinergic
terminals was measured in the frontal cortex and hippocampus.
Both neurotoxins reduced ChAT activity in frontal cortex but not
in hippocampus, indicating that ibotenate and AMPA produced a
206
TABLE 4.5 : Effect of 5,7-DHT Lesion on Specific fcHICitalopram
Binding
Specific P-Hlcitalopram binding (fmol/mq protein")
Control Lesion
Cortex 307.0 ±19.7 124.3 ±11.1*** (59.5)
Hippocampus 308.3 ±16.1 38.7 ± 6.7 *** (87.4)
Membranes were incubated with [3H]citalopram in the absence or
presence of unlabelled citalopram for 60 min at 25°C.
Non-specific binding was determined in the presence of 10 fjM
unlabelled citalopram. Specific [3H]citalopram binding at a
single ligand concentration of 0.5 nM was shown. Results are
the mean ± S.E.M. (n = 6) from the cortex and hippocampus of
unlesioned and 5,7-DHT injected (150/jg, i.e.v.) rats.
***
; p < 0.001 compared with control. % reduction versus
control was shown in parentheses.
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selective destruction of cholinergic nerve terminals in frontal
cortex. AMPA lesion produced a 67.5% reduction of ChAT
activity in frontal cortex and this was significantly greater
(P < 0.01) than the 49.8% reduction noted after ibotenate lesion.
This result is consistent with previous observations by Page et
al. (1991). They showed that AMPA- and ibotenate-induced
lesions reduced cortical ChAT activity by 70% and 50%
respectively and this difference was due to a less effective in
destruction of cholinergic neurons by an ibotenate lesion than an
AMPA lesion as shown by histological analysis.
Excitotoxic lesions of basal forebrain cholinergic neurones
using either ibotenate or AMPA did not effect the binding
affinity (Kd value) and density (Bmax value) for [3H]8-OH-DPAT
binding in either cortical or hippocampal membranes. These
data suggest that the 5-HTia binding sites are not localised on
the cortical nerve terminals of cholinergic neurones situated in
the basal forebrain. However these data should be contrasted
with the results of release experiments which suggest that
5-HTia receptor agonists increase cortical ACh release (Bianchi
et al., 1990). This discrepancy is presumably due either to
species differences between the two studies (guinea pigs were
used in the release experiments) or to an action of the 5-HTia
receptor agonist, which was administered systemically in the
release experiment, on cholinergic cell bodies in the basal
forebrain resulting in an alteration in cortical release of ACh.
Previously Cross and Deakin (1985) have showed that the lesion
of nbM by ibotenate produces a significant reduction in ChAT
activity (56%) and the Bmax value (18%) for [3H]5-HT binding in
rat cortex, indicating that a proportion of 5-HTi receptors may
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be associated with cholinergic terminals. However it is known
that [3H]5-HT binds to several distinct subtypes including
5-HTia,ib,ic and id. 5-HTic is now reclassified as the 5-HT2C
receptor. It has been shown that relative contributions of four
subtypes to total 5-HTi binding sites in rat cortex are 48%
(5-HT1 a), 14% (5-HT1 b), 20% (5-HT2C) and 18% (5-HTid)
(Herrick-Davis and Titeler, 1988). Judging from results in the
present experiment, a loss of cortical 5-HTi receptors by
ibotenate lesion might be due to the destruction of other 5-HTi
receptors except for the 5-HTia subtype. On the other hand,
Middlemiss et al. (1986) have demonstrated a 48% loss of
[3H]8-OH-DPAT binding sites in the frontal cortex from patients
with AD. The results in the present experiment indicate that a
loss of cortical 5-HTia receptors in AD is unlikely to be due to a
loss of cholinergic terminals. However, the serotonin
innervation in human frontal cortex might be different from that
in rats. Indeed, Hoyer et al (1986a) have demonstrated that
[3HJ8-OH-DPAT binding to the 5-HTia receptor in human brain is
dense in outer layers of the cerebral cortex whereas this is not
the case in rats (Pazos and Palacios, 1985). Thus a loss of
5-HTia receptors in AD may occurs especially in outer layers of
the cerebral cortex. Recently it has been suggested that the
degeneration of cortical glutamatergic neurones occurs in the
brain from patients with AD (Francis et al., 1993). Endogenous
5-HT may regulate glutamate transmission at 5-HTia receptors
located on cortical glutamatergic neurones (Francis et al.,
1993). Therefore a loss of 5-HTia receptors in AD might be due
to degeneration of cortical glutamatergic neurones.
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The destruction of serotonergic neurons by 5,7-DHT
reduced markedly and significantly the 5-HT levels in rat frontal
cortex and hippocampus in comparison with those in unlesioned
animals, indicating a loss of serotonergic terminals. Lesioning
of serotonergic neurones had no effect on [3H]8-OH-DPAT binding
in the cortex and hippocampus. Previously, Hall et al. (1985)
demonstrated that intracerebral 5,7-DHT injection produces a
significant reduction (51%) in the Bmax value for [3H]8-OH-DPAT
binding in the striatum but not in the hippocampus or cerebral
cortex. Thus data from the present study are in agreement with
their findings.
Lesions of basal forebrain cholinergic neurones by
ibotenate and AMPA did not effect the affinity or binding site
density of [3H]citalopram binding in either cortical or
hippocampal membranes. These results suggest that the 5-HT
uptake sites are not localised on cholinergic terminals in rat
frontal cortex. Therefore the reduction of [3H]citalopram
binding sites observed in human frontal cortex with AD (D'Amato
et al., 1987b) may not directly depend on a damage to cholinergic
terminals. Serotonergic lesions produced a reduction of binding
site density for [3H]citalopram binding in both the cortical and
hippocampal membranes. These results suggest that
[3H]citalopram can label the 5-HT transporter on serotonergic
terminals in rat frontal cortex and hippocampus. However there
was a marked difference in the extent of the reduction in the
cortex and hippocampus. The density of [3H]citalopram binding
sites was almost abolished in the hippocampus whereas its
reduction in the frontal cortex was only 47.2%. In the specific
[3H]citalopram binding, a 87.4% reduction was observed in the
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hippocampus when compared with unlesioned animals, whereas
that in the frontal cortex was 59.5%. It is possible that the
difference in reduction of transporter sites for the two brain
regions is due to lower penetration of the neurotoxin in the
cortex. However this seems an unlikely explanation since 5-HT
levels were reduced to a similar extent in frontal cortex (75.1%)
and hippocampus (78.6%). The discrepancy may suggest that
[3H]citalopram labels a second population of binding sites in the
frontal cortex that is not associated with serotonergic nerve
terminals. However there is no evidence to suggest that two
pharmacologically distinct [3H]citalopram binding sites exist in
rat brain. An alternative explanation is that the cellular
distribution of the binding site in the cortex and hippocampus
differs. 5-HT uptake sites have been demonstrated in primary
astrocyte cultures as well as in neurones (Katz and Kimelberg,
1985). A differential contribution of glial cells and neurones to
the pattern of binding in the two brain areas could explain these
data because the neurotoxic effect of 5,7-DHT would only be
expected to destroy the neuronal [3H]citalopram binding sites.
However Habert et al. (1985) showed that 5,7-DHT lesion
produces a 90% reduction in [3H]paroxetine binding to rat
cortical membranes. In addition it has been reported that
lesioning of the serotonergic neurons with p.-chloroamphetamine
causes a 90% reduction of [3H]citalopram binding sites to rat
cortical membranes (D'Amato et al., 1987a). Therefore the
difference in the extent of the reduction of [3H]citalopram
binding sites in the cortex and hippocampus observed in the
present study remain unclear.
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In conclusion, the 5-HTia receptors are not localised on
cholinergic terminals in the cortex, or serotonergic terminals in
the cortex and hippocampus. The 5-HT transporter sites are
located on terminals of serotonergic neurons in the cortex and
hippocampus, but not on cholinergic terminals in the cortex.
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CHAPTER 5
GENERAL DISCUSSION AND CONCLUSIONS
Characterisation of the NMDA receptor antagonist, FR115427
The novel isoquinoline derivative FR115427 ((+)-1-
methyl-1 -phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride),
is a novel NMDA antagonist and has antiischaemic and
anticonvulsive effects in animals. Therefore, FR115427 ((+)FR)
was characterised initially using in vitro [3H]MK-801 binding to
rat brain membranes. Subsequently, [3H]FR115427 was
synthesised, purified and then its in vivo distribution in rats
was examined.
(+)FR inhibited [3H]MK-801 binding to rat cortical
synaptosomal membranes in the presence of added L-glutamate
(10 |iM) with a Ki value of about 40 nM and although it was
12-fold less potent than (+)MK-801, the data are consistent
with (+)FR being a non-competitive NMDA antagonist. As
observed with (+)MK-801, the affinity of (+)FR was 2.9-fold
higher when 10 pM L-glutamate was present in the assay buffer.
These results suggest that binding of glutamate to the NMDA
receptor presumably causes a conformational change that
facilitates the interaction of (+)FR with its binding site within
the NMDA receptor ion channel. However the effect of
L-glutamate was more apparent for (+)MK-801 than (+)FR,
indicating that (+)FR and (+)MK-801 may not interact with the
binding site in the NMDA receptor-ion channel in an identical
manner. When compared with the corresponding (-)enantiomer,
(+)FR and (+)MK-801 were respectively 98- and 4.2-fold more
potent as inhibitors of [3H]MK-801 binding to rat cortical
synaptosomal membranes in the presence of added L-glutamate
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(10 jiM). These results suggest a more pronounced
stereoselectivity for FR compared with MK-801. This difference
is most likely due to the differences in the chemical structure
of MK-801 and FR115427.
[3H](+)FR synthesised by tritiation of (+)CI-FR (mono-
chlorinated aromatic precursor of (+)FR) was successfully
purified by an open column method, and its purity confirmed by
TLC and column chromatography. Intravenous injection of
[3H](+)FR resulted in a rapid accumulation of radioactivity in rat
brain. Therefore [3H](+)FR might be useful tool for in vivo
imaging of the NMDA receptor-ion channel complex, especially
under cerebral ischaemic conditions, although further detailed
experiments will be required.
Development of photoaffinitv and SPET ligands for the 5-HT
transporter
For evaluation of citalopram analogues as photoaffinity
and SPET ligands for the 5-HT transporter, assays for [3H]5-HT
uptake into rat cortical synaptosomes and the binding of
[3H]paroxetine and [3H]citalopram to rat cortical membranes
were established and evaluated. There was a good correlation
between the potency of various drugs to inhibit [3H]5-HT uptake,
[3H]paroxetine and [3H]citalopram binding.
5-Azido-citalopram (5-AC) synthesised as a candidate for
a photoaffinity ligand, had high affinity (Ki = 1.65 nM) for
[3H]citalopram binding sites and 5-AC was only 1.8-fold less
potent than citalopram itself. In the presence of 200 nM, a
concentration of 5-AC which can completely inhibit
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[3H]citalopram binding, repeated U.V. irradiation of rat cortical
membranes with 15 W for 2 min produced a significant 20%
reduction in the Bmax value for [3H]citalopram binding compared
with control, indicating formation of a covalent bond between
5-AC and [3H]citalopram binding sites. Therefore, radiolabeled
5-AC may provide a tool for isolation and characterisation of
the 5-HT transporter.
5-lodo-citalopram (5-IC) synthesised as a candidate for a
SPET ligand, was 5.8-fold less potent than citalopram as an
inhibitor of [3H]5-HT uptake into rat cortical synaptosomes with
a Ki value of 11.5 nM. This compound had high affinity (Ki =
4.0 nM and 2.9 nM) for [3H]paroxetine and [3H]citalopram binding
to rat cortical membranes respectively, being only 1.9- and
3.1-fold less potent than citalopram itself in the two binding
assays. These results suggest that 5-IC has a high affinity for
the 5-HT transporter sites and might be a potential SPET ligand.
The binding of radio-iodinated 5-IC ([125l]5-IC) to rat cortical
membranes was inhibited by 5-IC (Kd = 2.9 nM), paroxetine (Ki =
0.12 nM), citalopram (Ki = 1.42 nM) and 5-HT (Ki = 248 nM).
These Ki values corresponded well with data from [3H]citalopram
binding experiments and indicate that as for [3H]citalopram,
[125|]5-|C is a suitable ligand for the 5-HT transporter.
Intravenous injection of [125|]5-IC resulted in a rapid
accumulation of radioactivity in rat brain. At 2hr after
[125|]5-ic injection, the highest level of specific [1251]5-1C
binding was observed in the brainstem (0.042 %D/g) and
midbrain (0.037 %D/g), which are known to be rich in
serotonergic neurons. Pretreatment with paroxetine caused a
significant reduction in specific [125|]5-IC binding in all brain
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regions except cerebellum 2hr post-injection. The greatest
reductions were observed in the midbrain (84.4%), rostral cortex
(78.1%) and caudal cortex (63.2%). Smaller reductions occurred
in the brainstem (49.8%) and hippocampus (34.8%). The reason
for the brain regional variation in the inhibitory effect of
paroxetine on specific [125|]5-ic binding is not clear but these
phenomena may indicate that a change in brain regional delivery
of radioligand occurs by pretreatment with a pharmacologically
active dose of drug, in this case paroxetine (1 mg/kg, i.v.). The
results from the present work may indicate that [125|]5-IC is a
potential SPET ligand for the 5-HT transporter in human brain.
Such a SPET ligand would be valuable for monitoring
neuropsychiatric diseases such as depression and for detecting
damage of serotonergic neurons by potent neurotoxins such as
MDMA.
Binding of 5-HTia receptor and 5-HT transporter liaands in rat
cortex and hippocampus following cholinergic and serotonergic
lesion
The cellular localisation of 5-HTia binding sites and 5-HT
uptake sites in the rat frontal cortex and hippocampus was
examined using three different neurotoxins, ibotenate, AMPA and
5,7-DHT. Ibotenate and AMPA reduced ChAT activity in frontal
cortex but not in hippocampus, indicating that both neurotoxins
produced a selective destruction of cholinergic nerve terminals
in frontal cortex. The lesions of basal forebrain cholinergic
neurones using either ibotenate or AMPA did not effect the
binding affinity (Kd value) and density (Bmax value) for
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[3H]8-OH-DPAT binding in either cortical or hippocampal
membranes. These data suggest that the 5-HTia binding sites
are not localised on the cortical nerve terminals of cholinergic
neurones situated in the basal forebrain. Therefore a loss of
cortical 5-HTia receptors in AD is unlikely to be due to a loss of
cholinergic terminals. The destruction of serotonergic neurons
by 5,7-DHT reduced markedly and significantly the 5-HT levels
in rat frontal cortex and hippocampus in comparison with those
in unlesioned animals, indicating a loss of serotonergic
terminals. Lesioning of serotonergic neurones had no effect on
[3H]8-OH-DPAT binding in the cortex and hippocampus. Lesions
of basal forebrain cholinergic neurones by ibotenate and AMPA
did not effect the affinity or binding site density of
[3H]citalopram binding in either cortical or hippocampal
membranes. These- results suggest that the 5-HT uptake sites
are not localised on cholinergic terminals in rat frontal cortex.
Therefore a reduction of [3H]citalopram binding sites observed in
human frontal cortex with AD may not directly depend on damage
of cholinergic terminals. Serotonergic lesions produced a
reduction of binding site density for pHjcitalopram binding in
both the cortical and hippocampal membranes, suggesting that
[3H]citalopram can label the 5-HT transporter on serotonergic
terminals in rat frontal cortex and hippocampus. The density
of [3H]citalopram binding sites was almost abolished in the
hippocampus whereas its reduction in the frontal cortex was
only 47.2%. The reason for the difference in the cortex and
hippocampus remains unclear. This discrepancy may suggest
that [3H]citalopram labels a second population of binding sites in
the frontal cortex that is not associated with serotonergic nerve
217
terminals. An alternative explanation is that the cellular
distribution of the binding site in the cortex and hippocampus
differs. A differential contribution of glial cells and neurones
to the pattern of binding in the two brain areas could explain
these data because the neurotoxic effect of 5,7-DHT would only
be expected to destroy the neuronal [3H]citalopram binding sites.
In conclusion, the 5-HTia receptors are not localised on
cholinergic terminals in the cortex, or serotonergic terminals in
the cortex and hippocampus. The 5-HT transporter sites are
located on terminals of serotonergic neurons in the cortex and
hippocampus, but not on cholinergic terminals in the cortex.
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41 P THE LOCALISATION OF 5-HTi A AND 5-HT UPTAKE BINDING SITES IN THE RAT FOREBRAEN
'.A. Lawrence, K. Shirakawa, H.J. Olverman, J.S. Kelly & S.P. Butcher, (introduced by D.J. Lawrence) Department of
'harmacology, University of Edinburgh, 1 George Square, Edinburgh, EH8 9JZ
Although autoradiographic and binding studies have demonstrated the presence of 5-HTj a sites in rat cortex and hippocampus, the
ynaptic localization of these sites is not known (Pazos and Palacios, 1985). A loss ot o-FITi » binding sites has, however, been
ibsetved post-mortem in frontal cortex obtained fkim Alzheimer's patients (Middlemiss et al, t986). In the present study we have
nvestigated whether 5-HTj^ and uptake binding sites arc located on cholinergic and serotonergic nerve terminals in rat cortex and
lippocampus.
Cholinergic neurones in the nucleus basalis were lesioned by direct injection of ibotenic acid (25 nmoles; AP -0.9; ML +2.6; DV -
i.8mm). Rats were sacrificed after 7 days for the determination of choline acetyltransferase activity (ChAT, Fonnum, 1975) or for
linding studies. Serotonergic neurones were destroyed by i.e.v. injection of 5,7-dihydroxytryptamine (150|4g; animals pretreated for
0 min with 25mg/kg desmethylimipramine). Brain tissue was prepared for analysis of 5-HT levels or binding studies 14 days later.
-HTj^ binding sites were labelled with (^H]8-OHDPAT (0.5nM), using 10|iM 5-HT to define specific binding and the 5-HT uptake
ites using [^Hjcitaiopram (0.4nM), with 10|aM citalopram used to define specific binding. Whole brain membranes were prepared
rom frontal cortex and hippocampus of individual animals (n = 5 or 6 for each group).
ollowing ibotenate injection ChAT activity was reduced by 49.44+2.43% (n = 6) in the frontal cortex but was unaltered
98.69+5.13%) in the hippocampus suggesting that the cholinergic innervation of the cortex had been selectively destroyed. No
ignificant alteration in the number of binding sites was seen for [H-TJ8-OHDPAT (Bm^x [pmol/mg protein]; cortex, control =
.45+0.02, lesion = 0.52+0.03; hinnoenmpus. control = 1.83+0.06, lesion = 1.85+0.14) or (JH]citalopram (Bmax (pmol/mg protein];
-onex. control = 1.54+0.10, lesion = 1.33+0.11; hippocampus, control = 1.34+0.25, lesion = 1.37+0.31). ^Destruction of serotonergic
ibres led to 77+2% and 78+5% reductions in cortical and hippocampal levels of 5-HT respectively. [-TTJCitalopram binding was
educed by 45% in frontal cortex and was almost undetectable in the hippocampus of lesipned animals (Bmax (pmol/mg protein];
-ortex. control = 1.80+0.2, lesion = 1.00+0.16; P < 0.05). No alterations were observed in [^H]8-OHDPAT binding (Bmax (pmol/mg
rotein]; cortex, control = 0.68+0.04, lesion = 0.61+0.07; hippocampus, control = 1.96+0-12, lesion = 1.64+0-12). For both lesions
tere was no significant alteration in the affinity of either ligand for its binding site.
hese data suggest that the majority of (^Hjcitalopram binding sites are located on the terminals of serotonergic neurones in rat cortex
nd hippocampus. Binding of (^H]8-OHDPAT was not altered following lesions of the cholinergic and serotonergic innervation of
te frontal cortex.
azos, A. and Palacios, J.M. (1985) Brain Res. 346, 205-230
onnum, F. (1975) J.Neurochem. 24, 407-409
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258P COMPARISON OF AMPA AND 1BOTENIC ACID LESIONS IN RAT CORTEX
J.A. Lawrence, K. Shirakawa, HJ. Olverman, J.S. Kelly and S.P. Butcher, Dept. of Pharmacology, University of Edinburgh, 1
George Square, Edinburgh, EH8 9JZ
In our previous study employing ibotcnic acid and 5,7-DHT lesions (Lawrence et al, 1991), no evidence was found for a presynaptic
localisation of 5HT1A binding sites on cholinergic or serotonergic nerve terminals in the rat cortex or hippocampus.
This study has now been extended to include a unilateral excitotoxic lesion with the selective quisqualate receptor agonist, AMPA
((RS)-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and to compare this lesion with that of ibotenic acid at the 5HT1A
site, labelled with PH]8-OHDPAT (0.5nM).
Cholinergic neurones in the substantia innominata were destroyed by direct injection of either ibotenic acid (25nmoles) or AMPA
(7.5nmoles; AP - 0.9mm; ML ± 2.6mm; DV - 6.8mm). The lesions were verified by measurement of cortical and hippocampal
levels of choline acetyltransferase (ChAT) after 7 days.
Table L' ChAT activity and binding to 5HTt. i r-"—---:I —
Ibotenic acid (n = 6) AMPA fn = 6)
control lesion control lesion
54.4 + 3.9 27.3 ±3.1 46.5 ±4.1 15.1 ± 1.7
1.38+0.06 1.38 ±0.06 1.21 ±0.30 0.92 ±0.21
0.45 + 0.02 0.52 ±0.03 0.49 ±0.03 0.47 ± 0.05
61.3+5.8 62.3 ± 5.2 56.5 ± 5.5 55.9 ±5.3
1.51+0.14 1.28+0.08 1.11 ±0.23 1.33 ±0.11
1.83 + 0.06 1.85 ±0.14 1.61 ±0.02 1.72 ±0.03
CORTEX
ChAT activity (nmoles/mg protein/60 min)
8-OHDPAT binding; Kp (nM)
®max (pmol/mg protein)
■HIPPOCAMPUS
ChAT activity (nmoles/mg protein/60 min)
■8-OHDPAT binding: Kp (nM)
®max (pmol/mg protein)
Thus ibotenic acid and AMPA produced a similar level of neuronal destruction in the substantia innominata, as measured by the
ChAT activity. However, for both lesions no changes were observed in either the density or affinity of 5HT1A receptors in the
cortex. This data confirms our previous observation that 5HT;A receptors are not located on cholinergic terminals in the rat cortex.
This work was supported by the Wellcome Trust.
Lawrence, J.A., Shirakawa, K, Olverman, H.J., Kelly, J.S. and Butcher, S.P. (1991) Br.J.Pharmac. 102, 241P.
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Binding of 5-HT1A receptor and 5-HT transporter ligands in rat cortex
and hippocampus following cholinergic and serotonergic lesions
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cellular localisation of 5-HT1A receptor and 5-HT transporter binding sites in the rat cortex and hippocampus has been examined. Lesions of
er basal forebrain neurones or serotonergic neurones did not affect [3H]S-OH-DPAT binding, suggesting that 5-HT1A binding sites are not
lised on cholinergic or serotonergic nerve terminals. The binding of the 5-HT transporter ligand, [3H]citalopram was unaffected by the
linergic lesion whereas binding was reduced in both the hippocampus and cortex following serotonergic lesions. A reduction in binding site
sicy rather than an alteration in affinity was responsible for this effect. While these data suggest that [3Hlcitalopram binding sites are located
serotonergic nerve terminals, the abolition of hippocampal binding sites contrasted with a 50% loss in cortical tissue.
-Recent advances in human brain imaging technology
vide the basis for the development of diagnostic
ts for pathological conditions such as Alzheimer's
ease. Our group has concentrated on ligands for
^le positron emission tomography (SPET) directed
■ards the 5-HT1A subtype of serotonin receptors10-11
is approach was prompted by the observation that
ITlA binding is reduced in the brain of Alzheimer's
ients3-4-14.
The present study used a brain lesioning approach
itudy the cellular localisation of 5-HT1A receptors in
rat cortex and hippocampus. Binding to 5-HT1A
eptors was examined using [3H]8-hydroxy-2-(di-n-
pylamino)tetralin ([3H]8-OH-DPAT) as the radio-
nds.i3.i7.is A [QSS ch0iinerg ic and serotoner-
markers has been reported in the brains of Aiz-
mer's patients3-16, and the reduction in 5-HT,A
ding in the cortex of these patients could be related
the loss of either population of neurones. Excito-
c lesions were used to mimic the loss of cholinergic
ervation of the cortex observed in the brains of
heimer's patients. In further experiments, lesions of
serotonergic cell bodies that innervate the cortex
and hippocampus were performed. Binding to the sero¬
tonin transport site using [3H]citalopram was also stud¬
ied in both control and lesioned animals since this has
been shown to be a useful marker for serotonergic
nerve terminals4.
For excitotoxic lesions of basal forebrain cholinergic
neurones, Cobb-Wistar rats weighing 280-300 g were
anaesthetised with pentobarbitone (60 mg/kg) and
placed in a Kopf stereotaxic frame. 0.5 ^.1 of either
ibotenate (Research Biochemicals Inc.; 25 nmol in 50
mM phosphate-buffered saline (PBS); pH 7.4) or a-
amino-3-hydroxy-5-methylisoxazole-4-propionic acid
(AMPA; Tocris Neuramin; 7.5 nmol in 50 mM PBS;
pH 7.4) was injected into the basal forebrain (AP
-0.9; ML ±2.6; DV -6.8) over a 5-min period. The
needle was left in place for a further 5 min before
removal. Animals were killed 7 days later either for
binding studies or for determination of choline acetyl-
transferase (ChAT) activity6. Choline acetyltransferase
(ChAT) activity in the frontal cortex ipsilateral to the
excitotoxin injection site was 27.3 ±3.1 (n = 6) and
15.1 ± 1.7 (n = 6) nmol/mg protein/h for ibotenate
and AMPA lesions, respectively. Corresponding values
cspoitdencc: S.P. Butcher. Present address: Fujisawa Institute of Neuroscience, Department of Pharmacology, University of Edinburgh, I
rge Square. Edinburgh EH8 9JZ, UK. Fax: (44) (3D 667-9381.
327
the unlesioned contralateral cortex were 54.4 ± 3.9
= 6) and 46.5 + 4.1 (n = 6) nmol/mg protein/h. The
7o reduction noted following AMPA injection was
nificantly greater ( P < 0.0L) than the 50% reduction
ed atter ibotenate injection. In contrast, neither
ion affected ChAT activity in the hippocampus (data
. shown).
Serotonergic cell bodies were destroyed using 5,7-di-
iroxytryptamine (5,7-DHT; Sigma). Male Cobb-
star rats weighing 280-300 g were anaesthetised
h pentobarbitone (45 mg/kg, i.p.), and desmeth-
nipramine (25 mg/kg, i.p.) was administered to pro-
t noradrenergic neurones. After 30 min, 5,7-DHT
0 /ug in 20 0.9% saline containing 0.1% ascorbic
d) was infused over 2 min into the lateral ventricle
5 — 1.3; ML — 1.7). The needle was left in place for
irther 2 min before removal. After I4'days rats were
d either for binding studies or neurochemical as-
sment of the lesion by HPLC determination of 5-HT
tent. Values for control (untreated) and lesioned
ues are derived from separate groups of animals.
IT levels in the cortex and hippocampus of 5,7-
IT-lesioned animals were 1.23 ±0.13 (n = 6) and
] ± 0.09 (n = 6) pmol/mg wet weight, respectively,
responding values in untreated animals were 5.53
i.43 (n = 6) and 4.1+0.43 {n = 6) pmol/mg wet
ght. Thus, the tissue content of serotonin was re¬
ed by 78% and 83% in the cortex and hippocampus
esioned animals.
7or binding experiments, individual hippocampi and
ital cortices were homogenised in 40 vols, (v/w)
cold 50 mM Tris-HCl (pH 7.4) and centrifuged at
)00 x g for 10 min at 4°C. Membranes were washed
mes followed by a 10-min incubation at 37°C to
love endogenous 5-HT. After a final centrifugation
'0,000 X^, membranes were stored at -20°C. Im-
-iiately before use, membrane suspensions were
ved and diluted with 50 mM Tris-HCl (pH 7.4);
ices 300 vols., hippocampi 500 vols. The protein
tent of individual membrane suspensions was deter-
ed according to the method of Bradford3. For the
]S-OH-DPAT binding assay, aliquots of the mem-
le suspensions were incubated with 0.5 nM [3 H]8-
-DPAT (264 Ci/mmol; Amersham International)
0 mM Tris-HCl (pH 7.4), containing 5 mM MgS04
le absence or presence of 0.03-100 nM unlabelled
H-DPAT. Incubations were terminated following a
nin incubation at 25°C by rapid filtration through
ltman GF/B filters under vacuum. 10 juM 5-HT
used to define non-specific binding. For the
-Icitalopram binding assay, samples of the mem-
le suspensions were incubated in duplicate with 0.4

































Ibotenate AMPA 5,7 -DHT
Ibotenate AMPA 5,7-DHT
Fig. I. Effects of AMPA, ibotenate and 5.7-DHT lesions on the Bmax
of [JH]8-OH-DPAT binding to rat cortical (A) and hippocampal (B)
membranes. 10 /xM 5-HT was used to define non-specific binding.
Data (pmol/mg protein) are the mean±S.E.M. from 6 independent
samples with control (open bars) and lesion (filled bars) data being
derived from either the same rat (for ibotenate and AMPA lesions)
or different animals (for 5.7-DHT lesions).
Tris-HCl, pH 7.4 containing 150 mM NaCl and 5 mM
KC1 in the absence or presence of 0.03-100 nM unla¬
belled citalopram. Incubations were carried out for 60
min at 25°C and terminated as described previously.
Non-specific binding was defined using 10 juM citalo¬
pram. Binding data were fitted by least squares to the
logistic expression Y = MXP/(Xp + ICP0), and Kd and
Bmax values were calculated.
In unlesioned tissue, the binding affinity (Kd) of
[3H]8-OH-DPAT in cortical and hippocampal mem¬
branes was 1.35 + 0.06 nM and 1.45 ± 0.15 nM, respec¬
tively. In the case of [3H]citalopram, the Kd in cortical
and hippocampal membranes was 2.04 + 0.26 nM and
2.25 ± 0.26 nM, respectively. The Kd of both [3H]8-
OH-DPAT and [3Hjcitalopram for their respective
binding sites on cortical and hippocampal membranes
was not significantly affected by either excitotoxin or
5,7-DHT-induced lesions (data not shown).
Excitotoxic lesions of basal forebrain cholinergic
neurones using either ibotenate or AMPA did not
effect [3H]8-OH-DPAT binding site density (S,nax) in
either cortical or hippocampal membranes (Fig. 1). The
Bmax was also unaffected in membranes prepared from
the cortex and hippocampus of 5.7-DHT-lesioned ani¬
mals (Fig I). Basal forebrain cholinergic lesions using
































2. Effects of AMPA. ibotenate and 5.7-DHT lesions on the Bmax
■'Hlcitalopram binding to rat cortical (A) and hippocampal (B)
libraries. Non-specific binding was defined using 10 m.M citalo-
m. Data (pmol/mg protein) are the mean + S.E.M. from 6 inde-
dent samples with control (open bars) and lesion (filled bars)
t being derived either from the same rat (for ibotenate and
PA lesions) or from different animals (for 5,7-DHT lesions).
P <0.01. specific binding of [•'H]citalopram in 5,7-DHT-le-
ied hippocampal membranes was less than 10% of total binding.
> precludes accurate determination of the Bm;u value by satura¬
tion analysis of the data.
I]citalopram binding to cortical or hippocampai
mbranes (Fig 2). In contrast, 5,7-DHT lesions of
otonergic neurones caused a marked reduction in
^max °f [JH]citalopram binding (Fig 2). The Bmax
tortical membranes from lesioned animals was 47%
< 0.01) of that in unlesioned animals. Although the
,x of [5H]citalopram binding in hippocampal mem-
nes from 5,7-DHT lesioned animals could not be
urately determined (see Fig. 2 legend), specific
ding at a ligand concentration of 0.4 nM was 0.04 ±
I pmol/mg protein in lesioned hippocampi corn¬
ed with 0.31 ± 0.02 pmol/mg protein in unlesioned
pocampi. This suggests that the Bmax was reduced
greater than 85% in lesioned animals. The reduc-
l in specific [3H]citalopram binding was significantly
ater (P < 0.05) in hippocampal compared with cor-
l membranes.
Data from the present study suggest that 5-HT1A
Jing sites are not localised on the cortical nerve
ninals ot cholinergic basal forebrain neurones. Both
enate and AMPA lesions markedly reduced corti-
ChAT activity without effecting [JH]8-OH-DPAT
Jing to cortical membranes. The finding that AMPA
lesions produced a larger reduction in cortical ChAT
activity is consistent with recent reports15. These data
should be contrasted with the results of release experi¬
ments which suggest that 5-HT,A receptor agonists
increase cortical acetylcholine release1. This discrep¬
ancy can be explained by an action of 5-HTIA agonists,
administered systemically in the release experiment, on
cholinergic basal forebrain cell bodies resulting in al¬
tered cortical transmitter release. Serotonergic lesions
did not affect [3H]8-OH-DPAT binding in the cortex
and hippocampus. While this finding is in agreement
with previous data8, a presynaptic localisation of 5-
HT1A binding sites has been demonstrated on seroton¬
ergic cell bodies in the raphe nucleus18. Although a
non-significant 21% reduction in cortical [5H]8-OH-
DPAT binding following serotonergic lesioning has
been reported8, this finding was not confirmed in the
present study.
The present study also examined the localisation of
serotonin uptake sites using [JH]citalopram. While
cholinergic lesions were ineffective, serotonergic le¬
sions reduced [3H]citalopram binding in both cortical
and hippocampal membranes. Although this confirms
presynaptic localisation on serotonergic nerve termi¬
nals5, there was a marked difference in the extent of
the reduction in the cortex and hippocampus. Binding
was virtually abolished in hippocampal membranes
prepared from 5,7-DHT-lesioned rats, whereas a 50%
reduction was noted in cortical membranes prepared
from the same animals. Since serotonin levels were
depleted . to a similar extent in both brain areas,
[3H]citalopram may label a second population of bind¬
ing sites in the cortex that is not associated with
serotonergic nerve terminals. A possible explanation is
that serotonin uptake sites exist in astrocyte cultures9,
and the cellular distribution (neuronal versus glial) of
the binding site in the cortex and hippocampus may
differ. However, serotonergic lesions using p-chloro-
amphetamine are reported to abolish [3H]citalopram
binding in both the hippocampus and cortex, and the
degree of tissue serotonin depletion was similar to that
observed in the present study5. Alternatively, the 5-HT
system may be less uniform than at first thought'2, and
a small component of the cortical system enriched in
5-HT uptake sites could either be less sensitive to the
5,7-DHT lesion or be protected from the lesion by
desmethylimipramine pre treatment.
In conclusion, the majority of 5-HT1A binding sites
are not localised on cholinergic or serotonergic nerve
terminals in the rat cortex and hippocampus. A postsy¬
naptic localisation therefore appears likely and experi¬
mental evidence favouring this idea has been reported;
[3H]^-OH-DPAT binding is reduced both in hippocam-
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and cortical pyramidal cells following kainatc'7 and
ccnsin7 lesions, respectively. If 5-HTIA directed
gs can be developed as radioligands for PET and
iT studies, these agents are ideal tor imaging corti-
cell loss rather than as presynaptic markers. We are
sently developing radioiodinated analogues of
lopram and paroxetine for the study of serotonergic
ve terminal loss in the cerebral cortex.
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"he pharmacological profile of FR115427 has been examined using ligand binding and electrophysiological techniques,
ding of [3H]dizocilpine in the presence of L-glutamate was inhibited by the ( + ) isomers of dizocilpine and FR115427. The
esponding (-) isomers were less active, and stereoselectivity was particularly marked in the case of FR115427. In contrast to
cilpine, the affinity of FR115427 for [3H]dizocilpine binding sites was little affected by addition of either L-glutamate and/or
ine. In a cortical wedge preparation, FR115427 inhibited N-methyl-D-aspartate (NMDA)-induced responses in a non-compe-
e, use-dependent manner. Intracellular^ recorded excitatory synaptic responses in hippocampal neurones were only partially
bited by FR 115427 thereby confirming a selective effect on the NMDA-mediated component of neuronal excitation induced
he endogenous neurotransmitter. The data suggest that FR 115427 is a non-competitive, use-dependent NMDA receptor
gonist with more pronounced stereoselectivity and less marked use dependence than dizocilpine.
NMDA (N-methyl-D-aspartate); Non-competitive antagonism; Dizocilpine; FR115427; Cortical wedge; Hippocampus
introduction
"he N-methyl-D-aspartate (NMDA) receptor pro-
has recently been cloned (Moriyoshi et al., 1991).
irochemical and electrophysiological studies have
tonstrated that a number of pharmacologically dis-
t modulatory sites are present within its structure
recent reviews by Reynolds and Miller, 1990;
ng and Kemp, 1991). Research efforts aimed at
sloping compounds that selectively interact with
,e sites are ultimately directed at regulating NMDA
:ptor function in various disease states. The NMDA
:ptor subtype has been implicated in a range of
nal and pathological conditions including synaptic
ticity and learning (Lester et al., 1988), and neu-
ithological cell death (Meldrum and Garthwaite,
); Olney, 1990). NMDA receptor activation can be
-bited in a competitive manner by antagonists acting
le site that recognises the endogenous neurotrans-
:spondence to: S.P. Butcher, Fujisawa Institute of Neuro-
ce. Department of Pharmacology, University of Edinburgh, 1
ge Square, Edinburgh EH8 9JZ, UK. Tel. 44-031-650-8491; fax
-667-9381.
mitter, and a number of pharmacological agents have
been developed that selectively interact with this site
(see Olverman and Watkins, 1989). Receptor function
can also be blocked in a non-competitive manner by
drugs such as ( + )-5-methyl-10,ll-dihydro-5H-dibenzo-
[a,d]cyclohepten-5,10-imine maleate (dizocilpine or
MK801) and phencyclidine (PCP) that interact with
sites located within the NMDA receptor-associated ion
channel (Wong et al., 1986, 1988; MacDonald and
Nowak, 1990; MacDonald et al., 1990; Lodge and
Johnson, 1990).
In this study we have examined the inhibitory effect
of the novel isoquinoline derivative, (+ )-l-methyI-l-
phenyl-l,2,3,4-tetrahydroisoquinoline hydrochloride
(FR115427; fig. 1) on [3H]dizocilpine binding to rat
brain membranes. Both the stereoselectivity of this
interaction and the effects of L-glutamate and glycine
on the affinity of FR115427 for [3H]dizocilpine binding
sites have been studied. The functional significance of
this interaction has been studied using a cortical wedge
preparation to determine the mode of action of
FR 115427 and, in particular, to examine whether the
observed inhibition of NMDA-mediated responses is
competitive or non-competitive with use-dependent
properties. The effects of FR115427 on the excitatory
DIZOCILPINE
1. Chemical structures of dizocilpine and FRl 15427 (( + )-l-
methyl-l-phenyl-I,2.3,4 tetrahydroisoquinoline HCI).
tsynaptic potential (e.p.s.p.) elicited in hippocampal
1 neurones by stimulation of Schaffer collateral-
tmisural fibres in the stratum radiatum have also
n examined in order to examine the action of
115427 on responses produced by the endogenous
tatory amino acid transmitter.
Materials and methods
Preparation of rat brain membranes
lie cerebral cortices of male Cob-Wistar rats (250—
g) were dissected and homogenised in 15 volumes
n) of ice-cold 0.32 M sucrose using a glass teflon
togeniser. The homogenate was centrifuged at 1000
at 4°C for 10 min. and the supernatant recen-
tged (17 000 Xg, 20 min, 4°C). The resultant P2
et was lysed with 30 volumes of glass distilled
ix. After incubation at 37°C for 30 min, the mem-
te suspension was centrifuged at 50000 Xg for 10
at 4°C, the supernatant discarded and the pellet
hed by resuspension in glass distilled water (30
mes) and centrifugation (50000 Xg, 4°C, 10 min).
resultant pellet was resuspended to 10 volumes of
s distilled water and stored at — 20°C. The mem-
te suspension was thawed prior to use and diluted
0 volumes with glass distilled water, recentrifuged
)00 Xg, 4°C, 10 min) and the final pellet was resus-
ied in 30 volumes of 5 mM Tris-HCl (pH 7.4, 20°C)
kept on ice until required. The protein content of
membrane suspension was determined by the
iod of Bradford (1976), using bovine serine albu-
(fraction V) as the standard.
2.2. / 'HiDizocilpine binding assay
pHjDizocilpine (24 Ci/mmol; NEN; 1 nM final
ligand concentration) was preincubated at 25°C with 5
mM Tris-HCl buffer (pH 7.4), and increasing concen¬
trations of test drugs ((-F )-FRl 15427, 1 nM-30 ,u.M;
(-)-FRl 15427, 3 nM-100 /xM; (+ )-dizocilpine, 0.1
nM-3 yu.M; (-)-dizocilpine, 1 nM-30 yuM) for 2 min
prior to addition of 0.5 ml of the membrane suspension
(300-500 p.g protein) to give an assay volume of 1 ml.
The mixture was vortexed briefly then incubated for
120 min at 25°C. L-Glutamate and glycine, when pre¬
sent, were at a final concentration of 10 pM. Non¬
specific binding was determined in the presence of 30
yuM dizocilpine. Incubations were terminated by rapid
filtration through Whatman GF/B filters using a Bran-
del cell harvester, followed by two washes with 5 ml of
5 mM Tris-HCl buffer. Filters were transferred to
scintillation vials and 100 p\ of 100% formic acid was
added to digest membrane protein followed 10 min
later by 4 ml of Emulsifier Safe Scintillant. Radioactiv¬
ity was measured in a Canberra-Packard 1900CA liquid
scintillation analyser using automatic quench correc¬
tion.
2.3. Cortical-wedge experiments
Cortical slices (500 pxn thick) were prepared from
the brains of male Cobb-Wistar rats (200-250 g). The
brain was quickly removed and placed in ice-cold (4°C)
artificial cerebrospinal fluid (ACSF) of the following
composition (in mM; sodium chloride 134; potassium
chloride 2.75; sodium hydrogen carbonate 16; calcium
chloride 2.5; magnesium sulphate 2; potassium dihy-
drogen phosphate 1.25; D-glucose 10). A 3-4 mm slice
of the ventral surface of the brain was removed and
discarded. The remaining tissue was cut transversely
just anterior to the cerebellum and at the level of the
optic chiasm. The tissue between these cuts was fur¬
ther trimmed laterally to give a block about 8 mm
square. This was fixed with cyanoacrylate glue to the
mounting block of the vibratome (Vibroslice, Campden
Instruments) with the ventral aspect opposing the agar
block used-for support. The slices were further trimmed
to the shape of small wedges about 1 mm wide at the
cortical surface. They were maintained at the gas-liquid
interface of a stationary interface chamber in an ACSF
containing magnesium with a gas phase of 95% oxygen
and 5% carbon dioxide. After 60 min incubation at
room temperature one slice was transferred to the
two-chambered bath and both chambers were perfused
independently at 2 ml/min with oxygenated magne¬
sium free ACSF. The design of the bath was essentially
as described previously (Harrison and Simmonds, 1985).
The wedge-shaped slices were positioned so they passed
through the grease filled slot with a large proportion of
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: cortex in one compartment and all of the corpus
losum and a small area of ventral cortex in the other
npartment. The potential difference between the
) compartments was measured with silver/silver
oride electrodes in agar connected to a dc amplifier
rass model 7P1/7DA), displayed on a chart recorder
ould model 2200S) and also relayed to a modified
ital audio processor (Sony model PCM 701ES) and
red on videotape. The relationship between NMDA
icentration and depolarisation was determined be-
e exposure of the slice to FR115427. Depending on
: requirements of the particular experiment,
.115427 was left in contact with the preparation for
-20 min before responses to appropriate concentra-
ns of NMDA were determined. Four point Schild
4s were constructed using doses of FR115427 of
5-5 /:M. In some experiments tetrodotoxin (0.1
1) was added to the ACSF to inhibit spontaneous
leptiform spiking; this did not affect the depolarisa-
n produced by NMDA (Harrison and Simmonds,
!5). Schild plots were generated from multiple dose-
.ponse relationships using different concentrations of
115427 by plotting the logarithm of the concentra-
i of FR115427 against the logarithm of (DR - 1),
ere DR (dose ratio) = Da/D. Da is the dose of
«1DA needed to achieve a depolarisation of a given
: in the presence of the antagonist and D is the dose
NMDA which produces an identical response in the
ence of the antagonist. In order to obtain a four-
nt Schild plot a preparation had to be viable and
Me for at least 10 h; some of the preparations in this
dy still gave consistent responses 14 h after setting
(R,S)a-Amino-3-hydroxy-5-methyI-4-isoxazole-
prionic acid (AMPA), a non-NMDA receptor ago-
was applied at the end of each NMDA dose-re-
nse relationship to ensure that there was no signifi-
t deterioration in the integrity of the preparation.
; data reported here were obtained from 21 cortical
es.
2.4. Intracellular recording from hippocampal CA1 neu¬
rones
Transverse slices of rat hippocampus, cut using a
vibratome at a thickness of 400 /zm, were placed on
nylon netting in an interface chamber at 35°C. They
were left to equilibrate for about 60 min before record¬
ings were made from pyramidal neurones in the CA1
region. A pair of fine tungsten wire stimulating elec¬
trodes insulated except at the tip were placed on the
stratum radiatum and were connected to a Grass S88
stimulator via a photoelectric stimulus isolation unit
(PSIU6, Grass Instruments). Intracellular recordings
were obtained with microelectrodes made from thick
walled (1.2 mm o.d.) glass capillary tubing (GC 120F,
Clark Electromedical Instruments) pulled on a conven¬
tional puller (Flaming Brown P80/PC). When filled
with 2 M potassium acetate the electrodes had DC
resistances of 70-100 MO. Signals were recorded with
an Axoclamp 2A amplifier (Axon Instruments) dis¬
played on a Gould chart recorder, and were relayed to
a modified digital audio processor and stored on video¬
tape for later analysis. E.p.s.p.'s were evoked with
stimulating currents of 10-20 p.A; the e.p.s.p. often
appeared to consist of two components in low magne¬
sium solutions containing picrotoxin (100 p.M).
2.5. Materials
The ( + ) and ( —) isomers of both FR115427 and
dizocilpine were synthesised in the New Drug Re¬
search Laboratories, Fujisawa Pharmaceutical Co. Ltd.,
Osaka, Japan. AMPA was obtained from Tocris Neu-
ramin, Bristol, U.K. All drugs were dissolved in
deionised water or equivalent NaOH prior to experi¬
mentation. Other drugs and reagents were obtained
from Sigma and were of the highest available purity.
5LE l
alues for stereoisomers of dizocilpine and FR115427 in the presence and absence of L-glutamate (10 ^M) and/or glycine (10 /u.M).
affinity of the ( + ) and (-) isomers of dizocilpine and FR115427 for [3H]dizocilpine binding sites on rat cortical membranes was studied in
-presence or absence of 10 jiM L-glutamate, glycine or a combination of these amino acids in the assay buffer. Membranes were incubated
[3H]dizocilpine (1 nM) in absence or presence of increasing concentrations of test drug for 120 min at 25°C. Bound and free ligand were
rated using a Branded Cell Flarvester. K, values were calculated from the equation = lC5n/(l+L/KD). Data represent mean
es±S.E.M. of the number of separate determinations indicated in parentheses.
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■R115427 inhibited [3H]dizocilpine binding with a
value of 43.3 nM (fig. 2 and table 1) in the presence
10 ^.M L-glutamate. Dizocilpine was found to be
:old more potent as an inhibitor of binding with a
value of 3.14 nM under identical conditions (fig. 2
table 1). The difference in affinity was less appar-
in the absence of added L-glutamate; K; values of
1 and 76.8 nM were obtained for dizocilpine and
115427 respectively demonstrating a 4-fold differ-
e in affinity (table 1). Inhibition of binding by both
lpounds exhibited stereoselectivity but this was far
e pronounced in the case of FR115427. When
lpared with the corresponding ( + ) isomer, the (-)
ners of FR115427 and dizocilpine were respectively
- and 4.8-fold less potent as inhibitors of [3H]di-
ilpine binding in the presence of 10 /iM L-gluta-
e (fig. 2 and table 1). KD and Bmax values for
]dizocilpine binding were determined in the pres-
e of various fixed concentrations of FR115427 (25-
nM). Increasing concentrations of FR115427 re¬
ed the binding affinity of [3H]dizocilpine but the
ding site density was unaltered indicating that
115427 was a competitive inhibitor of binding (data
shown). The competitive nature of the interaction
~R115427 and [3H]dizocilpine for the binding sites
confirmed by Dixon analysis which gave a value
FR115427 of 32 nM. This suggests that the two
gs interact with a common binding site.
'he binding of [3H]dizocilpine was modulated by
presence of L-glutamate and/or glycine in the
11 -10 -9 -8 -7 -6 -5 -4
LOG [DRUG] (M)
2. Inhibition of [3H]dizocilpine binding by the ( + ) and (-)
:rs of dizocilpine and FR115427. Cortical membranes were
ated with [3H]dizocilpine (1 nM) for 120 min in the presence or
ice of varying concentrations of test compound. All assays were
rmed in the presence of 10 /xM L-glutamate. Bound and free
1 were separated using a Brandell Cell Harvester. Data are
a representative experiment. Each point is the mean value of
:ate determinations. (+ )-Dizocilpine (Filled circles); (-)-di-
ine (filled triangles); ( + )-FR 115427 (open circles); (-)-
FR115427 (open triangles).
assay buffer (table 1). The affinity of (-F)-dizocilpine
was increased by 6.2-fold from 19.4 to 3.14 nM in the
presence of 10 pM L-glutamate. Maximal stimulation
of binding was noted at this concentration of L-gluta-
mate, and the effect involved only an alteration in the
affinity of the binding site for dizocilpine rather than
an increase in the number of binding sites (unpub¬
lished data). The affinity of ( —)-dizocilpine was in¬
creased 2-fold under identical conditions (table 1). In
contrast, the presence of L-glutamate in the assay
buffer had little effect on the affinity of either ( + )- or
(-)-FR115427 for [3H]dizocilpine binding sites (table
1). The affinity of (+ )-dizocilpine was also increased
by 3.4-fold when 10 ^M glycine was included in the
assay buffer (table 1). An effect of 10 pM glycine on
the affinity of ( + )- and (-)-FRl 15427 was almost
undetectable (table 1). In the presence of a combina¬
tion of 10 /zM L-glutamate and 10 /zM glycine the
affinity of (+ )-dizocilpine for [3H]dizocilpine binding
sites was increased by 6.7-fold (table 1), an identical
increase to that observed in the presence of L-gluta-
mate alone (i.e. there was no indication of an additive
effect). Little change in the affinity of (+■)- and (-)-
FR115427 was noted in the presence of 10 /zM L-
glutamate and 10 /xM glycine (table 1).
3.2. Cortical wedge experiments
In the majority of preparations exposure to magne¬
sium-free ACSF led to the appearance of spontaneous
epileptiform spikes. The depolarisation induced by
NMDA was dose-dependent. The maximal response
was obtained at 100 /zM, and the relationship was
sigmoidal with an EC50 of 21 /zM (fig. 3A). Repetitive
challenges with the same dose gave consistent re¬
sponses which did not desensitise (fig. 4A, C). Expo¬
sure of the preparation to FR115427 (1 juM) had three
predominant actions: (i) a gradual reduction in the
amplitude of the depolarisation produced by NMDA
(fig. 4B, D), (ii) a reduction in the frequency of the
associated epileptiform-spike activity (fig. 4B), and (iii)
a reduction in the amplitude of the epileptiform spikes
(fig. 4B). The antagonism appeared to be selective for
the NMDA receptor since responses to the non-NMDA
agonist AMPA were relatively unaffected by FR115427
(1 /zM), a concentration that reduced the response to
NMDA by up to 50% (fig. 5C, D). Increasing the dose
of NMDA overcame the antagonism, but only tran¬
siently, since a second challenge with the same dose of
NMDA resulted in a smaller depolarisation (data not
shown). The Schild plot generated from the data in fig.
3B had a slope of 1.21 whereas a slope of 1 would be
expected for a competitive antagonist. Extrapolation of
the line gave a pA2 of 6.6 (fig. 3C). The corresponding
data from a second preparation gave a slope of 1.6 and
a pA2 of 6.45.
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Additional experiments investigated the possible use
pendence of FR115427. The response of cortical
dge preparations to NMDA was first examined at a
2d time after exposure to FR115427 (fig. 5A, B). The
Normalised Amplitude
0.00
size of the depolarisation relative to control was then
compared with that recorded in a second experiment in
which an identical preparation was exposed to NMDA
on several occasions following addition of FR115427.
The corresponding test NMDA response was then
measured at the same time interval used in the first
experiment (fig. 5C, D). Use dependence would be
manifest if the response relative to control in the
second experiment were smaller than the first; in the
absence of use dependence both responses would be
identical. A significant difference was found between
the two values in the present study (fig. 5E). The
depolarisation produced by a single challenge of
NMDA after exposure to FR115427 for 70 to 108 min
was on average 83 ± 20% (n = 5) of the control value.
In contrast, the size of the depolarisation produced by
NMDA following exposure to the antagonist (84-107
min exposure) in preparations challenged several times
in the intervening period with NMDA was 48.5 ± 15%
(n = 4) of control. The difference between these values
was significant (P < 0.03, two-tailed t-test; fig. 5E). In
some preparations, there was also a small fall in the
amplitude of the AMPA depolarisations. The control
amplitude of AMPA responses was 0.6 ± 0.13 mV (n =
8) which fell to 0.57 ± 0.14 mV (n = 8) in the presence
of FR115427 (1 ,u.M). This decrease possibly reflects a
slight deterioration in the preparations following multi¬
ple challenges with NMDA. The decrease was not
significant (P > 0.07, two-tailed t-test).
C,oo -Loa (DR"1)
1.50
Log (FB1 1 5427] (M)
3. (A) Composite dose-response relationship showing the nor-
sed DC shift vs. NMDA concentration. The data were obtained
( 12 different preparations with the response to 20 yaM NMDA
l the value 1.0. The numbers beside each point denotes the
ber of preparations of the 12 that received that dose. The line
fitted to the data points using the logistic equation (Y =
P/(XP + KP) where M is the maximum response, K is the dose
ucing half the maximum response and P determines the steep-
of the curve. (B) The dose-response relationships for NMDA
shifted to the right with increases in the concentration of
15427 (0.5-5 /xM). The filled circles show the control dose-re-
se relationship. The rightward shift was accompanied by a fall in
naximal response. FR115427 (1 jiMI caused an 83% fall in the
litude of the depolarisation elicited by NMDA (20 ^M) and this
entration of FR 115427 was chosen for the grease-gap experi-
s reported here. The doses of FR115427 used were 0.5 gM
a triangles), 1.0 /iM (closed triangles), 2.5 ^M (open circles) and
M (filled squares). (C) A Schild plot made from these data gave
a pA , value of 6.6, the slope of the line was 1.2.
3.3. Intracellular recording
Hippocampal CA1 pyramidal neurones became hy-
perexcitable and discharged bursts of action potentials
in bathing solutions containing no added magnesium
and 100 ^M picrotoxin to block y-aminobutyric acidA
(GABAA)-mediated inhibition. Stimulation of the stra¬
tum radiatum elicited an e.p.s.p. accompanied by a
discharge of action potentials which made it impossible
to accurately measure the amplitude of the underlying
synaptic potential. In three preparations it was possible
to elicit a subthreshold e.p.s.p. that was either a
monophasic (fig. 6A) or a dual component depolarisa¬
tion (fig. 6B). Exposure to FR115427 (15 p.M) reduced
the amplitude of the second component in the latter
category with little action on the first component. The
action of FR 115427 on the monophasic e.p.s.p. was
only detectable when the control and test e.p.s.p. were
superimposed since the decay phase of the e.p.s.p. was
reduced whereas the peak amplitude was not affected
(fig. 6C). The mean amplitude of the second compo¬
nent, or in the case of the monophasic e.p.s.p. the
amplitude of the decay phase at 170 ms, was signifi¬
cantly reduced from a mean of 11.8 + 3.2 to 8.1 ±4.2
mV (P = 0.037; paired t-test; n = 3). The spontaneous
epileptiform spiking observed in low magnesium solu-
is containing picrotoxin was blocked by prolonged
osure to FR115427 (15 /xM).
Discussion
Radioligand binding studies using [3H]dizocilpine
lrly show that the novel isoquinoline derivative
115427 inhibits binding of this ligand to rat brain
mbranes. While FR115427 is 14-fold less potent
n dizocilpine, the more pronounced stereoselectivity
ibited by FR115427 compared with dizocilpine rep¬
ents a major difference between the two com-
mds. This difference is indeed marked with the Kj
os for the ( + ) and (-) isomers of FR115427 and
acilpine being 100- and 4.8-fold respectively in
aur of the more active ( + ) isomers. Further differ-
es were revealed when the effects of L-glutamate
1 glycine on the affinity of FR115427 and dizocilpine
[3H]dizociIpine binding sites were examined. In the
; of dizocilpine, the affinity of the ( + ) isomer was
eased by 6.2- and 3.4-fold following addition to the
ly buffer of L-glutamate and glycine respectively,
ding of either glutamate or glycine to their recogni-
l sites on the NMDA receptor presumably causes a
conformational change that facilitates the interaction
of dizocilpine with its binding site within the NMDA
receptor associated ion channel (Foster and Wong,
1987; Reynolds and Miller, 1988). It was therefore of
interest to note that the affinity of FR115427 for
[3H]dizocilpine binding sites was little affected by ei¬
ther L-glutamate or glycine. While the precise signifi¬
cance of this finding remains unclear, it may be inter¬
preted as evidence that dizocilpine and FR115427 do
not interact with an identical binding site. However,
detailed analysis of the interaction of FR115427 with
the binding site for [3H]dizocilpine provided direct
evidence that the same site is involved. In the presence
of increasing concentrations of FR115427, the density
of [3H]dizocilpine binding sites was not altered whereas
binding site affinity was reduced. Dixon analysis of
these data confirmed that FR115427 competitively in¬
hibited [3H]dizocilpine binding. The access of
FR115427 to the same binding site may therefore be
less dependent on the ongoing activity of the NMDA
receptor.
Electrophysiological experiments using a cortical
wedge preparation demonstrate that blockade of
NMDA-mediated responses by FR115427 is non-com¬
petitive. The evidence for this is (1) the slopes of the
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4. Inhibition of NMDA depolarisation and spontaneous epileptiform-like activity in a rat cortical slice preparation by FRI15427. (A)
tion of 15 ;xM NMDA (NI5) to the solution entering the chamber containing the grey matter is indicated by solid circles. This resulted in a
otential change (depolarisation of the preparation is indicated by an upward shift) and a pronounced increase in the discharge frequency of
pileptiform spikes; the response was repeatable and consistent. (B) FRI 15427 (1 jxM) was added (solid arrow) to the solution perfusing the
natter. Repeated challenges with NMDA resulted in a significant fall in the amplitude of the NMDA depolarisations and a reduction in the
ency of the associated epileptiform spikes. Note that the frequency and amplitude of the spontaneous epileptiform spikes was also reduced,
pontaneous epileptiform activity was almost completely abolished in another preparation exposed to tetrodotoxin (0.1 /xM) but the
arisations produced by 15 jxM NMDA (N15) and 10 AMPA (A 10) were still seen. (D) After exposure to FRI 15427 (1 /xM; solid
), the NMDA depolarisations were significantly reduced in amplitude and fell by 40% relative to control whereas the AMPA
depolarisations fell by only 15% relative to control.
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ild plots were greater than 1, (2) antagonism of
IDA-induced depolarisation was use-dependent and




















5. Use-dependent inhibition of NMDA-induced depolarisation
R115427. (A) Depolarisations produced by 15 /iM NMDA (N15)
10 /xM AMPA (A10) in a rat cortical wedge preparation,
ititive challenges with NMDA gave consistent responses in con-
nagnesium-free ACSF (with 0.1 fiM tetrodotoxin added). At the
v FR115427 (1 ;u.M) was added to the ACSF perfusing the grey
er and left in contact with the preparation throughout the
riment. (B) When 15 jiM NMDA was added 81 min after
sure to FR115427 (first response) the NMDA depolarisation
not significantly altered although subsequent challenges with 15
NMDA produced smaller depolarisations. The response to 10
AMPA was unchanged. The break in record (A) represents 18
and the interval between records (A) and (B) is 16 min. (C)
)larisations produced by 15 /xM NMDA (N15) and 10 /xM
'A (A10) in another cortical wedge preparation exposed to
dotoxin. At the arrow FR 115427 (1 /xM) was added to the
F perfusing the grey matter and was left in contact with the
aration throughout the experiment. (D) The NMDA depolarisa-
recorded 81 min after exposure to the antagonist (first response)
awn in this record. It was significantly smaller than the control
tnse in (C) although the response to 10 jiM AMPA was not
'icantly different. The break in (C) represents 20 min and that in
5 min, the records at the end of (C) and the beginning of (D)
ontinuous. (E) Histograms showing the amplitude of NMDA
larisations as a percentage of control after exposure to FR115427
4) for periods of 70-108 min (single) and 84-107 min (repe-
). The data in the column labelled single were obtained from
irations unchallenged by NMDA prior to application of the test
of NMDA whereas the data in the column labelled repetitive
obtained from preparations challenged several times with
iA prior application of the test dose. A significant difference
found between the two groups, the error bars denote the S.D.
50 ms
Fig. 6. The effect of FR115427 (15 (iM) on the e.p.s.p. recorded in
hippocampal CA1 pyramidal neurones in response to stimulation of
the stratum radiatum. The preparations were exposed to
magnesium-tree AU5F containing picrotoxin UUU |iM). 1 he records
are averages of eight successive sweeps, (a) In this neurone a
monophasic e.p.s.p. was recorded, Em=-59 mV. Exposure to
FR115427 led to a more rapid decay of the falling phase of the
e.p.s.p. (b). Superimposition of the records in (a) and (b) shows that
the peak amplitude of the e.p.s.p. was relatively unchanged whereas
a clear effect can be seen on the falling phase of the e.p.s.p. (c). (d)
In another neurone an e.p.s.p. consisting of two components was
recorded, Em=—63 mV. FR115427 (15 gM) reduced the second
component of the e.p.s.p. (e). Superimposition of the records in
(d) and (e) shows a dramatic reduction in the amplitude of the
second component whereas the first component was relatively un¬
affected (f).
ing the dose of NMDA, (3) dose-response plots for
NMDA were progressively shifted to the right by in¬
creasing doses of FR115427, but the shift was not
parallel and was accompanied by a corresponding fall
in the maximal response to NMDA. The values ob¬
tained for pA2 from the Schild plots derived from two
experiments were 6.45 and 6.6. However, it is difficult
to ascribe a significance to these values since the slopes
of the Schild plots were greater than unity. Simmonds
(1990) does make the point that having established that
an antagonist is non-competitive it is still useful to
construct a Schild plot to determine the concentra¬
tion-effect characteristics of compounds within a group
of non-competitive antagonists. In this regard, it is of
interest that a pA2 of 5 was obtained for ketamine
(Harrison and Simmonds, 1985), which also acts non-
competitively by blocking the ion channel of the NMDA
receptor (MacDonald et al., 1987). We have also at¬
tempted to determine a pA2 value for dizocilpine but
this proved impossible because of the extreme use
dependence of this drug. However, in the present study
2.5-5.0 /x.M of FR115427 was required to completely
block responses to NMDA whereas under similar con¬
ditions 0.35 ^xM dizocilpine was required to achieve
the same result suggesting that dizocilpine is an order
of magnitude more potent than FR115427.
When the cortical wedge preparation was exposed
to FR115427, a small component (on average 17%) was
nd to be use-independent. This was the proportion
the NMDA response that was blocked in the ab-
ce of prior exposure to NMDA. It is possible that
slowly developing depolarisation induced by NMDA
lects use dependence during the rising phase of the
ial response leading to depression of its amplitude
illiwell et al., 1989). Although the experiments to
lblish use-dependence were carried out in the pres-
e of tetrodotoxin in order to block spike-dependent
ivity, spontaneous release of transmitter may still
e occurred allowing FR115427 access to its binding
. Alternatively, FR115427 may gain access to its
ding site other than through the ion channel of the
eptor. The latter possibility could be related to the
erence in the extent of use-dependent blockade of
■IDA-mediated responses by FR115427 and di-
ilpine noted in the present study.
After a period of equilibration in magnesium-free,
odotoxin-free solutions the cortical wedge exhibited
ntaneous epileptiform discharges that consisted of
Itiple rapid spike-like depolarisations superimposed
a depolarisation with a much slower time course.
: frequency of these depolarisations was increased
■NMDA, whereas the frequency and amplitude of
+i were reduced by FR115427. These observations
gest that NMDA plays a role in the generation of
n potentials and that this response is blocked by
115427 in parallel with the inhibition of NMDA-in-
ed depolarisations. Similar results have been re-
ted for dizocilpine (Wong et al., 1986).
'he intracellular study on hippocampal CA1 neu-
■es in a brain slice preparation demonstrated that
-115427 selectively blocked a second delayed compo-
t of the e.p.s.p. evoked in magnesium-free, picro-
n containing ACSF. This response is reported to be
iiated by NMDA receptors (Collingridge et al.,
Flestrin et al., 1990). This observation compli-
lts data obtained with the cortical wedge prepara-
thereby confirming the NMDA receptor as the
is of action of FR115427. The initial component of
e.p.s.p. that is mediated by non-NMDA receptors
llingridge et al., 1988) was little effected by
15427. This finding is in keeping with cortical
ge experiments in which FR115427 did not affect
PA-induced depolarisation.
'he binding experiments described in this paper
;est that FR115427 and dizocilpine interact with a
lar site on the NMDA receptor, and functional
ies using the cortical wedge and hippocampal slice
>arations confirm this pharmacological profile. In-
tion of NMDA-mediated responses by FR115427
sent data) and dizocilpine (Kemp et al., 1987)
Ived a non-competitive and use dependent mecha-
i of action. These functional properties are charac-
tic of non-competitive antagonists that interact with
te(s) within the NMDA receptor-associated ion
channel (MacDonald and Nowak, 1990; Lodge and
Johnson, 1990). Data obtained in the hippocampal slice
preparation demonstrate that FR 115427 inhibits the
NMDA-mediated component of neuronal excitation
evoked by endogenous transmitter in a specific hip¬
pocampal pathway.
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"he binding of [3H]FR115427 ([3HK + )-l-methyl-l-phenyl-l,2,3,4-tetrahydroisoquinoIine) to rat cortical synaptosomal mem-
tes was investigated. Binding was optimal at pH 7.4-8.0, and temperature had little effect on specific binding. Binding
hed equilibrium within 30 min at 25°C, and was reversible in the presence of excess unlabelled FR115427. [3H]FR115427
nd to a single population of non-interacting sites with an affinity of 45.4 ± 3.9 nM, and a binding site density of 9.12 ± 0.52
il/mg protein. The affinities of other N-methyl-D-aspartate (NMDA) receptor channel blockers for [3H]FR115427 binding
; were consistent with binding to a similar site to that occupied by dizocilpine. Binding was potentiated by L-glutamate and
ine with ECS0 values of around 80 nM. In the presence of L-glutamate (10 p.M), specific binding was increased 4-fold, whilst
ition of glycine (10 /xM) increased specific binding 2-fold. FR115427 exhibited marked stereoselectivity; ( + )-FR 115427 has
fold higher affinity than (-)-FRl 15427. This ligand may therefore be useful for the pharmacological investigation of the
DA receptor ion channel.
NMDA (A-methyl-D-aspartate); (Non-competitive), Dizocilpine; FR115427; Ligand binding
ntroduction
"he iV-methyl-D-aspartate (NMDA) receptor has
n implicated in many physiological and pathological
its in the brain. Studies using neurochemical and
trophysiological techniques have revealed a num-
of pharmacologically distinct modulatory sites on
receptor (reviews by Reynolds and Miller, 1988;
jblewski and Danysz, 1989; Wong and Kemp, 1991).
bition of NMDA receptor activation can be
eved via direct antagonism at the recognition site
the endogenous neurotransmitter, and a number of
petitive antagonists have been developed (Olver-
i and Watkins, 1989). Non-competitive antagonism
1MDA receptor mediated responses is also possible
several sites; blockade of the NMDA receptor ion
inel has been investigated using drugs such as
-5-methyl-10,l l-dihydro-5//-dibenzo[a,xf ]cyclo-
ten-5,10-imine (dizocilpine or MK801), the disso-
ve anaesthetics phencyclidine (PCP) and ketamine,
the sigma opiate, N-allylnormetazocine (NANM)
ng et al., 1986; McDonald et al., 1987; Wong and
rresponding author. Tel: 031-650-8491; Fax: 031-667-9381.
Kemp, 1991). The glycine modulatory site of the
NMDA receptor can be targetted by antagonists at this
site such as 7-chlorokynurenate and L-689,560 (Kemp
et al., 1988; Grimwood et al., 1991). Research aimed at
developing drugs that act selectively at the polyamine
recognition site of the NMDA receptor has yielded
compounds such as ifenprodil and SL82.0715 (Gotti et
al., 1988), and the role of tricyclic antidepressants has
also been investigated (Bakker et al., 1991). Further
research should reveal the role these sites play in
modulating the activity of the NMDA receptor ion
channel.
Radioligand binding techniques have been particu¬
larly useful in the characterisation of the NMDA re¬
ceptor with the development of potent and selective
ligands for the transmitter recognition site (Olverman
and Watkins, 1989; Murphy et al., 1987, 1988; Sills et
al., 1991), and for the ion channel (Wong et al., 1986;
Bonhaus et al., 1987). [3H]Dizocilpine has been widely
used in radioligand binding studies to examine the
NMDA receptor ion channel. This ligand binds to a
single population of sites on rat brain membranes, and
binding is inhibited by other NMDA receptor channel
blockers such as ketamine, PCP and NANM. Studies
using [3H]dizocilpine have shown that binding of the
nd is markedly enhanced by agonists for the trans-
ter recognition site, and this effect is inhibited by
ipetitive NMDA receptor antagonists (Foster and
ng, 1987). The enhancement seems to be due to an
•ease in the apparent on-rate for [3H]dizocilpine
ding presumably due to the opening of the NMDA
;ptor channel allowing easier access of the ligand to
binding site (Kloog et al., 1988a). When glycine is
sent a further enhancement of binding is seen, and
is probably due to the glycine-induced increase in
IDA receptor ion channel open time noted in elec-
)hysiological experiments (Johnson and Ascher,
7).
n the present study, we have examined the binding
racteristics of [3H]( + )-l-methyl-l-phenyl-l,2,3,4-te-
tydroisoquinoline ([3H]FR115427) to rat brain
nbranes. This novel dizocilpine analogue has previ-
ly been shown to interact with a site within the
IDA receptor ion channel (Hodgkiss et al., 1993).
Methods
Synthesis and radiochemical purity of [3H]FR115427
3H]FR115427 (18 Ci/mmol) was custom tritiated
\mersham International by catalytic reduction of a
lo-chlorinated aromatic precursor. The stock mate-
was stored in ethanol at a concentration of 10
i/ml under liquid nitrogen. [3H]FR115427 was pu-
:d on a Waters preparative resin (C-18, 55-105 p.).
ample of crude material was dissolved in eluting
ent (CH3CN/aq. 0.1% CF3COOH (TFA); 3:7)
applied to a 5 X 0.7 cm column of resin. The resin
eluted with 10 bed volumes of solvent and the
tions corresponding to FR115427 combined before
solvent was removed. Purified [3H]FR115427 as
TFA salt was diluted to 10 p.M with glass distilled
jr and stored in aliquots for experiments under
id nitrogen. Purity was confirmed by column chro-
ography as described above and by silica gel TLC
g CHCl3/MeOH (9:1) as solvent. Greater than
; of the radioactivity corresponded to authentic
15427 up to 6 months after purification.
Preparation of rat brain membrane
'he cerebral cortices of male Cob-Wistar rats (250—
g) were dissected and homogenised in 15 volumes
v) of ice cold 0.32 M sucrose, using a glass teflon
togeniser. The homogenate was centrifuged at 1000
for 10 min at 4°C and the supernatant recen-
ged (17,000 x g, 20 min, 4°C). The resultant synap-
mal pellet was lysed with 30 volumes glass distilled
:r. After incubation at 37°C for 30 min, the mem-
le suspension was centrifuged at 50,000 Xg for 10
min at 4°C, the supernatant discarded and the pellet
washed by resuspension in glass distilled water (30
volumes) and centrifugation (50,000 X g, 10 min, 4°C).
The resultant pellet was resuspended to 10 volumes
and stored at — 20°C. Prior to use, the 10 volume
suspension was thawed and diluted to 30 volumes with
glass distilled water, recentrifuged (50,000 Xg, 10 min,
4°C) and the final pellet resuspended in 30 volume of 5
mM Tris-HCl (pH 7.4, 20°C) and kept on ice until
required. Protein content was measured by the method
of Bradford (1976).
2.3. [3H]FR115427 binding assay
[3H]FR115427 (10 nM) was preincubated at 25°C
with 5 mM Tris-HCl buffer (pH 7.4) in the absence or
presence of increasing concentrations of test drug (0.1
nM-300 ^M) for 2 min prior to addition of 0.5 ml
membrane suspension (30-70 pg protein). Samples
were incubated at 25°C for 45 min unless otherwise
indicated. L-Glutamate (10 /J.M) was present except
when indicated. Non-specific binding was determined
in the presence of 30 pM FR115427. Incubation was
terminated by rapid filtration through Whatman GF/B
filters presoaked in 0.05% polyethylenimine for 60 min
followed by 2 X 5 ml washes using a Brandel cell har¬
vester. Filters were transferred to scintillation vials and
100 p 1 formic acid (100%) was added, followed 10 min
later by 4 ml Emulsifier Safe liquid scintillation fluid.
Radioactivity was measured in a Canberra-Packard
1900CA liquid scintillation analyser using automatic
quench correction.
2.4. [3H]Dizocilpine binding assay
[3H]Dizocilpine (1 nM; 24 Ci/mmol; NEN) was
preincubated at 25°C with 5 mM Tris-HCl buffer (pH
7.4) in the absence or presence of increasing concen¬
trations of test drug (0.1 nM-300 pM) for 2 min prior
to addition of 0.5 ml membrane suspension (30-70 p g
protein). Samples were incubated at 25°C for 120 min
unless otherwise indicated. L-Glutamate (10 ^M) was
present except when indicated. Non-specific binding
was determined in the presence of 30 /iM dizocilpine.
Incubation was terminated by rapid filtration through
Whatman GF/B filters followed by 2 X 5 ml washes
using a Brandel cell harvester and [3H]dizocilpine
binding was determined as described above.
3. Results
3.1. Timecourse of [3H]FR115427 and [3H]dizocilpine
binding
Specific binding of [3H]FR115427 to rat cortical
synaptosomal membranes reached equilibrium within
321
BLE 1
letic analysis of [3H]FR115427 and [3H]dizocilpine binding to rat cortical synaptosomal membranes
[3H]FR115427 [3H]dizocilpine
, (M"' s-') 2.1 X104± 0.32 xlO4 1.5 x 105 ±0.18 X 105
, (s-1) 9.1 X 10"4 ±0.62x 10~4 2.1 x 10" 4 ±0.25 x 10" 4
: KD (nM) 45.9 ±5.2 1.45 ±0.22
, dissociation (min) 12.9 ±0.9 56.6 ±5.2
tical synaptosomal membranes were incubated with 10 nM [3H]FR115427 or 1 nM [3HJdizocilpine for various times at 25°C in the presence
10 jiM L-glutamate. In dissociation experiments, following incubation for either 45 min ([3H]FR115427) or 90 min ([3H]dizociIpine), excess
abelled ligand was added and binding measured at various time intervals thereafter.
min at 25°C (Fig. 1). Specific binding was reversible;
: addition of 30 /a.M FR115427 displaced almost all
tcific binding within 45 min (Fig. 1). Dissociation of
and [3H]FR 115427 followed a typical single expo-
ltial decay curve, with a tl/2 of approximately 13
i (table 1). At equilibrium, specific binding com-
■sed approximately 40% of total binding at a ligand
icentration of 10 nM.
■In the same membrane preparation, [3H]dizocilpine
ding reached equilibrium within 120 min, and excess
abelled ligand (30 /aM dizocilpine) displaced almost
specific binding within 150 min. The single expo-
ltial decay curve for dissociation of [3H]dizocilpine
1 a f1/2 of 57 min (Table 1). Specific binding at
tilibrium accounted for approximately 90% of total
tnd bound at a ligand concentration of 1 nM. Ki-
ic analysis of these experiments provided associa-
i and dissociation rate constants (Table 1), and gave
;ulated KD values (k_l/k + l) of 45.9 ± 5.2 nM for
[]FR115427 binding and 1.45 ± 0.22 nM for [3H]di-
ilpine binding.
Tima (mini
1. Timecourse of [3H]FR115427 binding to rat cortical synapto-
tl membranes. Synaptosomal membranes suspended in 5 mM
HC! (pH 7.4) were incubated with 10 nM [3H]FR115427 in the
:nce of 10 L-glutamate for various times (•). Dissociation
nitiated at 45 min (indicated by arrow) by the addition of 30
telled FR 115427, and at various times following this specific
ng was measured (o). Results shown are from a single repre-
itive experiment from a group of five independent experiments.
3.2. Effect of pH, temperature and protein concentration
on [3H]FR115427 binding
Specific binding of [3H]FR115427 to cortical synap¬
tosomal membranes was measured over the pH range
6.5-8.5. An optimum was apparent between pH 7.5-8.0
(Fig. 2A). Routine assays were carried out at pH 7.4 to
allow direct comparison of [3H]FR115427 binding with
A
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Fig. 2. (A) pH dependence of [3H]FR115427 binding. Membranes
were incubated in 5 mM Tris-HCl buffer at pH ranging from 6.5-8.5
with 10 nM [3H]FR115427 in the presence of 10 fiM L-glutamate for
45 min. Non-specific binding was defined in the presence of 30 /xM
FR 115427. Values are mean of duplicated experiments performed in
triplicate. (B) Effect of protein concentration on [3H]FR115427
binding. [3H]FR115427 (10 nM) was incubated with 10 /iM L-gluta¬
mate for 45 min in the presence of increasing membrane protein
concentration (0-170 jig/assay). Non-specific binding was defined in
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3. Inhibition of [3H]FR115427 binding by unlabelled FR115427.
ibranes were incubated (45 min) with 10 nM [3H]FR115427 and
M L-glutamate in the absence or presence of increasing concen¬
sus of unlabelled FR115427 (1 nM-10 ^M). Non-specific bind-
vas determined in the presence of 30 jxM FR 115427. Results
n are from a single representative experiment from a group of
independent experiments. Data from individual experiments was
/sed by least squares fit to the logistic expression Y = MXP/(A"P
+ ICp0)and KD and Smax values were calculated.
]dizocilpine binding which is routinely measured at
7.4.
'emperature effects were measured over the range
7°C. Specific binding remained constant with tem-
iture. Specific binding of [3H]FR115427 was mea-
:d over a protein concentration range of 10-170 /xg
ein/tube and was linear up to 120 /xg/tube (Fig.
In routine experiments, a protein concentration of
70 /xg/assay was used.
Determination of the KD and Bmax for [3H]-
15427 binding
TABLE 2
Inhibition of [3H]FR115427 and [3H]dizocilpine binding to rat corti¬




( + )-FR115427 45.4 ±3.9 35.4 ±3.8
(-)-FR 115427 4732 + 395 3 756 ±227
(+ )-Dizocilpine 6.45 + 0.71 3.57 ±0.4
(— )-Dizocilpine 18.4 + 3.5 16.0 ± 1.6
Phencyclidine 35.8 ±2.8 36.2 ±4.5
Ketamine 576 ±107 354 ±59.0
N-Allylnormetazocine 304 ±41.8 316 ± 24.8
Cortical synaptosomal membranes were incubated with 10 nM
[3H]FR115427 (45 min) or 1 nM [3H]dizociipine (120 min) in the
presence of 10 /xM L-glutamate and increasing concentrations of test
drugs (0.1 nM-300 fiM). Non-specific binding was determined in the
presence of 30 ^M unlabelled ligand. values were calculated
from the equation Kt = IC50/(I + L/KD). Values are mean±
S.E.M. of at least three experiments performed in duplicate.
the inhibitory constant (Kt) for ( + )-dizocilpine was
6.45 ± 0.71 nM, indicating that ( + )-FRl 15427 has a
7-fold lower affinity than (+ )-dizocilpine. Binding was
stereoselective since (-t-)-FR 115427 showed 100-fold
higher affinity than (-)-FRl 15427 (Table 2). In con¬
trast, the affinity of (+ )-dizocilpine was only 3-fold
higher than its (-)-stereoisomer (Table 2). Other
NMDA receptor channel blockers (PCP, ketamine,
NANM) showed K, values for displacement of
[3H]FR115427 binding consistent with their inhibition
of [3H]dizocilpine binding (Fig. 4 and Table 2). Com¬
parison of K{ values measured against [3H]FR115427
and [3H]dizociIpine binding gave a regression coeffi¬
cient (r) of 0.964 (P < 0.05; Fig. 4).
'he binding of [3H]FR115427 was investigated by
■bating cortical synaptosomal membranes with 10
[3H]FR115427 and increasing concentrations of
ibelled ligand in the presence of 10 axM L-gluta-
e (Fig. 3). Analysis of saturation data from five
l experiments provided binding affinity (ATD) and
ling site density (Bmax) values of 45.4 ± 3.91 nM
9.12 ±0.52 pmol/mg protein, respectively. The
slope was 1.07 ±0.15, indicating binding to a sin-
population of sites.
Pharmacology of the [3H]FR115427 binding site
he pharmacological profile of the [3H]FR115427
ling site was evaluated by incubating cortical synap-
mal membranes with 10 nM [3H]FR115427 at 25°C
45 min in the absence or presence of increasing
:entrations (0.1 nM-300 jxM) of a number of
-DA receptor channel blockers (Table 2). The K0
e of ( + )-FR 115427 was 45.4 ±3.91 nM, whereas
[SHlDizocilpine Binding (Ki; nM)
Fig. 4. Pharmacological comparison of [3H]FR115427 and [3H]di-
zocilpine binding. Membranes were incubated with 10 nM
[3H]FR115427 (45 min) or 1 nM [3H]dizocilpine (120 min) in the
presence of 10 gM L-glutamate. Correlation between the AC, values
for various non-competitive NMDA receptor antagonists in the
[3H]FR115427 and [3H]dizociipine binding assays was evaluated by
least-squares fit regression analysis (r = 0.964, P < 0.05). Non-specitic
binding was defined in the presence of 30 nM unlabelled ligand.
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Effects of L-glutamate and glycine on [3H]FR115427
[3H1dizocilpine binding
n the absence of exogenous L-glutamate,
]FR115427 binding was variable and specific bind-
often represented less than 10% of total binding. It
therefore not possible to accurately determine KD
Bm3K values for [3H]FR115427 under these condi-
is. L-Glutamate (10 jaM) was therefore routinely
ed to the assay buffer. Both L-glutamate and glycine
eased specific [3H]FR 115427 binding to cortical
iptosomal membranes, with EC50 values of 75.0 ±
1 nM and 93.7 ± 16.8 nM, respectively. The magni-
e of the effect was different for the two transmit-
>; 10 fiM L-glutamate increased specific
JFR115427 binding maximally to 438 ± 55.7% of
trol binding (Fig. 5A), whilst 10 /aM glycine in-
ised specific [3H]FR115427 binding maximally to
± 17.0% of control binding (Fig. 5B). In the case of
cific [3H]dizocilpine binding, L-glutamate (10 p.M)





i. Potentiation of [3H]FR115427 and [3H]dizocilpine binding by
tamate and glycine. Membranes were incubated with 10 nM
:R115427 (45 min) or I nM [3H)dizocilpine (120 min) in the
ice or presence of increasing concentrations of L-glutamate (A)
•cine (B). A final concentration of 1 nM-100 (iM L-glutamate
or glycine was added. Potentiation was calculated as a percent-
>f control binding in the absence of added L-glutamate or
e. Data are the means (% control binding) of three experi-
; performed in duplicate. ([3H]FR115427, filled triangle;
[3H]MK801, filled circle).
34.2% and 309 ± 45.0% of control binding, respectively
(Fig. 5A and B). The EC50 values for L-glutamate and
glycine enhancement of specific [3H]dizocilpine bind¬
ing were 194 ± 20.7 nM and 214 ± 25.6 nM, respec¬
tively.
4. Discussion
The affinity of FR115427 for the [3H]]dizocilpine
binding site is in the mid-nanomolar range (Hodgkiss
et al., unpublished data). A ligand with a KD of this
order would be expected to have a f1/2 for dissociation
of around 15 s, a rate which would preclude the use of
filtration as a method to separate bound from free
ligand. However, [3H]FR115427 has been shown exper¬
imentally to have the much longer /1/2 for dissociation
of 13 min. [3H]FR115427 therefore behaves more like
a ligand with sub-nanomolar affinity in the filtration
assay, and the loss of specific binding during filtration
is negligible. Theoretical calculations assuming simple
binding to the receptor site would predict an associa¬
tion rate constant of around 106 M_1 s-1 (Bennett,
1978). However, kinetic analysis of [3H]FR115427 bind¬
ing measured in the filtration assay gave an association
rate constant of 2.1 X 104 M-1 s_l, nearly two orders
of magnitude lower than the predicted value. The
association rate constant for [3H]dizocilpine of 1.5 X
10s M"1 s-1 was also lower than predicted, and repre¬
sented a deviation from the theoretical value of 6-fold.
This is consistent with published data (Kloog et al.,
1988b), and in view of the kinetics of [3H]FR115427
binding is probably a true reflection of the kinetics of
[3H]dizocilpine binding rather than an experimentally
induced deviation from the predicted value. The slower
association rates imply that binding of both ligands to
the NMDA receptor involves more than a simple bind¬
ing process, and could be related to a transition from
an aqueous to a lipid environment. This proposal is
consistent with data from electrophysiological studies
that have suggested that the binding site for non-com¬
petitive NMDA antagonists is located in a lipophilic
environment within the NMDA receptor ion channel.
Saturation analysis demonstrated that [3H]FR115427
binds to a single population of sites with a £?max of
9.12 ± 0.52 pmol/mg protein. This binding site density
is similar to the value of 8.63 ± 0.47 pmol/mg protein
for [3H]dizocilpine binding in the same preparation
(data not shown). The K0 for [3H]FR115427 binding
of 45 nM was also in agreement with the Kt value of
35 nM for FR115427 measured in the [3H]dizocilpine
binding assay. The Hill slope was close to unity indicat¬
ing a single population of binding sites. The K, values
for non-competitive NMDA receptor antagonists (PCP,
ketamine, NANM) in the [3H]FR115427 and [3H]di-
zocilpine binding assays exhibit a close correlation sug-
ting that these radioligands bind to a similar site
hin the NMDA receptor ion channel.
Specific binding of [3H]FR115427 in the absence of
igenous L-glutamate was low and variable between
'eriments. The EC50 for L-glutamate stimulation of
1]FR115427 binding suggests that a low residual
lutamate concentration in washed membrane prepa-
ons will make a measurable difference to specific
ding. Specific [3H]FR115427 binding was enhanced
L-glutamate and this amino acid was therefore rou-
;ly added to the binding assay. The presence of a
.irating concentration of L-glutamate (10 /xM) in-
ased specific binding 4-fold. A 2-fold increase in
cific [3H]FR115427 binding was seen in the pres-
e of 10 juM glycine. In contrast, [3H]dizocilpine
ding was measurable in the absence of added exoge-
ts L-glutamate due to its higher affinity for the
■IDA receptor ion channel. The effects of L-gluta-
e and glycine on [3H]dizocilpine binding and
]FR115427 binding also showed differences; the
50 values for stimulation of [3H]FR115427 binding
--glutamate and glycine were approximately 80 nM,
:reas for [3H]dizocilpine binding the EC50 values
e 2-4-fold higher. The degree of potentiation was,
'ever, similar with specific [3H]dizocilpine binding
tg increased 6-fold and 3-fold by L-glutamate (10
) and glycine (10 /xM), respectively.
Although the affinity of [3H]FR 115427 for the
DA receptor ion channel is approximately 10-fold
-er than that of [3H]dizocilpine, thereby making it a
attractive radioligand for the study of this site, the
eoselectivity of FR115427 is much greater. The
-isomer of FR115427 is approximately 100-fold
e potent than the corresponding (-)-isomer, whilst
e is only a 3-fold separation in the affinities of the
eoisomers of dizocilpine (the ( + )-isomer having
higher affinity). [3H]FR115427 may therefore be a
ill pharmacological tool for the study of the NMDA
ptor ion channel.
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